<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.5.1//EN" "ep-patent-document-v1-5-1.dtd">
<!-- This XML data has been generated under the supervision of the European Patent Office -->
<ep-patent-document id="EP18199195B1" file="EP18199195NWB1.xml" lang="en" country="EP" doc-number="3486318" kind="B1" date-publ="20211006" status="n" dtd-version="ep-patent-document-v1-5-1">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................</B001EP><B005EP>J</B005EP><B007EP>BDM Ver 2.0.12 (4th of August) -  2100000/0</B007EP></eptags></B000><B100><B110>3486318</B110><B120><B121>EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B1</B130><B140><date>20211006</date></B140><B190>EP</B190></B100><B200><B210>18199195.1</B210><B220><date>20140808</date></B220><B240><B241><date>20191122</date></B241><B242><date>20200323</date></B242></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>201361864289 P</B310><B320><date>20130809</date></B320><B330><ctry>US</ctry></B330><B310>201414320370</B310><B320><date>20140630</date></B320><B330><ctry>US</ctry></B330><B310>201414320413</B310><B320><date>20140630</date></B320><B330><ctry>US</ctry></B330></B300><B400><B405><date>20211006</date><bnum>202140</bnum></B405><B430><date>20190522</date><bnum>201921</bnum></B430><B450><date>20211006</date><bnum>202140</bnum></B450><B452EP><date>20210315</date></B452EP></B400><B500><B510EP><classification-ipcr sequence="1"><text>C12N  15/113       20100101AFI20210219BHEP        </text></classification-ipcr><classification-ipcr sequence="2"><text>C12N   9/22        20060101ALI20210219BHEP        </text></classification-ipcr><classification-ipcr sequence="3"><text>C12Q   1/6869      20180101ALI20210219BHEP        </text></classification-ipcr><classification-ipcr sequence="4"><text>C12Q   1/6816      20180101ALI20210219BHEP        </text></classification-ipcr></B510EP><B520EP><classifications-cset><classification-cset group-number="2"><classification-cpc rank="1"><text>C12Q   1/6816      20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="2"><text>C12Q2521/301       20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="3"><text>C12Q2522/101       20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="4"><text>C12Q2535/122       20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="5"><text>C12Q2563/131       20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="6"><text>C12Q2563/149       20130101 LI20150622BHEP        </text></classification-cpc></classification-cset><classification-cset group-number="3"><classification-cpc rank="1"><text>C12Q   1/6869      20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="2"><text>C12Q2521/301       20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="3"><text>C12Q2522/101       20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="4"><text>C12Q2535/122       20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="5"><text>C12Q2563/131       20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc rank="6"><text>C12Q2563/149       20130101 LI20150622BHEP        </text></classification-cpc></classification-cset></classifications-cset><classifications-cpc><classification-cpc sequence="1"><text>C12Y 301/00        20130101 LI20161117BHEP        </text></classification-cpc><classification-cpc sequence="2"><text>A61P  31/18        20180101 LI20200327BHEP        </text></classification-cpc><classification-cpc sequence="3"><text>A61P  35/00        20180101 LI20200327BHEP        </text></classification-cpc><classification-cpc sequence="4"><text>C12Q   1/6816      20130101 LI20150622BHEP        </text></classification-cpc><classification-cpc sequence="5"><text>C12Q   1/6869      20130101 LI20150622BHEP        </text></classification-cpc></classifications-cpc></B520EP><B540><B541>de</B541><B542>NUKLEASEPROFILIERUNGSSYSTEM</B542><B541>en</B541><B542>NUCLEASE PROFILING SYSTEM</B542><B541>fr</B541><B542>SYSTÈME DE PROFILAGE DE NUCLÉASE</B542></B540><B560><B561><text>WO-A2-2013/066438</text></B561><B562><text>PRASHANT MALI ET AL: "CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering", NATURE BIOTECHNOLOGY, vol. 31, no. 9, 1 August 2013 (2013-08-01) , pages 833-838, XP055149275, ISSN: 1087-0156, DOI: 10.1038/nbt.2675</text></B562><B562><text>PATRICK D HSU ET AL: "DNA targeting specificity of RNA-guided Cas9 nucleases", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, UNITED STATES, vol. 31, no. 9, 21 July 2013 (2013-07-21), pages 827-832, XP002718604, ISSN: 1546-1696, DOI: 10.1038/NBT.2647 [retrieved on 2013-07-21]</text></B562><B562><text>VIKRAM PATTANAYAK ET AL: "High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity", NATURE BIOTECHNOLOGY, vol. 31, no. 9, 11 August 2013 (2013-08-11), pages 839-843, XP055148795, ISSN: 1087-0156, DOI: 10.1038/nbt.2673</text></B562><B562><text>JOHN P GUILINGER ET AL: "Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity", NATURE METHODS, vol. 11, no. 4, 16 February 2014 (2014-02-16), pages 429-435, XP055148794, ISSN: 1548-7091, DOI: 10.1038/nmeth.2845</text></B562></B560></B500><B600><B620><parent><pdoc><dnum><anum>14755947.0</anum><pnum>3030650</pnum></dnum><date>20140808</date></pdoc></parent></B620></B600><B700><B720><B721><snm>LIU, David, R.</snm><adr><str>3 Whitman Circle</str><city>Lexington, MA 02420</city><ctry>US</ctry></adr></B721><B721><snm>PATTANAYAK, Vikram</snm><adr><str>123 Holden Green</str><city>Cambridge, MA 02138</city><ctry>US</ctry></adr></B721></B720><B730><B731><snm>President and Fellows of Harvard College</snm><iid>101646268</iid><irf>P103019EP1</irf><adr><str>17 Quincy Street</str><city>Cambridge, MA 02138</city><ctry>US</ctry></adr></B731></B730><B740><B741><snm>Atkins, James Gordon John</snm><sfx>et al</sfx><iid>101536405</iid><adr><str>Kilburn &amp; Strode LLP 
Lacon London 
84 Theobalds Road</str><city>London WC1X 8NL</city><ctry>GB</ctry></adr></B741></B740></B700><B800><B840><ctry>AL</ctry><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>HR</ctry><ctry>HU</ctry><ctry>IE</ctry><ctry>IS</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LT</ctry><ctry>LU</ctry><ctry>LV</ctry><ctry>MC</ctry><ctry>MK</ctry><ctry>MT</ctry><ctry>NL</ctry><ctry>NO</ctry><ctry>PL</ctry><ctry>PT</ctry><ctry>RO</ctry><ctry>RS</ctry><ctry>SE</ctry><ctry>SI</ctry><ctry>SK</ctry><ctry>SM</ctry><ctry>TR</ctry></B840></B800></SDOBI>
<description id="desc" lang="en"><!-- EPO <DP n="1"> -->
<heading id="h0001"><b>BACKGROUND OF THE INVENTION</b></heading>
<p id="p0001" num="0001">Site-specific endonucleases theoretically allow for the targeted manipulation of a single site within a genome and are useful in the context of gene targeting as well as for therapeutic applications. In a variety of organisms, including mammals, site-specific endonucleases have been used for genome engineering by stimulating either non-homologous end joining or homologous recombination. In addition to providing powerful research tools, site-specific nucleases also have potential as gene therapy agents, and two site-specific endonucleases have recently entered clinical trials: one, CCR5-2246, targeting a human CCR-5 allele as part of an anti-HIV therapeutic approach (NCT00842634, NCT01044654, NCT01252641), and the other one, VF24684, targeting the human VEGF-A promoter as part of an anti-cancer therapeutic approach (NCT01082926).</p>
<p id="p0002" num="0002">Specific cleavage of the intended nuclease target site without or with only minimal off-target activity is a prerequisite for clinical applications of site-specific endonuclease, and also for high-efficiency genomic manipulations in basic research applications, as imperfect specificity of engineered site-specific binding domains has been linked to cellular toxicity and undesired alterations of genomic loci other than the intended target. Most nucleases available today, however, exhibit significant off-target activity, and thus may not be suitable for clinical applications. <patcit id="pcit0001" dnum="WO2013066438A2"><text>WO2013/066438A2</text></patcit> relates to evaluation and improvement of nuclease cleavage specificity.</p>
<p id="p0003" num="0003">Technology for evaluating nuclease specificity and for engineering nucleases with improved specificity are therefore needed.</p>
<heading id="h0002"><b>SUMMARY OF THE INVENTION</b></heading>
<p id="p0004" num="0004">The invention is defined in the appended claims. Some aspects of this disclosure are based on the recognition that the reported toxicity of some engineered site-specific endonucleases is based on off-target DNA cleavage, rather than on off-target binding alone. Some aspects of this disclosure provide strategies, compositions, systems, and methods to evaluate and characterize the sequence specificity of site-specific nucleases, for example, RNA-programmable endonucleases, such as Cas9 endonucleases, zinc finger nucleases (ZNFs), homing endonucleases, or transcriptional activator-like element nucleases (TALENs).</p>
<p id="p0005" num="0005">The strategies, methods, and reagents of the present disclosure represent, in some aspects, an improvement over previous methods for assaying nuclease specificity. For example, some previously reported methods for determining nuclease target site specificity<!-- EPO <DP n="2"> --> profiles by screening libraries of nucleic acid molecules comprising candidate target sites relied on a "two-cut" <i>in vitro</i> selection method which requires indirect reconstruction of target sites from sequences of two half-sites resulting from two adjacent cuts of the nuclease of a library member nucleic acid (see <i>e.g.,</i> <patcit id="pcit0002" dnum="WO2013066438A"><text>PCT Application WO 2013/066438</text></patcit>; and <nplcit id="ncit0001" npl-type="s"><text>Pattanayak, V., Ramirez, C.L., Joung, J.K. &amp; Liu, D.R. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nature methods 8, 765-770 (2011</text></nplcit>),). In contrast to such "two-cut" strategies, the methods of the present disclosure utilize an optimized "one cut" screening strategy, which allows for the identification of library members that have been cut at least once by the nuclease. As explained in more detail elsewhere herein, the "one-cut" selection strategies provided herein are compatible with single end high-throughput sequencing methods and do not require computational reconstruction of cleaved target sites from cut half-sites, thus streamlining the nuclease profiling process.</p>
<p id="p0006" num="0006">Some aspects of this disclosure provide <i>in vitro</i> selection methods for evaluating the cleavage specificity of endonucleases and for selecting nucleases with a desired level of specificity. Such methods are useful, for example, for characterizing an endonuclease of interest and for identifying a nuclease exhibiting a desired level of specificity, for example, for identifying a highly specific endonuclease for clinical applications.</p>
<p id="p0007" num="0007">Some aspects of this disclosure provide methods of identifying suitable nuclease target sites that are sufficiently different from any other site within a genome to achieve specific cleavage by a given nuclease without any or at least minimal off-target cleavage. Such methods are useful for identifying candidate nuclease target sites that can be cleaved with high specificity on a genomic background, for example, when choosing a target site for genomic manipulation <i>in vitro</i> or <i>in vivo.</i></p>
<p id="p0008" num="0008">Some aspects of this disclosure provide methods of evaluating, selecting, and/or designing site-specific nucleases with enhanced specificity as compared to current nucleases. For example, provided herein are methods that are useful for selecting and/or designing site-specific nucleases with minimal off-target cleavage activity, for example, by designing variant nucleases with binding domains having decreased binding affinity, by lowering the final concentration of the nuclease, by choosing target sites that differ by at least three base pairs from their closest sequence relatives in the genome, and, in the case of RNA-programmable nucleases, by selecting a guide RNA that results in the fewest off-target sites being bound and/or cut.<!-- EPO <DP n="3"> --></p>
<p id="p0009" num="0009">Compositions and kits useful in the practice of the methods described herein are also provided.</p>
<p id="p0010" num="0010">In a first aspect, the invention provides a method for identifying a target site of a nuclease the method comprising (a) providing a nuclease that cuts a double-stranded nucleic acid target site, wherein cutting of the target site results in cut nucleic acid strands comprising a 5' phosphate moiety; (b) contacting the nuclease of (a) with a library of candidate nucleic acid molecules, wherein each nucleic acid molecule comprises a concatemer of a sequence comprising a candidate nuclease target site and a constant insert sequence of at least 10 and not more than 80 nucleotides, under conditions suitable for the nuclease to cut a candidate nucleic acid molecule comprising a target site of the nuclease; and (c) identifying nuclease target sites cut by the nuclease in (b) by determining the sequence of an uncut nuclease target site on the nucleic acid strand that was cut by the nuclease in step (b), wherein the determining of step (c) comprises (i) ligating a first nucleic acid adapter to the 5' end of a nucleic acid strand that was cut by the nuclease in step (b) via 5'-phosphate-dependent ligation, and (ii) amplifying a fragment of the concatemer cut by the nuclease that comprises an uncut target site via a PCR reaction using a PCR primer that hybridizes with the adapter and a PCR primer that hybridizes with the constant insert sequence. In some embodiments, the nuclease creates blunt ends. In some embodiments, the nuclease creates a 5' overhang. In some embodiments, the nucleic acid adapter is provided in double-stranded form. In some embodiments, the 5'-phosphate-dependent ligation is a blunt end ligation. In some embodiments, the method comprises filling in the 5'-overhang before ligating the first nucleic acid adapter to the nucleic acid strand that was cut by the nuclease. In some embodiments, the method further comprises enriching the amplified nucleic acid molecules for molecules comprising a single uncut target sequence. In some embodiments, the step of enriching comprises a size fractionation. In some embodiments, the determining of step (c) comprises sequencing the nucleic acid strand that was cut by the nuclease in step (b), or a copy thereof obtained via PCR. In some embodiments, the library of candidate nucleic acid molecules comprises at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, or at least 10<sup>12</sup> different candidate nuclease cleavage sites. In some embodiments, the nuclease is a therapeutic nuclease which cuts a specific nuclease target site in a gene associated with a disease. In some embodiments, the method further comprises determining a maximum concentration of the therapeutic nuclease at which the therapeutic nuclease cuts the specific nuclease target site, and does not cut more than 10, more than 5, more than 4, more than 3, more than 2, more than 1, or no additional nuclease target sites. The therapeutic nuclease can be administered to<!-- EPO <DP n="4"> --> a subject in an amount effective to generate a final concentration equal or lower than the maximum concentration. In some embodiments, the nuclease is an RNA-programmable nuclease that forms a complex with an RNA molecule, and wherein the nuclease:RNA complex specifically binds a nucleic acid sequence complementary to the sequence of the RNA molecule. In some embodiments, the RNA molecule is a single-guide RNA (sgRNA). In some embodiments, the sgRNA comprises 5-50 nucleotides, 10-30 nucleotides, 15-25 nucleotides, 18-22 nucleotides, 19-21 nucleotides, <i>e.g</i>., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the nuclease is a Cas9 nuclease. In some embodiments, the nuclease target site comprises a [sgRNA-complementary sequence]-[protospacer adjacent motif (PAM)] structure, and the nuclease cuts the target site within the sgRNA-complementary sequence. In some embodiments, the sgRNA-complementary sequence comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the nuclease comprises an unspecific nucleic acid cleavage domain. In some embodiments, the nuclease comprises a FokI cleavage domain. In some embodiments, the nuclease comprises a nucleic acid cleavage domain that cleaves a target sequence upon cleavage domain dimerization. In some embodiments, the nuclease comprises a binding domain that specifically binds a nucleic acid sequence. In some embodiments, the binding domain comprises a zinc finger. In some embodiments, the binding domain comprises at least 2, at least 3, at least 4, or at least 5 zinc fingers. In some embodiments, the nuclease is a Zinc Finger Nuclease. In some embodiments, the binding domain comprises a Transcriptional Activator-Like Element. In some embodiments, the nuclease is a Transcriptional Activator-Like Element Nuclease (TALEN). In some embodiments, the nuclease is an organic compound. In some embodiments, the nuclease comprises an enediyne functional group. In some embodiments, the nuclease is an antibiotic. In some embodiments, the compound is dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof. In some embodiments, the nuclease is a homing endonuclease.</p>
<p id="p0011" num="0011">Some aspects of this disclosure provide libraries of nucleic acid molecules, in which each nucleic acid molecule comprises a concatemer of a sequence comprising a candidate nuclease target site and a constant insert sequence of 10-100 nucleotides. In some embodiments, the constant insert sequence is at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, or at least 95 nucleotides long. In some embodiments, the constant insert sequence is not more than 15, not more than 20, not more than 25, not more than 30, not<!-- EPO <DP n="5"> --> more than 35, not more than 40, not more than 45, not more than 50, not more than 55, not more than 60, not more than 65, not more than 70, not more than 75, not more than 80, or not more than 95 nucleotides long. In some embodiments, the candidate nuclease target sites are sites that can be cleaved by an RNA-programmable nuclease, a Zinc Finger Nuclease (ZFN), a Transcription Activator-Like Effector Nuclease (TALEN), a homing endonuclease, an organic compound nuclease, or an enediyne antibiotic (e.g., dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin). In some embodiments, the candidate nuclease target site can be cleaved by a Cas9 nuclease. In some embodiments, the library comprises at least 10<sup>5</sup>, at least 10<sup>6</sup>, at least 10<sup>7</sup>, at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, or at least 10<sup>12</sup> different candidate nuclease target sites. In some embodiments, the library comprises nucleic acid molecules of a molecular weight of at least 0.5kDa, at least 1 kDa, at least 2 kDa, at least 3 kDa, at least 4 kDa, at least 5 kDa, at least 6 kDa, at least 7 kDa, at least 8 kDa, at least 9 kDa, at least 10 kDa, at least 12 kDa, or at least 15kDa. In some embodiments, the library comprises candidate nuclease target sites that are variations of a known target site of a nuclease of interest. In some embodiments, the variations of a known nuclease target site comprise 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, or 2 or fewer mutations as compared to a known nuclease target site. In some embodiments, the variations differ from the known target site of the nuclease of interest by more than 5%, more than 10%, more than 15%, more than 20%, more than 25%, or more than 30% on average, distributed binomially. In some embodiments, the variations differ from the known target site by no more than 10%, no more than 15%, no more than 20%, no more than 25%, nor more than 30%, no more than 40%, or no more than 50% on average, distributed binomially. In some embodiments, the nuclease of interest is a Cas9 nuclease, a zinc finger nuclease, a TALEN, a homing endonuclease, an organic compound nuclease, or an enediyne antibiotic (<i>e.g.</i>, dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin). In some embodiments, the candidate nuclease target sites are Cas9 nuclease target sites that comprise a [sgRNA-complementary sequence]-[PAM] structure, wherein the sgRNA-complementary sequence comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides.</p>
<p id="p0012" num="0012">According to a second aspect, the invention provides a methodof selecting a nuclease that specifically cuts a consensus target site from a plurality of nucleases,the method comprising (a) providing a plurality of candidate nucleases that cut the same consensus sequence; (b) for each of the candidate nucleases of step (a), identifying a nuclease target site cleaved by the candidate nuclease that differ from the consensus target site using a method<!-- EPO <DP n="6"> --> provided herein; (c) selecting a nuclease based on the nuclease target site(s) identified in step (b), which cleaves the consensus target site with the highest specificity. In some embodiments, the nuclease that cleaves the consensus target site with the highest specificity is the candidate nuclease that cleaves the lowest number of target sites that differ from the consensus site. In some embodiments, the candidate nuclease that cleaves the consensus target site with the highest specificity is the candidate nuclease that cleaves the lowest number of target sites that are different from the consensus site in the context of a target genome. In some embodiments, the candidate nuclease selected in step (c) is a nuclease that does not cleave any target site other than the consensus target site. In some embodiments, the candidate nuclease selected in step (c) is a nuclease that does not cleave any target site other than the consensus target site within the genome of a subject at a therapeutically effective concentration of the nuclease. In some embodiments, the nuclease selected in step (c) cleaves a genome <i>in vitro.</i> Also disclosed is a further step of contacting a genome with the nuclease selected in step (c). In some embodiments, the genome is a vertebrate, mammalian, human, non-human primate, rodent, mouse, rat, hamster, goat, sheep, cattle, dog, cat, reptile, amphibian, fish, nematode, insect, or fly genome. In some embodiments, the genome is within a living cell. In some embodiments disclosed herein, the genome is within a subject. In some embodiments, the consensus target site is within an allele that is associated with a disease or disorder. In some embodiments disclosed herein, cleavage of the consensus target site results in treatment or prevention of a disease or disorder, <i>e.g</i>., amelioration or prevention of at least one sign and/or symptom of the disease or disorder. In some embodiments disclosed herein, cleavage of the consensus target site results in the alleviation of a sign and/or symptom of the disease or disorder. In some embodiments disclosed herein, cleavage of the consensus target site results in the prevention of the disease or disorder. In some embodiments, the disease is HIV/AIDS. In some embodiments, the allele is a CCR5 allele. In some embodiments, the disease is a proliferative disease. In some embodiments, the disease is cancer. In some embodiments, the allele is a VEGFA allele.</p>
<p id="p0013" num="0013">Some aspects of this disclosure provide isolated nucleases that have been selected according to a method provided herein. In some embodiments, the nuclease has been engineered to cleave a target site within a genome. In some embodiments, the nuclease is a Cas9 nuclease comprising an sgRNA that is complementary to the target site within the genome. In some embodiments, the nuclease is a Zinc Finger Nuclease (ZFN) or a Transcription Activator-Like Effector Nuclease (TALEN), a homing endonuclease, or an organic compound nuclease (e.g., an enediyne, an antibiotic nuclease, dynemicin,<!-- EPO <DP n="7"> --> neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof). In some embodiments, the nuclease has been selected based on cutting no other candidate target site, not more than one candidate target site, not more than two candidate target sites, not more than three candidate target sites, not more than four candidate target sites, not more than five candidate target sites, not more than six candidate target sites, not more than seven candidate target sites, not more than eight candidate target sites, not more than eight candidate target sites, not more than nine candidate target sites, or not more than ten candidate target sites in addition to its known nuclease target site.</p>
<p id="p0014" num="0014">Some aspects of this disclosure provide kits comprising a library of nucleic acid molecules comprising candidate nuclease target sites as provided herein. Some aspects of this disclosure provide kits comprising an isolated nuclease as provided herein. In some embodiments, the nuclease is a Cas9 nuclease. In some embodiments, the kit further comprises a nucleic acid molecule comprising a target site of the isolated nuclease. In some embodiments, the kit comprises an excipient and instructions for contacting the nuclease with the excipient to generate a composition suitable for contacting a nucleic acid with the nuclease. In some embodiments, the composition is suitable for contacting a nucleic acid within a genome. In some embodiments, the composition is suitable for contacting a nucleic acid within a cell. In some embodiments, the composition is suitable for contacting a nucleic acid within a subject. In some embodiments, the excipient is a pharmaceutically acceptable excipient.</p>
<p id="p0015" num="0015">Some aspects of this disclosure provide pharmaceutical compositions that are suitable for administration to a subject. In some embodiments, the composition comprises an isolated nuclease as provided herein. In some embodiments, the composition comprises a nucleic acid encoding such a nuclease. In some embodiments, the composition comprises a pharmaceutically acceptable excipient.</p>
<p id="p0016" num="0016">Other advantages, features, and uses of the invention will be apparent from the detailed description of certain non-limiting embodiments of the invention; the drawings, which are schematic and not intended to be drawn to scale; and the claims.</p>
<heading id="h0003"><b>BRIEF DESCRIPTION OF THE DRAWINGS</b></heading>
<p id="p0017" num="0017">
<ul id="ul0001" list-style="none" compact="compact">
<li><figref idref="f0001 f0002"><b>Figure 1</b></figref><b>. <i>In vitro</i> selection overview.</b> (A) Cas9 complexed with a short guide RNA (sgRNA) recognizes -20 bases of a target DNA substrate that is complementary to the sgRNA sequence and cleaves both DNA strands. The white triangles represent cleavage locations. (B) A modified version of our previously described <i>in vitro</i> selection was<!-- EPO <DP n="8"> --> used to comprehensively profile Cas9 specificity. A concatemeric pre-selection DNA library in which each molecule contains one of 10<sup>12</sup> distinct variants of a target DNA sequence (white rectangles) was generated from synthetic DNA oligonucleotides by ligation and rolling-circle amplification. This library was incubated with a Cas9:sgRNA complex of interest. Cleaved library members contain 5' phosphate groups (circles with "P") and therefore are substrates for adapter ligation and PCR. The resulting amplicons were subjected to high-throughput DNA sequencing and computational analysis.</li>
<li><figref idref="f0003 f0004 f0005"><b>Figure 2</b></figref><b>. <i>In vitro</i> selection results for Cas9:CLTA1 sgRNA.</b> Heat maps<sup>21</sup> show the specificity profiles of Cas9:CLTA1 sgRNA v2.1 under enzyme-limiting conditions (A, B), <b>Cas9:CLTA1</b> sgRNA v1.0 under enzyme-saturating conditions (C, D), and <b>Cas9:CLTA1</b> sgRNA v2.1 under enzyme-saturating conditions (E, F). Heat maps show all post-selection sequences (A, C, E) or only those sequences containing a single mutation in the 20-base pair sgRNA-specified target site and two-base pair PAM (B, D, F). Specificity scores of 1.0 and -1.0 corresponds to 100% enrichment for and against, respectively, a particular base pair at a particular position. Black boxes denote the intended target nucleotides. (G) Effect of Cas9:sgRNA concentration on specificity. Positional specificity changes between enzyme-limiting (200 nM DNA, 100 nM Cas9:sgRNA v2.1) and enzyme-saturating (200 nM DNA, 1000 nM Cas9:sgRNA v2.1) conditions, normalized to the maximum possible change in positional specificity, are shown for CLTA1. (H) Effect of sgRNA architecture on specificity. Positional specificity changes between sgRNA v1.0 and sgRNA v2.1 under enzyme-saturating conditions, normalized to the maximum possible change in positional specificity, are shown for CLTA1. See <figref idref="f0014 f0015 f0016 f0017 f0018">Figures 6-8</figref>, <figref idref="f0050">25</figref>, and <figref idref="f0052">26</figref> for corresponding data for CLTA2, CLTA3, and CLTA4. Sequence Identifiers: The sgRNA sequences shown in (A-F) correspond to SEQ ID NO:1.</li>
<li><figref idref="f0006 f0007 f0008"><b>Figure 3</b></figref><b>. Target sites profiled in this study.</b> (A) The 5' end of the sgRNA has 20 nucleotides that are complementary to the target site. The target site contains an NGG motif (PAM) adjacent to the region of RNA:DNA complementarity. (B) Four human clathrin gene (CLTA) target sites are shown. (C, D) Four human clathrin gene (CLTA) target sites are shown with sgRNAs. sgRNA v1.0 is shorter than sgRNA v2.1. The PAM is shown for each site. The non-PAM end of the target site corresponds to the 5' end of the sgRNA. Sequence Identifiers: The sequences shown in (B), from top to bottom, are SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; and SEQ ID NO:7. The sequences shown in (C), from top to bottom, are SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15;<!-- EPO <DP n="9"> --> SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; and SEQ ID NO:19. The sequences shown in (D), from top to bottom, are SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; and SEQ ID NO:31.</li>
<li><figref idref="f0009"><b>Figure 4</b></figref><b>. Cas9:guide RNA cleavage of on-target DNA sequences <i>in vitro.</i></b> Discrete DNA cleavage assays on an approximately 1-kb linear substrate were performed with 200 nM on-target site and 100 nM Cas9:v1.0 sgRNA, 100 nM Cas9:v2.1 sgRNA, 1000 nM Cas9:v1.0 sgRNA, and 1000 nM Cas9:v2.1 sgRNA for each of four CLTA target sites. For CLTA1, CLTA2, and CLTA4, Cas9:v2.1 sgRNA shows higher activity than Cas9:v1.0 sgRNA. For CLTA3, the activities of the Cas9:v1.0 sgRNA and Cas9:v2.1 sgRNA were comparable.</li>
<li><figref idref="f0010 f0011 f0012"><b>Figure 5</b></figref><b>. <i>In vitro</i> selection results for four target sites.</b> <i>In vitro</i> selections were performed on 200 nM pre-selection library with 100 nM Cas9:sgRNA v2.1, 1000 nM Cas9:sgRNA v1.0, or 1000 nM Cas9:sgRNA v2.1. (A) Post-selection PCR products are shown for the 12 selections performed. DNA containing 1.5 repeats were quantified for each selection and pooled in equimolar amounts before gel purification and sequencing. (B-E) Distributions of mutations are shown for pre-selection (black) and post-selection libraries (colored). The post-selection libraries are enriched for sequences with fewer mutations than the pre-selection libraries. Mutations are counted from among the 20 base pairs specified by the sgRNA and the two-base pair PAM. P-values are &lt; 0.01 for all pairwise comparisons between distributions in each panel. <i>P</i>-values were calculated using t-tests, assuming unequal size and unequal variance.</li>
<li><figref idref="f0013 f0014"><b>Figure 6</b></figref><b>. <i>In vitro</i> selection results for Cas9:CLTA2 sgRNA.</b> Heat maps<sup>24</sup> show the specificity profiles of Cas9:CLTA2 sgRNA v2.1 under enzyme-limiting conditions (A, B), Cas9:CLTA2 sgRNA v1.0 under enzyme-excess conditions (C, D), and Cas9:CLTA2 sgRNA v2.1 under enzyme-excess conditions (E, F). Heat maps show all post-selection sequences (A, C, E) or only those sequences containing a single mutation in the 20-base pair sgRNA-specified target site and two-base pair PAM (B, D, F). Specificity scores of 1.0 and - 1.0 corresponds to 100% enrichment for and against, respectively, a particular base pair at a particular position. Black boxes denote the intended target nucleotides. Sequence Identifiers: The sgRNA sequences shown in (A-F) correspond to SEQ ID NO:32.</li>
<li><figref idref="f0015 f0016"><b>Figure 7</b></figref><b>. <i>In vitro</i> selection results for Cas9:CLTA3 sgRNA.</b> Heat maps<sup>24</sup> show the specificity profiles of Cas9:CLTA3 sgRNA v2.1 under enzyme-limiting conditions (A, B), Cas9:CLTA3 sgRNA v1.0 under enzyme-excess conditions (C, D), and Cas9:CLTA3<!-- EPO <DP n="10"> --> sgRNA v2.1 under enzyme- saturating conditions (E, F). Heat maps show all post-selection sequences (A, C, E) or only those sequences containing a single mutation in the 20-base pair sgRNA-specified target site and two-base pair PAM (B, D, F). Specificity scores of 1.0 and - 1.0 corresponds to 100% enrichment for and against, respectively, a particular base pair at a particular position. Black boxes denote the intended target nucleotides. Sequence Identifiers: The sgRNA sequences shown in (A-F) correspond to SEQ ID NO:32.</li>
<li><figref idref="f0017 f0018"><b>Figure 8</b></figref><b>. <i>In vitro</i> selection results for Cas9:CLTA4</b> sgRNA. Heat maps<sup>24</sup> show the specificity profiles of Cas9:CLTA4 sgRNA v2.1 under enzyme-limiting conditions (A, B), Cas9:CLTA4 sgRNA v1.0 under enzyme-excess conditions (C, D), and Cas9:CLTA4 sgRNA v2.1 under enzyme- saturating conditions (E, F). Heat maps show all post-selection sequences (A, C, E) or only those sequences containing a single mutation in the 20-base pair sgRNA-specified target site and two-base pair PAM (B, D, F). Specificity scores of 1.0 and - 1.0 corresponds to 100% enrichment for and against, respectively, a particular base pair at a particular position. Black boxes denote the intended target nucleotides. Sequence Identifiers: The sgRNA sequences shown in (A-F) correspond to SEQ ID NO:33.</li>
<li><figref idref="f0019"><b>Figure 9</b></figref><b>. <i>In vitro</i> selection results as sequence logos.</b> Information content is plotted<sup>25</sup> for each target site position (1-20) specified by CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D) sgRNA v2.1 under enzyme-limiting conditions. Positions in the PAM are labelled "PI," "P2," and "P3." Information content is plotted in bits. 2.0 bits indicates absolute specificity and 0 bits indicates no specificity.</li>
<li><figref idref="f0020 f0021"><b>Figure 10</b></figref><b>. Tolerance of mutations distal to the PAM for CLTA1.</b> The maximum specificity scores at each position are shown for the <b>Cas9:CLTA1</b> v2.1 sgRNA selections when considering only those sequences with on-target base pairs in gray, while allowing mutations in the first 1-12 base pairs (A-L). The positions that are not constrained to on-target base pairs are indicated by dark bars. Higher specificity score values indicate higher specificity at a given position. The positions that were not allowed to contain any mutations (gray) were plotted with a specificity score of +1. For all panels, specificity scores were calculated from pre-selection library sequences and post-selection library sequences with an n ≥ 5,130 and n ≥ 74,538, respectively.</li>
<li><figref idref="f0022 f0023"><b>Figure 11</b></figref><b>. Tolerance of mutations distal to the PAM for CLTA2.</b> The maximum specificity scores at each position are shown for the Cas9:CLTA2 v2.1 sgRNA selections when considering only those sequences with on-target base pairs in gray, while allowing mutations in the first 1-12 base pairs (A-L). The positions that are not constrained to on-target base pairs are indicated by dark bars. Higher specificity score values indicate<!-- EPO <DP n="11"> --> higher specificity at a given position. The positions that were not allowed to contain any mutations (gray) were plotted with a specificity score of +1. For all panels, specificity scores were calculated from pre-selection library sequences and post-selection library sequences with an n ≥ 3,190 and n ≥ 25,365, respectively.</li>
<li><figref idref="f0024 f0025"><b>Figure 12</b></figref><b>. Tolerance of mutations distal to the PAM for CLTA3.</b> The maximum specificity scores at each position are shown for the Cas9:CLTA3 v2.1 sgRNA selections when considering only those sequences with on-target base pairs in gray, while allowing mutations in the first 1-12 base pairs (A-L). The positions that are not constrained to on-target base pairs are indicated by dark bars. Higher specificity score values indicate higher specificity at a given position. The positions that were not allowed to contain any mutations (gray) were plotted with a specificity score of +1. For all panels, specificity scores were calculated from pre-selection library sequences and post-selection library sequences with an n ≥ 5,604 and n ≥ 158,424, respectively.</li>
<li><figref idref="f0026 f0027"><b>Figure 13</b></figref><b>. Tolerance of mutations distal to the PAM for CLTA4.</b> The maximum specificity scores at each position are shown for the Cas9:CLTA4 v2.1 sgRNA selections when considering only those sequences with on-target base pairs in gray, while allowing mutations in the first 1-12 base pairs (A-L). The positions that are not constrained to on-target base pairs are indicated by dark bars. Higher specificity score values indicate higher specificity at a given position. The positions that were not allowed to contain any mutations (gray) were plotted with a specificity score of +1. For all panels, specificity scores were calculated from pre-selection library sequences and post-selection library sequences with an n ≥ 2,323 and n ≥ 21,819, respectively.</li>
<li><figref idref="f0028 f0029"><b>Figure 14</b></figref><b>. Tolerance of mutations distal to the PAM in CLTA1 target sites.</b> Distributions of mutations are shown for <i>in vitro</i> selection on 200 nM pre-selection library with 1000 nM <b>Cas9:CLTA1</b> sgRNA v2.1. The number of mutations shown are in a 1-12 base pair target site subsequence farthest from the PAM (A-L) when the rest of the target site, including the PAM, contains only on-target base pairs. The pre-selection and post-selection distributions are similar for up to three base pairs, demonstrating tolerance for target sites with mutations in the three base pairs farthest from the PAM when the rest of the target sites have optimal interactions with the Cas9:sgRNA. For all panels, graphs were generated from pre-selection library sequences and post-selection library sequences with an n ≥ 5,130 and n ≥ 74,538, respectively.</li>
<li><figref idref="f0030 f0031"><b>Figure 15</b></figref><b>. Tolerance of mutations distal to the PAM in CLTA2 target sites.</b> Distributions of mutations are shown for <i>in vitro</i> selection on 200 nM pre-selection<!-- EPO <DP n="12"> --> library with 1000 nM Cas9:CLTA2 sgRNA v2.1. The number of mutations shown are in a 1-12 base pair target site subsequence farthest from the PAM (A-L) when the rest of the target site, including the PAM, contains only on-target base pairs. The pre-selection and post-selection distributions are similar for up to three base pairs, demonstrating tolerance for target sites with mutations in the three base pairs farthest from the PAM when the rest of the target sites have optimal interactions with the Cas9:sgRNA. For all panels, graphs were generated from pre-selection library sequences and post-selection library sequences with an n ≥ 3,190 and n ≥ 21,265, respectively.</li>
<li><figref idref="f0032 f0033"><b>Figure 16</b></figref><b>. Tolerance of mutations distal to PAM in CLTA3 target sites.</b> Distributions of mutations are shown for <i>in vitro</i> selection on 200 nM pre-selection library with 1000 nM Cas9:CLTA3 sgRNA v2.1. The number of mutations shown are in a 1-12 base pair target site subsequence farthest from the PAM (A-L) when the rest of the target site, including the PAM, contains only on-target base pairs. The pre-selection and post-selection distributions are similar for up to three base pairs, demonstrating tolerance for target sites with mutations in the three base pairs farthest from the PAM when the rest of the target sites have optimal interactions with the Cas9:sgRNA. For all panels, graphs were generated from pre-selection library sequences and post-selection library sequences with an n ≥ 5,604 and n ≥ 158,424, respectively.</li>
<li><figref idref="f0034 f0035"><b>Figure 17</b></figref><b>. Tolerance of mutations distal to PAM in CLTA4 target sites.</b> Distributions of mutations are shown for <i>in vitro</i> selection on 200 nM pre-selection library with 1000 nM Cas9:CLTA4 sgRNA v2.1. The number of mutations shown are in a 1-12 base pair target site subsequence farthest from the PAM (A-L) when the rest of the target site, including the PAM, contains only on-target base pairs. The pre-selection and post-selection distributions are similar for up to three base pairs, demonstrating tolerance for target sites with mutations in the three base pairs farthest from the PAM when the rest of the target sites have optimal interactions with the Cas9:sgRNA. For all panels, graphs were generated from pre-selection library sequences and post-selection library sequences with an n ≥ 2,323 and n ≥ 21,819, respectively.</li>
<li><figref idref="f0036 f0037"><b>Figure 18</b></figref><b>. Positional specificity patterns for 100 nM Cas9:sgRNA v2.1.</b> Positional specificity, defined as the sum of the magnitude of the specificity score for each of the four possible base pairs recognized at a certain position in the target site, is plotted for each target site under enzyme-limiting conditions for sgRNA v2.1. The positional specificity is shown as a value normalized to the maximum positional specificity value of the target site.<!-- EPO <DP n="13"> --> Positional specificity is highest at the end of the target site proximal to the PAM and is lowest in the middle of the target site and in the several nucleotides most distal to the PAM</li>
<li><figref idref="f0038 f0039"><b>Figure 19</b></figref><b>. Positional specificity patterns for 1000 nM Cas9:sgRNA v1.0.</b> Positional specificity, defined as the sum of the magnitude of the specificity score for each of the four possible base pairs recognized at a certain position in the target site, is plotted for each target site under enzyme-excess conditions with sgRNA v1.0. The positional specificity is shown as a value normalized to the maximum positional specificity value of the target site. Positional specificity is relatively constant across the target site but is lowest in the middle of the target site and in the several nucleotides most distal to the PAM</li>
<li><figref idref="f0040 f0041"><b>Figure 20</b></figref><b>. Positional specificity patterns for 1000 nM Cas9:sgRNA v2.1.</b> Positional specificity, defined as the sum of the magnitude of the specificity score for each of the four possible base pairs recognized at a certain position in the target site, is plotted for each target site under enzyme-excess conditions with sgRNA v2.1. The positional specificity is shown as a value normalized to the maximum positional specificity value of the target site. Positional specificity is relatively constant across the target site but is lowest in the middle of the target site and in the several nucleotides most distal to the PAM</li>
<li><figref idref="f0042 f0043"><b>Figure 21</b></figref><b>. PAM nucleotide preferences.</b> The abundance in the pre-selection library and post-selection libraries under enzyme-limiting or enzyme-excess conditions are shown for all 16 possible PAM dinucleotides for selections with CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D) sgRNA v2.1. GG dinucleotides increased in abundance in the post-selection libraries, while the other possible PAM dinucleotides decreased in abundance after the selection.</li>
<li><figref idref="f0044 f0045"><b>Figure 22</b></figref><b>. PAM nucleotide preferences for on-target sites.</b> Only post-selection library members containing no mutations in the 20 base pairs specified by the guide RNAs were included in this analysis. The abundance in the pre-selection library and post-selection libraries under enzyme-limiting and enzyme-excess conditions are shown for all 16 possible PAM dinucleotides for selections with CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D) sgRNA v2.1. GG dinucleotides increased in abundance in the post-selection libraries, while the other possible PAM dinucleotides generally decreased in abundance after the selection, although this effect for the enzyme-excess concentrations of Cas9:sgRNA was modest or non-existent for many dinucleotides.</li>
<li><figref idref="f0046 f0047"><b>Figure 23</b></figref><b>. PAM dinucleotide specificity scores.</b> The specificity scores under enzyme-limiting and enzyme-excess conditions are shown for all 16 possible PAM dinucleotides (positions 2 and 3 of the three-nucleotide NGG PAM) for selections with<!-- EPO <DP n="14"> --> CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D) sgRNA v2.1. The specificity score indicates the enrichment of the PAM dinucleotide in the post-selection library relative to the pre-selection library, normalized to the maximum possible enrichment of that dinucleotide. A specificity score of +1.0 indicates that a dinucleotide is 100% enriched in the post-selection library, and a specificity score of -1.0 indicates that a dinucleotide is 100% de-enriched. GG dinucleotides were the most enriched in the post-selection libraries, and AG, GA, GC, GT, and TG show less relative de-enrichment compared to the other possible PAM dinucleotides.</li>
<li><figref idref="f0048 f0049"><b>Figure 24</b></figref><b>. PAM dinucleotide specificity scores for on-target sites.</b> Only post-selection library members containing no mutations in the 20 base pairs specified by the guide RNAs were included in this analysis. The specificity scores under enzyme-limiting and enzyme-excess conditions are shown for all 16 possible PAM dinucleotides (positions 2 and 3 of the three-nucleotide NGG PAM) for selections with CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D) sgRNA v2.1. The specificity score indicates the enrichment of the PAM dinucleotide in the post-selection library relative to the pre-selection library, normalized to the maximum possible enrichment of that dinucleotide. A specificity score of +1.0 indicates that a dinucleotide is 100% enriched in the post-selection library, and a specificity score of - 1.0 indicates that a dinucleotide is 100% de-enriched. GG dinucleotides were the most enriched in the post-selection libraries, AG and GA nucleotides were neither enriched or de-enriched in at least one selection condition, and GC, GT, and TG show less relative de-enrichment compared to the other possible PAM dinucleotides.</li>
<li><figref idref="f0050 f0051"><b>Figure 25</b></figref><b>. Effects of Cas9:sgRNA concentration on specificity.</b> Positional specificity changes between enzyme-limiting (200 nM DNA, 100 nM Cas9:sgRNA v2.1) and enzyme-excess (200 nM DNA, 1000 nM Cas9:sgRNA v2.1) conditions are shown for selections with sgRNAs targeting CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D) target sites. Lines indicate the maximum possible change in positional specificity for a given position. The highest changes in specificity occur proximal to the PAM as enzyme concentration is increased.</li>
<li><figref idref="f0052 f0053"><b>Figure 26</b></figref><b>. Effects of sgRNA architecture on specificity.</b> Positional specificity changes between Cas9:sgRNA v1.0 and Cas9:sgRNA v2.1 under enzyme-excess (200 nM DNA, 1000 nM Cas9:sgRNA v2.1) conditions are shown for selections with sgRNAs targeting CLTA1 (A), CLTA2 (B), CLTA3 (C), and CLTA4 (D) target sites. Lines indicate the maximum possible change in positional specificity for a given position.</li>
<li><figref idref="f0054"><b>Figure 27</b></figref><b>. Cas9:guide RNA cleavage of off-target DNA sequences</b> <i><b>in vitro.</b></i> Discrete DNA cleavage assays on a 96-bp linear substrate were performed with 200<!-- EPO <DP n="15"> --> nM DNA and 1000 nM Cas9:CLTA4 v2.1 sgRNA for the on-target CLTA4 site (CLTA4-0) and five CLTA4 off-target sites identified by <i>in vitro</i> selection. Enrichment values shown are from the <i>in vitro</i> selection with 1000 nM Cas9:CLTA4 v2.1 sgRNA. CLTA4-1 and CLTA4-3 were the most highly enriched sequences under these conditions. CLTA4-2a, CLTA4-2b, and CLTA4-2c are two-mutation sequences that represent a range of enrichment values from high enrichment to no enrichment to high de-enrichment. Lowercase letters indicate mutations relative to the on-target CLTA4 site. The enrichment values are qualitatively consistent with the observed amount of cleavage <i>in vitro.</i> Sequence Identifiers: The sequences shown from top to bottom, are SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; and SEQ ID NO:39.</li>
<li><figref idref="f0055"><b>Figure 28</b></figref><b>. Effect of guide RNA architecture and Cas9:sgRNA concentration on <i>in vitro</i> cleavage of an off-target site.</b> Discrete DNA cleavage assays on a 96-bp linear substrate were performed with 200 nM DNA and 100 nM Cas9:v1.0 sgRNA, 100 nM Cas9:v2.1 sgRNA, 1000 nM Cas9:v1.0 sgRNA, or 1000 nM Cas9:v2.1 sgRNA for the CLTA4-3 off-target site (5' GggGATGTAGTGTTTCCACtGGG 3' (SEQ ID NO:39)-mutations are shown in lowercase letters). DNA cleavage is observed under all four conditions tested, and cleavage rates are higher under enzyme-excess conditions, or with v2.1 sgRNA compared with v1.0 sgRNA.</li>
</ul></p>
<heading id="h0004"><b>DEFINITIONS</b></heading>
<p id="p0018" num="0018">As used herein and in the claims, the singular forms "a," "an," and "the" include the singular and the plural reference unless the context clearly indicates otherwise. Thus, for example, a reference to "an agent" includes a single agent and a plurality of such agents.</p>
<p id="p0019" num="0019">The term "Cas9" or "Cas9 nuclease" refers to an RNA-guided nuclease comprising a Cas9 protein, or a fragment thereof. A Cas9 nuclease is also referred to sometimes as a casn1 nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease. CRISPR is an adaptive immune system that provides protection against mobile genetic elements (e.g., viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided<!-- EPO <DP n="16"> --> processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3'-5' exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNA species. However, single guide RNAs ("sgRNA", or simply "gNRA") can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA molecule. See, <i>e.g.,</i> <nplcit id="ncit0002" npl-type="s"><text>Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. Science 337:816-821(2012</text></nplcit>). Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self. Cas9 nuclease sequences and structures are well known to those of skill in the art (see, <i>e.g.,</i> "<nplcit id="ncit0003" npl-type="s"><text>Complete genome sequence of an M1 strain of Streptococcus pyogenes." Ferretti J.J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P., Qian Y., Jia H.G., Najar F.Z., Ren Q., Zhu H., Song L. expand/collapse author list McLaughlin R.E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001</text></nplcit>); "<nplcit id="ncit0004" npl-type="s"><text>CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E., Chylinski K., Sharma C.M., Gonzales K., Chao Y., Pirzada Z.A., Eckert M.R., Vogel J., Charpentier E., Nature 471:602-607(2011</text></nplcit>); and "<nplcit id="ncit0005" npl-type="s"><text>A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. Science 337:816-821(2012</text></nplcit>),). Cas9 orthologs have been described in various species, including, but not limited to, <i>S. pyogenes</i> and <i>S. thermophilus.</i> Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in <nplcit id="ncit0006" npl-type="s"><text>Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737</text></nplcit>. In some embodiments, proteins comprising Cas9 or fragments thereof proteins are referred to as "Cas9 variants." A Cas9 variant shares homology to Cas9, or a fragment thereof. For example a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to wild type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (<i>e.g.,</i> a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to the corresponding<!-- EPO <DP n="17"> --> fragment of wild type Cas9. In some embodiments, wild type Cas9 corresponds to Cas9 from <i>Streptococcus pyogenes</i> (NCBI Reference Sequence: NC_017053.1, SEQ ID NO:40 (nucleotide); SEQ ID NO:41 (amino acid)).
<img id="ib0001" file="imgb0001.tif" wi="151" he="218" img-content="dna" img-format="tif"/><!-- EPO <DP n="18"> -->
<img id="ib0002" file="imgb0002.tif" wi="151" he="104" img-content="dna" img-format="tif"/>
<img id="ib0003" file="imgb0003.tif" wi="151" he="82" img-content="dna" img-format="tif"/></p>
<p id="p0020" num="0020">The term "concatemer," as used herein in the context of nucleic acid molecules, refers to a nucleic acid molecule that contains multiple copies of the same DNA sequences linked in a series. For example, a concatemer comprising ten copies of a specific sequence of nucleotides (e.g., [XYZ]<sub>10</sub>), would comprise ten copies of the same specific sequence linked to each other in series, <i>e.g.,</i> 5'-XYZXYZXYZXYZXYZXYZXYZXYZXYZXYZ -3'. A concatemer may comprise any<!-- EPO <DP n="19"> --> number of copies of the repeat unit or sequence, <i>e.g.,</i> at least 2 copies, at least 3 copies, at least 4 copies, at least 5 copies, at least 10 copies, at least 100 copies, at least 1000 copies, <i>etc.</i> An example of a concatemer of a nucleic acid sequence comprising a nuclease target site and a constant insert sequence would be [(target site)-(constant insert sequence)]<sub>300</sub>. A concatemer may be a linear nucleic acid molecule, or may be circular.</p>
<p id="p0021" num="0021">The terms "conjugating," "conjugated," and "conjugation" refer to an association of two entities, for example, of two molecules such as two proteins, two domains (<i>e.g.,</i> a binding domain and a cleavage domain), or a protein and an agent, <i>e.g.,</i> a protein binding domain and a small molecule. In some aspects, the association is between a protein (<i>e.g.,</i> RNA-programmable nuclease) and a nucleic acid (<i>e.g.,</i> a guide RNA). The association can be, for example, via a direct or indirect (<i>e.g.</i>, via a linker) covalent linkage or via noncovalent interactions. In some embodiments, the association is covalent. In some embodiments, two molecules are conjugated via a linker connecting both molecules. For example, in some embodiments where two proteins are conjugated to each other, <i>e.g.,</i> a binding domain and a cleavage domain of an engineered nuclease, to form a protein fusion, the two proteins may be conjugated via a polypeptide linker, <i>e.g.,</i> an amino acid sequence connecting the C-terminus of one protein to the N-terminus of the other protein.</p>
<p id="p0022" num="0022">The term "consensus sequence," as used herein in the context of nucleic acid sequences, refers to a calculated sequence representing the most frequent nucleotide residues found at each position in a plurality of similar sequences. Typically, a consensus sequence is determined by sequence alignment in which similar sequences are compared to each other and similar sequence motifs are calculated. In the context of nuclease target site sequences, a consensus sequence of a nuclease target site may, in some embodiments, be the sequence most frequently bound, or bound with the highest affinity, by a given nuclease. With respect to RNA-programmable nuclease (e.g., Cas9) target site sequences, the consensus sequence may, in some embodiments, be the sequence or region to which a gRNA, or a plurality of gRNAs, is expected or designed to bind, <i>e.g</i>., based on complementary base pairing.</p>
<p id="p0023" num="0023">The term "effective amount," as used herein, refers to an amount of a biologically active agent that is sufficient to elicit a desired biological response. For example, in some embodiments, an effective amount of a nuclease may refer to the amount of the nuclease that is sufficient to induce cleavage of a target site specifically bound and cleaved by the nuclease. As will be appreciated by the skilled artisan, the effective amount of an agent, <i>e.g.,</i> a nuclease, a hybrid protein, or a polynucleotide, may vary depending on<!-- EPO <DP n="20"> --> various factors as, for example, on the desired biological response, the specific allele, genome, target site, cell, or tissue being targeted, and the agent being used.</p>
<p id="p0024" num="0024">The term "enediyne," as used herein, refers to a class of bacterial natural products characterized by either nine- and ten-membered rings containing two triple bonds separated by a double bond (see, <i>e.g.,</i> <nplcit id="ncit0007" npl-type="s"><text>K. C. Nicolaou; A. L. Smith; E. W. Yue (1993). "Chemistry and biology of natural and designed enediynes". PNAS 90 (13): 5881-5888</text></nplcit>). Some enediynes are capable of undergoing Bergman cyclization, and the resulting diradical, a 1,4-dehydrobenzene derivative, is capable of abstracting hydrogen atoms from the sugar backbone of DNA which results in DNA strand cleavage (see, <i>e.g.,</i> <nplcit id="ncit0008" npl-type="s"><text>S. Walker; R. Landovitz; W.D. Ding; G.A. Ellestad; D. Kahne (1992). "Cleavage behavior of calicheamicin gamma 1 and calicheamicin T". Proc Natl Acad Sci U.S.A. 89 (10): 4608-12</text></nplcit>). Their reactivity with DNA confers an antibiotic character to many enediynes, and some enediynes are clinically investigated as anticancer antibiotics. Nonlimiting examples of enediynes are dynemicin, neocarzinostatin, calicheamicin, esperamicin (see, <i>e.g.,</i> <nplcit id="ncit0009" npl-type="s"><text>Adrian L. Smith and K. C. Bicolaou, "The Enediyne Antibiotics" J. Med. Chem., 1996, 39 (11), pp 2103-2117</text></nplcit>; and <nplcit id="ncit0010" npl-type="b"><text>Donald Borders, "Enediyne antibiotics as antitumor agents," Informa Healthcare; 1st edition (November 23, 1994, ISBN-10: 0824789385</text></nplcit>).</p>
<p id="p0025" num="0025">The term "homing endonuclease," as used herein, refers to a type of restriction enzymes typically encoded by introns or inteins <nplcit id="ncit0011" npl-type="s"><text>Edgell DR (February 2009). "Selfish DNA: homing endonucleases find a home". Curr Biol 19 (3): R115-R117</text></nplcit>; <nplcit id="ncit0012" npl-type="s"><text>Jasin M (Jun 1996). "Genetic manipulation of genomes with rare-cutting endonucleases". Trends Genet 12 (6): 224-8</text></nplcit>; <nplcit id="ncit0013" npl-type="s"><text>Burt A, Koufopanou V (December 2004). "Homing endonuclease genes: the rise and fall and rise again of a selfish element". Curr Opin Genet Dev 14 (6): 609-15</text></nplcit>. Homing endonuclease recognition sequences are long enough to occur randomly only with a very low probability (approximately once every 7×10<sup>10</sup> bp), and are normally found in only one instance per genome.</p>
<p id="p0026" num="0026">The term "library," as used herein in the context of nucleic acids or proteins, refers to a population of two or more different nucleic acids or proteins, respectively. For example, a library of nuclease target sites comprises at least two nucleic acid molecules comprising different nuclease target sites. In some embodiments, a library comprises at least 10<sup>1</sup>, at least 10<sup>2</sup>, at least 10<sup>3</sup>, at least 10<sup>4</sup>, at least 10<sup>5</sup>, at least 10<sup>6</sup>, at least 10<sup>7</sup>, at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, at least 10<sup>12</sup>, at least 10<sup>13</sup>, at least 10<sup>14</sup>, or at least 10<sup>15</sup> different nucleic acids or proteins. In some embodiments, the members of the library may comprise randomized sequences, for example, fully or partially randomized sequences. In<!-- EPO <DP n="21"> --> some embodiments, the library comprises nucleic acid molecules that are unrelated to each other, <i>e.g.,</i> nucleic acids comprising fully randomized sequences. In other embodiments, at least some members of the library may be related, for example, they may be variants or derivatives of a particular sequence, such as a consensus target site sequence.</p>
<p id="p0027" num="0027">The term "linker," as used herein, refers to a chemical group or a molecule linking two adjacent molecules or moieties, <i>e.g</i>., a binding domain and a cleavage domain of a nuclease. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two. In some embodiments, the linker is an amino acid or a plurality of amino acids (<i>e.g.,</i> a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety.</p>
<p id="p0028" num="0028">The term "nuclease," as used herein, refers to an agent, for example a protein or a small molecule, capable of cleaving a phosphodiester bond connecting nucleotide residues in a nucleic acid molecule. In some embodiments, a nuclease is a protein, <i>e.g.,</i> an enzyme that can bind a nucleic acid molecule and cleave a phosphodiester bond connecting nucleotide residues within the nucleic acid molecule. A nuclease may be an endonuclease, cleaving a phosphodiester bonds within a polynucleotide chain, or an exonuclease, cleaving a phosphodiester bond at the end of the polynucleotide chain. In some embodiments, a nuclease is a site-specific nuclease, binding and/or cleaving a specific phosphodiester bond within a specific nucleotide sequence, which is also referred to herein as the "recognition sequence," the "nuclease target site," or the "target site." In some embodiments, a nuclease is a RNA-guided (<i>i.e.,</i> RNA-programmable) nuclease, which complexes with (<i>e.g.,</i> binds with) an RNA having a sequence that complements a target site, thereby providing the sequence specificity of the nuclease. In some embodiments, a nuclease recognizes a single stranded target site, while in other embodiments, a nuclease recognizes a double-stranded target site, for example a double-stranded DNA target site. The target sites of many naturally occurring nucleases, for example, many naturally occurring DNA restriction nucleases, are well known to those of skill in the art. In many cases, a DNA nuclease, such as EcoRI, HindIII, or BamHI, recognize a palindromic, double-stranded DNA target site of 4 to 10 base pairs in length, and cut each of the two DNA strands at a specific position within the target site. Some endonucleases cut a double-stranded nucleic acid target site symmetrically, <i>i.e.,</i> cutting both strands at the same position so that the ends comprise base-paired nucleotides, also referred to herein as blunt ends. Other endonucleases cut a double-stranded nucleic acid target sites asymmetrically, <i>i.e.,</i> cutting each strand at a different position so that the ends<!-- EPO <DP n="22"> --> comprise unpaired nucleotides. Unpaired nucleotides at the end of a double-stranded DNA molecule are also referred to as "overhangs," <i>e.g</i>., as "5'-overhang" or as "3'-overhang," depending on whether the unpaired nucleotide(s) form(s) the 5' or the 3' end of the respective DNA strand. Double-stranded DNA molecule ends ending with unpaired nucleotide(s) are also referred to as sticky ends, as they can "stick to" other double-stranded DNA molecule ends comprising complementary unpaired nucleotide(s). A nuclease protein typically comprises a "binding domain" that mediates the interaction of the protein with the nucleic acid substrate, and also, in some cases, specifically binds to a target site, and a "cleavage domain" that catalyzes the cleavage of the phosphodiester bond within the nucleic acid backbone. In some embodiments a nuclease protein can bind and cleave a nucleic acid molecule in a monomeric form, while, in other embodiments, a nuclease protein has to dimerize or multimerize in order to cleave a target nucleic acid molecule. Binding domains and cleavage domains of naturally occurring nucleases, as well as modular binding domains and cleavage domains that can be fused to create nucleases binding specific target sites, are well known to those of skill in the art. For example, zinc fingers or transcriptional activator like elements can be used as binding domains to specifically bind a desired target site, and fused or conjugated to a cleavage domain, for example, the cleavage domain of FokI, to create an engineered nuclease cleaving the target site.</p>
<p id="p0029" num="0029">The terms "nucleic acid" and "nucleic acid molecule," as used herein, refer to a compound comprising a nucleobase and an acidic moiety, <i>e.g.,</i> a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, <i>e.g</i>., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, "nucleic acid" refers to individual nucleic acid residues (e.g. nucleotides and/or nucleosides). In some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms "oligonucleotide" and "polynucleotide" can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, "nucleic acid" encompasses RNA as well as single and/or double-stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, <i>e.g.,</i> a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or including<!-- EPO <DP n="23"> --> non-naturally occurring nucleotides or nucleosides. Furthermore, the terms "nucleic acid," "DNA," "RNA," and/or similar terms include nucleic acid analogs, <i>i.e.</i> analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, <i>etc.</i> Where appropriate, <i>e.g.,</i> in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the 5' to 3' direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides (<i>e.g.</i> adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (<i>e.g.</i>, 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (<i>e.g.</i>, 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g., phosphorothioates and 5'-<i>N-</i>phosphoramidite linkages).</p>
<p id="p0030" num="0030">The term "pharmaceutical composition," as used herein, refers to a composition that can be administrated to a subject in the context of treatment of a disease or disorder. In some embodiments of the disclosure, a pharmaceutical composition comprises an active ingredient, <i>e.g</i>., a nuclease or a nucleic acid encoding a nuclease, and a pharmaceutically acceptable excipient.</p>
<p id="p0031" num="0031">The term "proliferative disease," as used herein, refers to any disease in which cell or tissue homeostasis is disturbed in that a cell or cell population exhibits an abnormally elevated proliferation rate. Proliferative diseases include hyperproliferative diseases, such as pre-neoplastic hyperplastic conditions and neoplastic diseases. Neoplastic diseases are characterized by an abnormal proliferation of cells and include both benign and malignant neoplasias. Malignant neoplasia is also referred to as cancer.</p>
<p id="p0032" num="0032">The terms "protein," "peptide," and "polypeptide" are used interchangeably herein, and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an individual protein or a collection of proteins.<!-- EPO <DP n="24"> --> One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, <i>etc.</i> A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof. A protein may comprise different domains, for example, a nucleic acid binding domain and a nucleic acid cleavage domain. In some embodiments, a protein comprises a proteinaceous part, <i>e.g.,</i> an amino acid sequence constituting a nucleic acid binding domain, and an organic compound, <i>e.g.,</i> a compound that can act as a nucleic acid cleavage agent. In some embodiments, a protein is in a complex with, or is in association with, a nucleic acid, <i>e.g.,</i> RNA.</p>
<p id="p0033" num="0033">The term "randomized," as used herein in the context of nucleic acid sequences, refers to a sequence or residue within a sequence that has been synthesized to incorporate a mixture of free nucleotides, for example, a mixture of all four nucleotides A, T, G, and C. Randomized residues are typically represented by the letter N within a nucleotide sequence. In some embodiments, a randomized sequence or residue is fully randomized, in which case the randomized residues are synthesized by adding equal amounts of the nucleotides to be incorporated (<i>e.g.</i>, 25% T, 25% A, 25% G, and 25% C) during the synthesis step of the respective sequence residue. In some embodiments, a randomized sequence or residue is partially randomized, in which case the randomized residues are synthesized by adding non-equal amounts of the nucleotides to be incorporated (<i>e.g.</i>, 79% T, 7% A, 7% G, and 7% C) during the synthesis step of the respective sequence residue. Partial randomization allows for the generation of sequences that are templated on a given sequence, but have incorporated mutations at a desired frequency. For example, if a known nuclease target site is used as a synthesis template, partial randomization in which at each step the nucleotide represented at the respective residue is added to the synthesis at 79%, and the other three nucleotides are added at 7% each, will result in a mixture of partially randomized target sites being synthesized, which still represent the consensus sequence of the original target site, but which differ from the original target site at each residue with a statistical frequency of 21% for each residue so synthesized (distributed binomially). In some embodiments, a partially randomized sequence differs from the consensus sequence by more than 5%, more than 10%, more than 15%, more than 20%, more than 25%, or more than 30%<!-- EPO <DP n="25"> --> on average, distributed binomially. In some embodiments, a partially randomized sequence differs from the consensus site by no more than 10%, no more than 15%, no more than 20%, no more than 25%, nor more than 30%, no more than 40%, or no more than 50% on average, distributed binomially.</p>
<p id="p0034" num="0034">The term "RNA-programmable nuclease," and "RNA-guided nuclease" are used interchangeably herein and refer to a nuclease that forms a complex with (<i>e.g.</i>, binds or associates with) one or more RNA that is not a target for cleavage. In some embodiments, an RNA-programmable nuclease, when in a complex with an RNA, may be referred to as a nuclease:RNA complex. Typically, the bound RNA(s) is referred to as a guide RNA (gRNA) or a single-guide RNA (sgRNA). The gRNA/sgRNA comprises a nucleotide sequence that complements a target site, which mediates binding of the nuclease/RNA complex to said target site and providing the sequence specificity of the nuclease:RNA complex. In some embodiments, the RNA-programmable nuclease is the (<u style="single">C</u>RISPR-<u style="single">a</u>ssociated <u style="single">s</u>ystem) Cas9 endonuclease, for example Cas9 (Csn1) from <i>Streptococcus pyogenes</i> (see, <i>e.g.,</i> "<nplcit id="ncit0014" npl-type="s"><text>Complete genome sequence of an M1 strain of Streptococcus pyogenes." Ferretti J.J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P., Qian Y., Jia H.G., Najar F.Z., Ren Q., Zhu H., Song L. expand/collapse author list McLaughlin R.E., Proc. Natl. Acad. Sci. U.S.A. 98:4658-4663(2001</text></nplcit>); "<nplcit id="ncit0015" npl-type="s"><text>CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E., Chylinski K., Sharma C.M., Gonzales K., Chao Y., Pirzada Z.A., Eckert M.R., Vogel J., Charpentier E., Nature 471:602-607(2011</text></nplcit>); and "<nplcit id="ncit0016" npl-type="s"><text>A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. Science 337:816-821(2012</text></nplcit>).</p>
<p id="p0035" num="0035">Because RNA-programmable nucleases (<i>e.g.</i>, Cas9) use RNA:DNA hybridization to determine target DNA cleavage sites, these proteins are able to cleave, in principle, any sequence specified by the guide RNA. Methods of using RNA-programmable nucleases, such as Cas9, for site-specific cleavage (<i>e.g.,</i> to modify a genome) are known in the art (See <i>e.g.,</i> <nplcit id="ncit0017" npl-type="s"><text>Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013</text></nplcit>); <nplcit id="ncit0018" npl-type="s"><text>Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013</text></nplcit>); <nplcit id="ncit0019" npl-type="s"><text>Hwang, W.Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013</text></nplcit>); <nplcit id="ncit0020" npl-type="s"><text>Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013</text></nplcit>); <nplcit id="ncit0021" npl-type="s"><text>Dicarlo, J.E. et al. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic acids<!-- EPO <DP n="26"> --> research (2013</text></nplcit>); <nplcit id="ncit0022" npl-type="s"><text>Jiang, W. et al. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology 31, 233-239 (2013</text></nplcit>)).</p>
<p id="p0036" num="0036">The terms "small molecule" and "organic compound" are used interchangeably herein and refer to molecules, whether naturally-occurring or artificially created (<i>e.g.,</i> via chemical synthesis) that have a relatively low molecular weight. Typically, an organic compound contains carbon. An organic compound may contain multiple carbon-carbon bonds, stereocenters, and other functional groups (<i>e.g.</i>, amines, hydroxyl, carbonyls, or heterocyclic rings). In some embodiments, organic compounds are monomeric and have a molecular weight of less than about 1500 g/mol. In certain embodiments, the molecular weight of the small molecule is less than about 1000 g/mol or less than about 500 g/mol. In certain embodiments, the small molecule is a drug, for example, a drug that has already been deemed safe and effective for use in humans or animals by the appropriate governmental agency or regulatory body. In certain embodiments, the organic molecule is known to bind and/or cleave a nucleic acid. In some embodiments, the organic compound is an enediyne. In some embodiments, the organic compound is an antibiotic drug, for example, an anticancer antibiotic such as dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof.</p>
<p id="p0037" num="0037">The term "subject," as used herein, refers to an individual organism, for example, an individual mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a rodent. In some embodiments, the subject is a sheep, a goat, a cattle, a cat, or a dog. In some embodiments, the subject is a vertebrate, an amphibian, a reptile, a fish, an insect, a fly, or a nematode.</p>
<p id="p0038" num="0038">The terms "target nucleic acid," and "target genome," as used herein in the context of nucleases, refer to a nucleic acid molecule or a genome, respectively, that comprises at least one target site of a given nuclease.</p>
<p id="p0039" num="0039">The term "target site," used herein interchangeably with the term "nuclease target site," refers to a sequence within a nucleic acid molecule that is bound and cleaved by a nuclease. A target site may be single-stranded or double-stranded. In the context of nucleases that dimerize, for example, nucleases comprising a FokI DNA cleavage domain, a target sites typically comprises a left-half site (bound by one monomer of the nuclease), a right-half site (bound by the second monomer of the nuclease), and a spacer sequence between the half sites in which the cut is made. This structure ([left-half site]-[spacer sequence]-[right-half site]) is referred to herein as an LSR structure. In some embodiments,<!-- EPO <DP n="27"> --> the left-half site and/or the right-half site is between 10-18 nucleotides long. In some embodiments, either or both half-sites are shorter or longer. In some embodiments, the left and right half sites comprise different nucleic acid sequences. In the context of zinc finger nucleases, target sites may, in some embodiments comprise two half-sites that are each 6-18 bp long flanking a non-specified spacer region that is 4-8 bp long. In the context of TALENs, target sites may, in some embodiments, comprise two half-sites sites that are each 10-23 bp long flanking a non-specified spacer region that is 10-30 bp long. In the context of RNA-guided (e.g., RNA-programmable) nucleases, a target site typically comprises a nucleotide sequence that is complementary to the sgRNA of the RNA-programmable nuclease, and a protospacer adjacent motif (PAM) at the 3' end adjacent to the sgRNA-complementary sequence. For the RNA-guided nuclease Cas9, the target site may be, in some embodiments, 20 base pairs plus a 3 base pair PAM (<i>e.g.,</i> NNN, wherein N represents any nucleotide). Typically, the first nucleotide of a PAM can be any nucleotide, while the two downstream nucleotides are specified depending on the specific RNA-guided nuclease. Exemplary target sites for RNA-guided nucleases, such as Cas9, are known to those of skill in the art and include, without limitation, NNG, NGN, NAG, and NGG, wherein N represents any nucleotide. In addition, Cas9 nucleases from different species (<i>e.g.,</i> S. thermophilus instead of S. pyogenes) recognizes a PAM that comprises the sequence NGGNG. Additional PAM sequences are known, including, but not limited to NNAGAAW and NAAR (see, <i>e.g.,</i> <nplcit id="ncit0023" npl-type="s"><text>Esvelt and Wang, Molecular Systems Biology, 9:641 (2013</text></nplcit>)). For example, the target site of an RNA-guided nuclease, such as, <i>e.g.,</i> Cas9, may comprise the structure [Nz]-[PAM], where each N is, independently, any nucleotide, and z is an integer between 1 and 50. In some embodiments, z is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50. In some embodiments, z is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, or 50. In some embodiments, Z is 20.</p>
<p id="p0040" num="0040">The term "Transcriptional Activator-Like Effector," (TALE) as used herein, refers to bacterial proteins comprising a DNA binding domain, which contains a highly conserved 33-34 amino acid sequence comprising a highly variable two-amino acid motif (Repeat Variable Diresidue, RVD). The RVD motif determines binding specificity to a nucleic acid sequence, and can be engineered according to methods well known to those of skill in the art to specifically bind a desired DNA sequence (see, <i>e.g.,</i> <nplcit id="ncit0024" npl-type="s"><text>Miller, Jeffrey; et.al.<!-- EPO <DP n="28"> --> (February 2011). "A TALE nuclease architecture for efficient genome editing". Nature Biotechnology 29 (2): 143-8</text></nplcit>; <nplcit id="ncit0025" npl-type="s"><text>Zhang, Feng; et.al. (February 2011). "Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription". Nature Biotechnology 29 (2): 149-53</text></nplcit>; <nplcit id="ncit0026" npl-type="b"><text>Geiβler, R.; Scholze, H.; Hahn, S.; Streubel, J.; Bonas, U.; Behrens, S. E.; Boch, J. (2011), Shiu, Shin-Han. ed. "Transcriptional Activators of Human Genes with Programmable DNA-Specificity". PLoS ONE 6 (5): e19509</text></nplcit>; <nplcit id="ncit0027" npl-type="s"><text>Boch, Jens (February 2011). "TALEs of genome targeting". Nature Biotechnology 29 (2): 135-6</text></nplcit>; <nplcit id="ncit0028" npl-type="s"><text>Boch, Jens; et.al. (December 2009). "Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors". Science 326 (5959): 1509-12</text></nplcit>; and <nplcit id="ncit0029" npl-type="s"><text>Moscou, Matthew J.; Adam J. Bogdanove (December 2009). "A Simple Cipher Governs DNA Recognition by TAL Effectors". Science 326 (5959): 1501</text></nplcit>). The simple relationship between amino acid sequence and DNA recognition has allowed for the engineering of specific DNA binding domains by selecting a combination of repeat segments containing the appropriate RVDs.</p>
<p id="p0041" num="0041">The term "Transcriptional Activator-Like Element Nuclease," (TALEN) as used herein, refers to an artificial nuclease comprising a transcriptional activator like effector DNA binding domain to a DNA cleavage domain, for example, a FokI domain. A number of modular assembly schemes for generating engineered TALE constructs have been reported (see <i>e.g.,</i> <nplcit id="ncit0030" npl-type="s"><text>Zhang, Feng; et.al. (February 2011). "Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription". Nature Biotechnology 29 (2): 149-53</text></nplcit>; <nplcit id="ncit0031" npl-type="b"><text>Geiβler, R.; Scholze, H.; Hahn, S.; Streubel, J.; Bonas, U.; Behrens, S. E.; Boch, J. (2011), Shiu, Shin-Han. ed. "Transcriptional Activators of Human Genes with Programmable DNA-Specificity". PLoS ONE 6 (5): e19509</text></nplcit>; <nplcit id="ncit0032" npl-type="s"><text>Cermak, T.; Doyle, E. L.; Christian, M.; Wang, L.; Zhang, Y.; Schmidt, C.; Baller, J. A.; Somia, N. V. et al. (2011). "Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting". Nucleic Acids Research</text></nplcit><i>;</i> <nplcit id="ncit0033" npl-type="s"><text>Morbitzer, R.; Elsaesser, J.; Hausner, J.; Lahaye, T. (2011). "Assembly of custom TALE-type DNA binding domains by modular cloning". Nucleic Acids Research</text></nplcit><i>;</i> <nplcit id="ncit0034" npl-type="s"><text>Li, T.; Huang, S.; Zhao, X.; Wright, D. A.; Carpenter, S.; Spalding, M. H.; Weeks, D. P.; Yang, B. (2011). "Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes". Nucleic Acids Research</text></nplcit><i>.;</i> <nplcit id="ncit0035" npl-type="b"><text>Weber, E.; Gruetzner, R.; Werner, S.; Engler, C.; Marillonnet, S. (2011). Bendahmane, Mohammed. ed. "Assembly of Designer TAL Effectors by Golden Gate Cloning". PLoS ONE 6 (5): e19722</text></nplcit>).</p>
<p id="p0042" num="0042">The terms "treatment," "treat," and "treating," refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder,<!-- EPO <DP n="29"> --> or one or more symptoms thereof, as described herein. As used herein, the terms "treatment," "treat," and "treating" refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed and/or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, <i>e.g</i>., to prevent or delay onset of a symptom or inhibit onset or progression of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.</p>
<p id="p0043" num="0043">The term "zinc finger," as used herein, refers to a small nucleic acid-binding protein structural motif characterized by a fold and the coordination of one or more zinc ions that stabilize the fold. Zinc fingers encompass a wide variety of differing protein structures (see, <i>e.g.,</i> <nplcit id="ncit0036" npl-type="s"><text>Klug A, Rhodes D (1987). "Zinc fingers: a novel protein fold for nucleic acid recognition". Cold Spring Harb. Symp. Quant. Biol. 52: 473-82</text></nplcit>). Zinc fingers can be designed to bind a specific sequence of nucleotides, and zinc finger arrays comprising fusions of a series of zinc fingers, can be designed to bind virtually any desired target sequence. Such zinc finger arrays can form a binding domain of a protein, for example, of a nuclease, <i>e.g.,</i> if conjugated to a nucleic acid cleavage domain. Different type of zinc finger motifs are known to those of skill in the art, including, but not limited to, Cys<sub>2</sub>His<sub>2</sub>, Gag knuckle, Treble clef, Zinc ribbon, Zn<sub>2</sub>/Cys<sub>6</sub>, and TAZ2 domain-like motifs (see, <i>e.g</i>., <nplcit id="ncit0037" npl-type="s"><text>Krishna SS, Majumdar I, Grishin NV (January 2003). "Structural classification of zinc fingers: survey and summary". Nucleic Acids Res. 31 (2): 532-50</text></nplcit>). Typically, a single zinc finger motif binds 3 or 4 nucleotides of a nucleic acid molecule. Accordingly, a zinc finger domain comprising 2 zinc finger motifs may bind 6-8 nucleotides, a zinc finger domain comprising 3 zinc finger motifs may bind 9-12 nucleotides, a zinc finger domain comprising 4 zinc finger motifs may bind 12-16 nucleotides, and so forth. Any suitable protein engineering technique can be employed to alter the DNA-binding specificity of zinc fingers and/or design novel zinc finger fusions to bind virtually any desired target sequence from 3 - 30 nucleotides in length (see, <i>e.g.,</i> <nplcit id="ncit0038" npl-type="s"><text>Pabo CO, Peisach E, Grant RA (2001). "Design and selection of novel cys2His2 Zinc finger proteins". Annual Review of Biochemistry 70: 313-340</text></nplcit>; <nplcit id="ncit0039" npl-type="s"><text>Jamieson AC, Miller JC, Pabo CO (2003). "Drug discovery with engineered zinc-finger proteins". Nature Reviews Drug Discovery 2 (5): 361-368</text></nplcit>; and <nplcit id="ncit0040" npl-type="s"><text>Liu Q, Segal DJ, Ghiara JB, Barbas CF (May 1997). "Design<!-- EPO <DP n="30"> --> of polydactyl zinc-finger proteins for unique addressing within complex genomes". Proc. Natl. Acad. Sci. U.S.A. 94 (11</text></nplcit>)). Fusions between engineered zinc finger arrays and protein domains that cleave a nucleic acid can be used to generate a "zinc finger nuclease." A zinc finger nuclease typically comprises a zinc finger domain that binds a specific target site within a nucleic acid molecule, and a nucleic acid cleavage domain that cuts the nucleic acid molecule within or in proximity to the target site bound by the binding domain. Typical engineered zinc finger nucleases comprise a binding domain having between 3 and 6 individual zinc finger motifs and binding target sites ranging from 9 base pairs to 18 base pairs in length. Longer target sites are particularly attractive in situations where it is desired to bind and cleave a target site that is unique in a given genome.</p>
<p id="p0044" num="0044">The term "zinc finger nuclease," as used herein, refers to a nuclease comprising a nucleic acid cleavage domain conjugated to a binding domain that comprises a zinc finger array. In some embodiments, the cleavage domain is the cleavage domain of the type II restriction endonuclease Fokl. Zinc finger nucleases can be designed to target virtually any desired sequence in a given nucleic acid molecule for cleavage, and the possibility to the design zinc finger binding domains to bind unique sites in the context of complex genomes allows for targeted cleavage of a single genomic site in living cells, for example, to achieve a targeted genomic alteration of therapeutic value. Targeting a double-strand break to a desired genomic locus can be used to introduce frame-shift mutations into the coding sequence of a gene due to the error-prone nature of the non-homologous DNA repair pathway. Zinc finger nucleases can be generated to target a site of interest by methods well known to those of skill in the art. For example, zinc finger binding domains with a desired specificity can be designed by combining individual zinc finger motifs of known specificity. The structure of the zinc finger protein Zif268 bound to DNA has informed much of the work in this field and the concept of obtaining zinc fingers for each of the 64 possible base pair triplets and then mixing and matching these modular zinc fingers to design proteins with any desired sequence specificity has been described (<nplcit id="ncit0041" npl-type="s"><text>Pavletich NP, Pabo CO (May 1991). "Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A". Science 252 (5007): 809-17</text></nplcit>). In some embodiments, separate zinc fingers that each recognize a 3 base pair DNA sequence are combined to generate 3-, 4-, 5-, or 6-finger arrays that recognize target sites ranging from 9 base pairs to 18 base pairs in length. In some embodiments, longer arrays are contemplated. In other embodiments, 2-finger modules recognizing 6-8 nucleotides are combined to generate 4-, 6-, or 8- zinc finger arrays. In some embodiments, bacterial or phage display is employed to develop a zinc finger domain that<!-- EPO <DP n="31"> --> recognizes a desired nucleic acid sequence, for example, a desired nuclease target site of 3-30 bp in length. Zinc finger nucleases, in some embodiments, comprise a zinc finger binding domain and a cleavage domain fused or otherwise conjugated to each other via a linker, for example, a polypeptide linker. The length of the linker determines the distance of the cut from the nucleic acid sequence bound by the zinc finger domain. If a shorter linker is used, the cleavage domain will cut the nucleic acid closer to the bound nucleic acid sequence, while a longer linker will result in a greater distance between the cut and the bound nucleic acid sequence. In some embodiments, the cleavage domain of a zinc finger nuclease has to dimerize in order to cut a bound nucleic acid. In some such embodiments, the dimer is a heterodimer of two monomers, each of which comprise a different zinc finger binding domain. For example, in some embodiments, the dimer may comprise one monomer comprising zinc finger domain A conjugated to a FokI cleavage domain, and one monomer comprising zinc finger domain B conjugated to a FokI cleavage domain. In this nonlimiting example, zinc finger domain A binds a nucleic acid sequence on one side of the target site, zinc finger domain B binds a nucleic acid sequence on the other side of the target site, and the dimerize FokI domain cuts the nucleic acid in between the zinc finger domain binding sites.</p>
<heading id="h0005"><b>DETAILED DESCRIPTION</b></heading>
<heading id="h0006"><i>Introduction</i></heading>
<p id="p0045" num="0045">Site-specific nucleases are powerful tools for targeted genome modification <i>in vitro</i> or <i>in vivo.</i> Some site specific nucleases can theoretically achieve a level of specificity for a target cleavage site that would allow one to target a single unique site in a genome for cleavage without affecting any other genomic site. It has been reported that nuclease cleavage in living cells triggers a DNA repair mechanism that frequently results in a modification of the cleaved, repaired genomic sequence, for example, via homologous recombination. Accordingly, the targeted cleavage of a specific unique sequence within a genome opens up new avenues for gene targeting and gene modification in living cells, including cells that are hard to manipulate with conventional gene targeting methods, such as many human somatic or embryonic stem cells. Nuclease-mediated modification of disease-related sequences, <i>e.g.</i>, the CCR-5 allele in HIV/AIDS patients, or of genes necessary for tumor neovascularization, can be used in the clinical context, and two site specific nucleases are currently in clinical trials.</p>
<p id="p0046" num="0046">One important aspect in the field of site-specific nuclease-mediated modification are off-target nuclease effects, <i>e.g.,</i> the cleavage of genomic sequences that<!-- EPO <DP n="32"> --> differ from the intended target sequence by one or more nucleotides. Undesired side effects of off-target cleavage range from insertion into unwanted loci during a gene targeting event to severe complications in a clinical scenario. Off-target cleavage of sequences encoding essential gene functions or tumor suppressor genes by an endonuclease administered to a subject may result in disease or even death of the subject. Accordingly, it is desirable to characterize the cleavage preferences of a nuclease before using it in the laboratory or the clinic in order to determine its efficacy and safety. Further, the characterization of nuclease cleavage properties allows for the selection of the nuclease best suited for a specific task from a group of candidate nucleases, or for the selection of evolution products obtained from a plurality of nucleases. Such a characterization of nuclease cleavage properties may also inform the de-novo design of nucleases with enhanced properties, such as enhanced specificity or efficiency.</p>
<p id="p0047" num="0047">In many scenarios where a nuclease is employed for the targeted manipulation of a nucleic acid, cleavage specificity is a crucial feature. The imperfect specificity of some engineered nuclease binding domains can lead to off-target cleavage and undesired effects both <i>in vitro</i> and <i>in vivo.</i> Current methods of evaluating site-specific nuclease specificity, including ELISA assays, microarrays, one-hybrid systems, SELEX, and its variants, and Rosetta-based computational predictions, are all premised on the assumption that the binding specificity of the nuclease is equivalent or proportionate to their cleavage specificity.</p>
<p id="p0048" num="0048">It was previously discovered that the prediction of nuclease off-target binding effects constitute an imperfect approximation of a nuclease's off-target cleavage effects that may result in undesired biological effects (see <patcit id="pcit0003" dnum="WO2013066438A"><text>PCT Application WO 2013/066438</text></patcit>; and <nplcit id="ncit0042" npl-type="s"><text>Pattanayak, V., Ramirez, C.L., Joung, J.K. &amp; Liu, D.R. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nature methods 8, 765-770 (2011</text></nplcit>)). This finding was consistent with the notion that the reported toxicity of some site specific DNA nucleases results from off-target DNA cleavage, rather than off-target binding alone.</p>
<p id="p0049" num="0049">The methods and reagents of the present disclosure represent, in some aspects, an improvement over previous methods and allow for an accurate evaluation of a given nuclease's target site specificity and provide strategies for the selection of suitable unique target sites and the design or selection of highly specific nucleases for the targeted cleavage of a single site in the context of a complex genome. For example, some previously reported methods for determining nuclease target site specificity profiles by screening libraries of nucleic acid molecules comprising candidate target sites relied on a "two-cut" <i>in vitro</i><!-- EPO <DP n="33"> --> selection method which requires indirect reconstruction of target sites from sequences of two half-sites resulting from two adjacent cuts of the nuclease of a library member nucleic acid (see <i>e.g.,</i> <nplcit id="ncit0043" npl-type="s"><text>Pattanayak, V. et al., Nature Methods 8, 765-770 (2011</text></nplcit>)). In contrast to such "two-cut" strategies, the methods of the present disclosure utilize a "one cut" screening strategy, which allows for the identification of library members that have been cut at least once by the nuclease. The "one-cut" selection strategies provided herein are compatible with single end high-throughput sequencing methods and do not require computational reconstruction of cleaved target sites from cut half-sites because they feature, in some embodiments, direct sequencing of an intact target nuclease sequence in a cut library member nucleic acid.</p>
<p id="p0050" num="0050">Additionally, the presently disclosed "one-cut" screening methods utilize concatemers of a candidate nuclease target site and constant insert region that are about 10-fold shorter than previously reported constructs used for two-cut strategies (∼50bp repeat sequence length versus ∼500bp repeat sequence length in previous reports). This difference in repeat sequence length in the concatemers of the library allows for the generation of highly complex libraries of candidate nuclease target sites, <i>e.g.,</i> of libraries comprising 10<sup>12</sup> different candidate nuclease target sequences. As described herein, an exemplary library of such complexity has been generated, templated on a known Cas9 nuclease target site by varying the sequence of the known target site. The exemplary library demonstrated that a greater than 10-fold coverage of all sequences with eight or fewer mutations of the known target site can be achieved using the strategies provided herein. The use of a shorter repeat sequence also allows the use of single-end sequencing, since both a cut half-site and an adjacent uncut site of the same library member are contained within a 100 nucleotide sequencing read.</p>
<p id="p0051" num="0051">The strategies, methods, libraries, and reagents provided herein can be utilized to analyze the sequence preferences and specificity of any site-specific nuclease, for example, to Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), homing endonucleases, organic compound nucleases, and enediyne antibiotics (e.g., dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin). Suitable nucleases in addition to the ones described herein will be apparent to those of skill in the art based on this disclosure.</p>
<p id="p0052" num="0052">Further, the methods, reagents, and strategies provided herein allow those of skill in the art to identify, design, and/or select nucleases with enhanced specificity and minimize the off-target effects of any given nuclease (<i>e.g.</i>, site-specific nucleases such as ZFNs, and TALENS which produce cleavage products with sticky ends, as well as RNA-programmable nucleases, for example Cas9, which produce cleavage products having blunt<!-- EPO <DP n="34"> --> ends). While of particular relevance to DNA and DNA-cleaving nucleases, the inventive concepts, methods, strategies, and reagents provided herein are not limited in this respect, but can be applied to any nucleic acid:nuclease pair.</p>
<heading id="h0007"><i>Identifying Nuclease Target Sites Cleaved by a Site-Specific Nuclease</i></heading>
<p id="p0053" num="0053">Some aspects of this disclosure provide improved methods and reagents to determine the nucleic acid target sites cleaved by any site-specific nuclease. The methods provided herein can be used for the evaluation of target site preferences and specificity of both nucleases that create blunt ends and nucleases that create sticky ends. In general, such methods comprise contacting a given nuclease with a library of target sites under conditions suitable for the nuclease to bind and cut a target site, and determining which target sites the nuclease actually cuts. A determination of a nuclease's target site profile based on actual cutting has the advantage over methods that rely on binding in that it measures a parameter more relevant for mediating undesired off-target effects of site-specific nucleases. In general, the methods provided herein comprise ligating an adapter of a known sequence to nucleic acid molecules that have been cut by a nuclease of interest via 5'-phosphate-dependent ligation. Accordingly, the methods provided herein are particularly useful for identifying target sites cut by nucleases that leave a phosphate moiety at the 5'-end of the cut nucleic acid strand when cleaving their target site. After ligating an adapter to the 5'-end of a cut nucleic acid strand, the cut strand can directly be sequenced using the adapter as a sequencing linker, or a part of the cut library member concatemer comprising an intact target site identical to the cut target site can be amplified via PCR and the amplification product can then be sequenced.</p>
<p id="p0054" num="0054">The method of the first aspect of the invention comprises (a) providing a nuclease that cuts a double-stranded nucleic acid target site, wherein cutting of the target site results in cut nucleic acid strands comprising a 5'-phosphate moiety; (b) contacting the nuclease of (a) with a library of candidate nucleic acid molecules, wherein each nucleic acid molecule comprises a concatemer of a sequence comprising a candidate nuclease target site and a constant insert sequence of at least 10 and not more than 80 nucleotides, under conditions suitable for the nuclease to cut a candidate nucleic acid molecule comprising a target site of the nuclease; and (c) identifying nuclease target sites cut by the nuclease in (b) by determining the sequence of an uncut nuclease target site on the nucleic acid strand that was cut by the nuclease in step (b)), wherein the determining of step (c) comprises (i) ligating a first nucleic acid adapter to the 5' end of a nucleic acid strand that was cut by the nuclease in step (b) via 5'-phosphate-dependent ligation, and (ii) amplifying a fragment of the<!-- EPO <DP n="35"> --> concatemer cut by the nuclease that comprises an uncut target site via a PCR reaction using a PCR primer that hybridizes with the adapter and a PCR primer that hybridizes with the constant insert sequence.</p>
<p id="p0055" num="0055">Disclosed herein is a method comprising providing a nuclease and contacting the nuclease with a library of candidate nucleic acid molecules comprising candidate target sites. In some embodiments, the candidate nucleic acid molecules are double-stranded nucleic acid molecules. In some embodiments, the candidate nucleic acid molecules are DNA molecules. In some embodiments, each nucleic acid molecule in the library comprises a concatemer of a sequence comprising a candidate nuclease target site and a constant insert sequence. For example, in some embodiments, the library comprises nucleic acid molecules that comprise the structure R<sub>1</sub>-[(candidate nuclease target site)-(constant insert sequence)]<sub>n</sub> - R<sub>2</sub>, wherein R<sub>1</sub> and R<sub>2</sub> are, independently, nucleic acid sequences that may comprise a fragment of the [(candidate nuclease target site)-(constant insert sequence)] structure, and n is an integer between 2 and y. In some embodiments, y is at least 10<sup>1</sup>, at least 10<sup>2</sup>, at least 10<sup>3</sup>, at least 10<sup>4</sup>, at least 10<sup>5</sup>, at least 10<sup>6</sup>, at least 10<sup>7</sup>, at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, at least 10<sup>12</sup>, at least 10<sup>13</sup>, at least 10<sup>14</sup>, or at least 10<sup>15</sup>. In some embodiments, y is less than 10<sup>2</sup>, less than 10<sup>3</sup>, less than 10<sup>4</sup>, less than 10<sup>5</sup>, less than 10<sup>6</sup>, less than 10<sup>7</sup>, less than 10<sup>8</sup>, less than 10<sup>9</sup>, less than 10<sup>10</sup>, less than 10<sup>11</sup>, less than 10<sup>12</sup>, less than 10<sup>13</sup>, less than 10<sup>14</sup>, or less than 10<sup>15</sup>.</p>
<p id="p0056" num="0056">For example, in some embodiments, the candidate nucleic acid molecules of the library comprise a candidate nuclease target site of the structure [(Nz)-(PAM)], and, thus, the nucleic acid molecules of the library comprise the structure R<sub>1</sub>-[(N<sub>Z</sub>)-(PAM)-(constant region)]<sub>X</sub>-R<sub>2</sub>, wherein R<sub>1</sub> and R<sub>2</sub> are, independently, nucleic acid sequences that may comprise a fragment of the [(Nz)-(PAM)-(constant region)] repeat unit; each N represents, independently, any nucleotide; Z is an integer between 1 and 50; and X is an integer between 2 and y. In some embodiments, y is at least 10<sup>1</sup>, at least 10<sup>2</sup>, at least 10<sup>3</sup>, at least 10<sup>4</sup>, at least 10<sup>5</sup>, at least 10<sup>6</sup>, at least 10<sup>7</sup>, at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, at least 10<sup>12</sup>, at least 10<sup>13</sup>, at least 10<sup>14</sup>, or at least 10<sup>15</sup>. In some embodiments, y is less than 10<sup>2</sup>, less than 10<sup>3</sup>, less than 10<sup>4</sup>, less than 10<sup>5</sup>, less than 10<sup>6</sup>, less than 10<sup>7</sup>, less than 10<sup>8</sup>, less than 10<sup>9</sup>, less than 10<sup>10</sup>, less than 10<sup>11</sup>, less than 10<sup>12</sup>, less than 10<sup>13</sup>, less than 10<sup>14</sup>, or less than 10<sup>15</sup>. In some embodiments, Z is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50. In some embodiments, Z is 20. Each N represents, independently,<!-- EPO <DP n="36"> --> any nucleotide. Accordingly, a sequence provided as Nz with z=2 would be NN, with each N, independently, representing A, T, G, or C. Accordingly, Nz with z=2 can represent AA, AT, AG, AC, TA, TT, TG, TC, GA, GT, GG, GC, CA, CT, CG, and CC.</p>
<p id="p0057" num="0057">In other embodiments, the candidate nucleic acid molecules of the library comprise a candidate nuclease target site of the structure [left-half site]-[spacer sequence]-[right-half site] ("LSR"), and, thus, the nucleic acid molecules of the library comprise the structure R<sub>1</sub>-[(LSR)-(constant region)]<sub>X</sub>-R<sub>2</sub>, wherein R<sub>1</sub> and R<sub>2</sub> are, independently, nucleic acid sequences that may comprise a fragment of the [(LSR)-(constant region)] repeat unit, and X is an integer between 2 and y. In some embodiments, y is at least 10<sup>1</sup>, at least 10<sup>2</sup>, at least 10<sup>3</sup>, at least 10<sup>4</sup>, at least 10<sup>5</sup>, at least 10<sup>6</sup>, at least 10<sup>7</sup>, at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, at least 10<sup>12</sup>, at least 10<sup>13</sup>, at least 10<sup>14</sup>, or at least 10<sup>15</sup>. In some embodiments, y is less than 10<sup>2</sup>, less than 10<sup>3</sup>, less than 10<sup>4</sup>, less than 10<sup>5</sup>, less than 10<sup>6</sup>, less than 10<sup>7</sup>, less than 10<sup>8</sup>, less than 10<sup>9</sup>, less than 10<sup>10</sup>, less than 10<sup>11</sup>, less than 10<sup>12</sup>, less than 10<sup>13</sup>, less than 10<sup>14</sup>, or less than 10<sup>15</sup>. The constant region, in some embodiments, is of a length that allows for efficient self-ligation of a single repeat unit. Suitable lengths will be apparent to those of skill in the art. For example, in some embodiments, the constant region is between 5 and 100 base pairs long, for example, about 5 base pairs, about 10 base pairs, about 15 base pairs, about 20 base pairs, about 25 base pairs, about 30 base pairs, about 35 base pairs, about 40 base pairs, about 50 base pairs, about 60 base pairs, about 70 base pairs, about 80 base pairs, about 90 base pairs, or about 100 base pairs long. In some embodiments, the constant region is 16 base pairs long. In some embodiments, the nuclease cuts a double-stranded nucleic acid target site and creates blunt ends. In other embodiments, the nuclease creates a 5'-overhang. In some such embodiments, the target site comprises a [left-half site]-[spacer sequence]-[right-half site] (LSR) structure, and the nuclease cuts the target site within the spacer sequence.</p>
<p id="p0058" num="0058">In some embodiments, a nuclease cuts a double-stranded target site and creates blunt ends. In some embodiments, a nuclease cuts a double-stranded target site and creates an overhang, or sticky end, for example, a 5'-overhang. In some such embodiments, the method comprises filling in the 5'-overhangs of nucleic acid molecules produced from a nucleic acid molecule that has been cut once by the nuclease, wherein the nucleic acid molecules comprise a constant insert sequence flanked by a left or right half-site and cut spacer sequence on one side, and an uncut target site sequence on the other side, thereby creating blunt ends.<!-- EPO <DP n="37"> --></p>
<p id="p0059" num="0059">According to the invention, the determining of step (c) comprises ligating a first nucleic acid adapter to the 5' end of a nucleic acid strand that was cut by the nuclease in step (b) via 5'-phosphate-dependent ligation. In some embodiments, the nuclease creates blunt ends. In such embodiments, an adapter can directly be ligated to the blunt ends resulting from the nuclease cut of the target site by contacting the cut library members with a double-stranded, blunt-ended adapter lacking 5' phosphorylation. In some embodiments, the nuclease creates an overhang (sticky end). In some such embodiments, an adapter may be ligated to the cut site by contacting the cut library member with an excess of adapter having a compatible sticky end. If a nuclease is used that cuts within a constant spacer sequence between variable half-sites, the sticky end can be designed to match the 5' overhang created from the spacer sequence. In embodiments, where the nuclease cuts within a variable sequence, a population of adapters having a variable overhang sequence and a constant annealed sequence (for use as a sequencing linker or PCR primer) may be used, or the 5' overhangs may be filled in to form blunt ends before adapter ligation.</p>
<p id="p0060" num="0060">According to the invention, the determining of step (c) further comprises amplifying a fragment of the concatemer cut by the nuclease that comprises an uncut target site via PCR using a PCR primer that hybridizes with the adapter and a PCR primer that hybridizes with the constant insert sequence. Typically, the amplification of concatemers via PCR will yield amplicons comprising at least one intact candidate target site identical to the cut target sites because the target sites in each concatemer are identical. For single-direction sequencing, an enrichment of amplicons that comprise one intact target site, no more than two intact target sites, no more than three intact target sites, no more than four intact target sites, or no more than five intact target sites may be desirable. In embodiments where PCR is used for amplification of cut nucleic acid molecules, the PCR parameters can be optimized to favor the amplification of short sequences and disfavor the amplification of longer sequences, <i>e.g.,</i> by using a short elongation time in the PCR cycle. Another possibility for enrichment of short amplicons is size fractionation, <i>e.g.</i>, via gel electrophoresis or size exclusion chromatography. Size fractionation can be performed before and/or after amplification. Other suitable methods for enrichment of short amplicons will be apparent to those of skill in the art and the disclosure is not limited in this respect.</p>
<p id="p0061" num="0061">In some embodiments, the determining of step (c) comprises sequencing the nucleic acid strand that was cut by the nuclease in step (b), or a copy thereof obtained via amplification, <i>e.g.</i>, by PCR. Sequencing methods are well known to those of skill in the art. The disclosure is not limited in this respect.<!-- EPO <DP n="38"> --></p>
<p id="p0062" num="0062">In some embodiments, the nuclease being profiled using the disclosed system is an RNA-programmable nuclease that forms a complex with an RNA molecule, and wherein the nuclease:RNA complex specifically binds a nucleic acid sequence complementary to the sequence of the RNA molecule. In some embodiments, the RNA molecule is a single-guide RNA (sgRNA). In some embodiments, the sgRNA comprises 5-50 nucleotides, 10-30 nucleotides, 15-25 nucleotides, 18-22 nucleotides, 19-21 nucleotides, <i>e.g.,</i> 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the sgRNA comprises 5-50 nucleotides, 10-30 nucleotides, 15-25 nucleotides, 18-22 nucleotides, 19-21 nucleotides, <i>e.g.</i>, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides that are complementary to a sequence of the nuclease target site. In some embodiments, the sgRNA comprises 20 nucleotides that are complementary to the nuclease target site. In some embodiments, the nuclease is a Cas9 nuclease. In some embodiments, the nuclease target site comprises a [sgRNA-complementary sequence]-[protospacer adjacent motif (PAM)] structure, and the nuclease cuts the target site within the sgRNA-complementary sequence. In some embodiments, the sgRNA-complementary sequence comprises 5-50 nucleotides, 10-30 nucleotides, 15-25 nucleotides, 18-22 nucleotides, 19-21 nucleotides, <i>e.g.</i>, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides.</p>
<p id="p0063" num="0063">In some embodiments, the RNA-programmable nuclease is a Cas9 nuclease. The RNA-programmable Cas9 endonuclease cleaves double-stranded DNA (dsDNA) at sites adjacent to a two-base-pair PAM motif and complementary to a guide RNA sequence (sgRNA). Typically, the sgRNA sequence that is complementary to the target site sequence is about 20 nucleotides long, but shorter and longer complementary sgRNA sequences can be used as well. For example, in some embodiments, the sgRNA comprises 5-50 nucleotides, 10-30 nucleotides, 15-25 nucleotides, 18-22 nucleotides, 19-21 nucleotides, <i>e.g.</i>, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. The Cas9 system has been used to modify genomes in multiple cell types, demonstrating its potential as a facile genome-engineering tool.</p>
<p id="p0064" num="0064">In some embodiments, the nuclease comprises an unspecific nucleic acid cleavage domain. In some embodiments, the nuclease comprises a FokI cleavage domain. In some embodiments, the nuclease comprises a nucleic acid cleavage domain that cleaves a target sequence upon cleavage domain dimerization. In some embodiments, the nuclease comprises a binding domain that specifically binds a nucleic acid sequence. In some embodiments, the binding domain comprises a zinc finger. In some embodiments, the<!-- EPO <DP n="39"> --> binding domain comprises at least 2, at least 3, at least 4, or at least 5 zinc fingers. In some embodiments, the nuclease is a Zinc Finger Nuclease. In some embodiments, the binding domain comprises a Transcriptional Activator-Like Element. In some embodiments, the nuclease is a Transcriptional Activator-Like Element Nuclease (TALEN). In some embodiments, the nuclease is a homing endonuclease. In some embodiments, the nuclease is an organic compound. In some embodiments, the nuclease comprises an enediyne functional group. In some embodiments, the nuclease is an antibiotic. In some embodiments, the compound is dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof.</p>
<p id="p0065" num="0065">Incubation of the nuclease with the library nucleic acids will result in cleavage of those concatemers in the library that comprise target sites that can be bound and cleaved by the nuclease. If a given nuclease cleaves a specific target site with high efficiency, a concatemer comprising target sites will be cut, <i>e.g.,</i> once or multiple times, resulting in the generation of fragments comprising a cut target site adjacent to one or more repeat units. Depending on the structure of the library members, an exemplary cut nucleic acid molecule released from a library member concatemer by a single nuclease cleavage may, for example, be of the structure (cut target site)-(constant region)-[(target site)-(constant region)]<sub>X</sub>-R<sub>2</sub>. For example, in the context of an RNA-guided nuclease, an exemplary cut nucleic acid molecule released from a library member concatemer by a single nuclease cleavage may, for example, be of the structure (PAM)-(constant region)-[(Nz)-(PAM)-(constant region)]<sub>X</sub>-R<sub>2</sub>. And in the context of a nuclease cutting an LSR structure within the spacer region, an exemplary cut nucleic acid molecule released from a library member concatemer by a single nuclease cleavage may, for example, be of the structure (cut spacer region)-(right half site)-(constant region)-[(LSR)-(constant region)]<sub>X</sub>-R<sub>2</sub>. Such cut fragments released from library candidate molecules can then be isolated and/or the sequence of the target site cleaved by the nuclease identified by sequencing an intact target site (<i>e.g.,</i> an intact (Nz)-(PAM) site of released repeat units. See, <i>e.g.,</i> <figref idref="f0002">Figure 1B</figref> for an illustration.</p>
<p id="p0066" num="0066">Suitable conditions for exposure of the library of nucleic acid molecules will be apparent to those of skill in the art. In some embodiments, suitable conditions do not result in denaturation of the library nucleic acids or the nuclease and allow for the nuclease to exhibit at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% of its nuclease activity.</p>
<p id="p0067" num="0067">Additionally, if a given nuclease cleaves a specific target site, some cleavage products will comprise a cut half site and an intact, or uncut target site. As described herein,<!-- EPO <DP n="40"> --> such products can be isolated by routine methods, and because the insert sequence, in some aspects, is less than 100 base pairs, such isolated cleavage products may be sequenced in a single read-through, allowing identification of the target site sequence without reconstructing the sequence, <i>e.g.</i>, from cut half sites.</p>
<p id="p0068" num="0068">Any method suitable for isolation and sequencing of the repeat units can be employed to elucidate the LSR sequence cleaved by the nuclease. For example, since the length of the constant region is known, individual released repeat units can be separated based on their size from the larger uncut library nucleic acid molecules as well as from fragments of library nucleic acid molecules that comprise multiple repeat units (indicating non-efficient targeted cleavage by the nuclease). Suitable methods for separating and/or isolating nucleic acid molecules based on their size are well-known to those of skill in the art and include, for example, size fractionation methods, such as gel electrophoresis, density gradient centrifugation, and dialysis over a semi-permeable membrane with a suitable molecular cutoff value. The separated/isolated nucleic acid molecules can then be further characterized, for example, by ligating PCR and/or sequencing adapters to the cut ends and amplifying and/or sequencing the respective nucleic acids. Further, if the length of the constant region is selected to favor self-ligation of individual released repeat units, such individual released repeat units may be enriched by contacting the nuclease treated library molecules with a ligase and subsequent amplification and/or sequencing based on the circularized nature of the self-ligated individual repeat units.</p>
<p id="p0069" num="0069">In some embodiments, where a nuclease is used that generates 5'-overhangs as a result of cutting a target nucleic acid, the 5'-overhangs of the cut nucleic acid molecules are filled in. Methods for filling in 5'-overhangs are well known to those of skill in the art and include, for example, methods using DNA polymerase I Klenow fragment lacking exonuclease activity (Klenow (3'-&gt;5' exo-)). Filling in 5'-overhangs results in the overhang-templated extension of the recessed strand, which, in turn, results in blunt ends. In the case of single repeat units released from library concatemers, the resulting structure is a blunt-ended S<sub>2</sub>'R-(constant region)-LSi', with S<sub>1</sub>' and S<sub>2</sub>' comprising blunt ends. PCR and/or sequencing adapters can then be added to the ends by blunt end ligation and the respective repeat units (including S<sub>2</sub>'R and LS<sub>1</sub>' regions) can be sequenced. From the sequence data, the original LSR region can be deduced. Blunting of the overhangs created during the nuclease cleavage process also allows for distinguishing between target sites that were properly cut by the respective nuclease and target sites that were non-specifically cut, <i>e.g.,</i> based on non-nuclease effects such as physical shearing. Correctly cleaved nuclease target sites can be<!-- EPO <DP n="41"> --> recognized by the existence of complementary S<sub>2</sub>'R and LSi' regions, which comprise a duplication of the overhang nucleotides as a result of the overhang fill in while target sites that were not cleaved by the respective nuclease are unlikely to comprise overhang nucleotide duplications. In some embodiments, the method comprises identifying the nuclease target site cut by the nuclease by determining the sequence of the left-half site, the right-half-site, and/or the spacer sequence of a released individual repeat unit. Any suitable method for amplifying and/or sequencing can be used to identify the LSR sequence of the target site cleaved by the respective nuclease. Methods for amplifying and/or sequencing nucleic acids are well known to those of skill in the art and the disclosure is not limited in this respect. In the case of nucleic acids released from library concatemers that comprise a cut half site and an uncut target site (e.g., comprises at least about 1.5 repeat sequences), filling in the 5'-overhangs also provides for assurance that the nucleic acid was cleaved by the nuclease. Because the nucleic acid also comprises an intact, or uncut target site, the sequence of said site can be determined without having to reconstruct the sequence from a left-half site, right-half site, and/or spacer sequence.</p>
<p id="p0070" num="0070">Some of the methods and strategies provided herein allow for the simultaneous assessment of a plurality of candidate target sites as possible cleavage targets for any given nuclease. Accordingly, the data obtained from such methods can be used to compile a list of target sites cleaved by a given nuclease, which is also referred to herein as a target site profile. If a sequencing method is used that allows for the generation of quantitative sequencing data, it is also possible to record the relative abundance of any nuclease target site detected to be cleaved by the respective nuclease. Target sites that are cleaved more efficiently by the nuclease will be detected more frequently in the sequencing step, while target sites that are not cleaved efficiently will only rarely release an individual repeat unit from a candidate concatemer, and thus, will only generate few, if any, sequencing reads. Such quantitative sequencing data can be integrated into a target site profile to generate a ranked list of highly preferred and less preferred nuclease target sites.</p>
<p id="p0071" num="0071">The methods and strategies of nuclease target site profiling provided herein can be applied to any site-specific nuclease, including, for example, ZFNs, TALENs, homing endonucleases, and RNA-programmable nucleases, such as Cas9 nucleases. As described in more detail herein, nuclease specificity typically decreases with increasing nuclease concentration, and the methods described herein can be used to determine a concentration at which a given nuclease efficiently cuts its intended target site, but does not efficiently cut any off-target sequences. In some embodiments, a maximum concentration of a therapeutic<!-- EPO <DP n="42"> --> nuclease is determined at which the therapeutic nuclease cuts its intended nuclease target site but does not cut more than 10, more than 5, more than 4, more than 3, more than 2, more than 1, or any additional sites. A therapeutic nuclease can be administered to a subject in an amount effective to generate a final concentration equal or lower than the maximum concentration determined as described above.</p>
<p id="p0072" num="0072">In some embodiments, the library of candidate nucleic acid molecules used in the methods provided herein comprises at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, or at least 10<sup>12</sup> different candidate nuclease target sites.</p>
<p id="p0073" num="0073">In some embodiments, the nuclease is a therapeutic nuclease which cuts a specific nuclease target site in a gene associated with a disease. In some embodiments, the method further comprises determining a maximum concentration of the therapeutic nuclease at which the therapeutic nuclease cuts the specific nuclease target site and does not cut more than 10, more than 5, more than 4, more than 3, more than 2, more than 1, or no additional sites. The therapeutic nuclease can be administered to a subject in an amount effective to generate a final concentration equal or lower than the maximum concentration.</p>
<heading id="h0008"><i>Nuclease Target Site Libraries</i></heading>
<p id="p0074" num="0074">Some embodiments of this disclosure provide libraries of nucleic acid molecules for nuclease target site profiling. In some embodiments, the candidate nucleic acid molecules of the library comprise the structure R<sub>1</sub>-[(N<sub>Z</sub>)-(PAM)-(constant region)]<sub>X</sub>-R<sub>2</sub>, wherein R<sub>1</sub> and R<sub>2</sub> are, independently, nucleic acid sequences that may comprise a fragment of the [(Nz)-(PAM)-(constant region)] repeat unit; each N represents, independently, any nucleotide; Z is an integer between 1 and 50; and X is an integer between 2 and y. In some embodiments, y is at least 10<sup>1</sup>, at least 10<sup>2</sup>, at least 10<sup>3</sup>, at least 10<sup>4</sup>, at least 10<sup>5</sup>, at least 10<sup>6</sup>, at least 10<sup>7</sup>, at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, at least 10<sup>12</sup>, at least 10<sup>13</sup>, at least 10<sup>14</sup>, or at least 10<sup>15</sup>. In some embodiments, y is less than 10<sup>2</sup>, less than 10<sup>3</sup>, less than 10<sup>4</sup>, less than 10<sup>5</sup>, less than 10<sup>6</sup>, less than 10<sup>7</sup>, less than 10<sup>8</sup>, less than 10<sup>9</sup>, less than 10<sup>10</sup>, less than 10<sup>11</sup>, less than 10<sup>12</sup>, less than 10<sup>13</sup>, less than 10<sup>14</sup>, or less than 10<sup>15</sup>. In some embodiments, Z is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50. In some embodiments, Z is 20. Each N represents, independently, any nucleotide. Accordingly, a sequence provided as N<sub>z</sub> with z=2 would be NN, with each N, independently,<!-- EPO <DP n="43"> --> representing A, T, G, or C. Accordingly, Nz with z=2 can represent AA, AT, AG, AC, TA, TT, TG, TC, GA, GT, GG, GC, CA, CT, CG, and CC.</p>
<p id="p0075" num="0075">In some embodiments of this disclosure, a library is provided comprising candidate nucleic acid molecules that comprise target sites with a partially randomized left-half site, a partially randomized right-half site, and/or a partially randomized spacer sequence. In some embodiments, the library is provided comprising candidate nucleic acid molecules that comprise target sites with a partially randomized left half site, a fully randomized spacer sequence, and a partially randomized right half site. In some embodiments, a library is provided comprising candidate nucleic acid molecules that comprise target sites with a partially or fully randomized sequence, wherein the target sites comprise the structure [Nz-(PAM)], for example as described herein. In some embodiments, partially randomized sites differ from the consensus site by more than 5%, more than 10%, more than 15%, more than 20%, more than 25%, or more than 30% on average, distributed binomially.</p>
<p id="p0076" num="0076">In some embodiments of this disclosure such a library comprises a plurality of nucleic acid molecules, each comprising a concatemer of a candidate nuclease target site and a constant insert sequence, also referred to herein as a constant region. For example, in some embodiments, the candidate nucleic acid molecules of the library comprise the structure R<sub>1</sub>-[(sgRNA-complementary sequence)-(PAM)-(constant region)]<sub>X</sub>-R<sub>2</sub>, or the structure R<sub>1</sub>-[(LSR)-(constant region)]<sub>X</sub>-R<sub>2</sub>, wherein the structure in square brackets ("[...]") is referred to as a repeat unit or repeat sequence; R<sub>1</sub> and R<sub>2</sub> are, independently, nucleic acid sequences that may comprise a fragment of the repeat unit, and X is an integer between 2 and y. In some embodiments, y is at least 10<sup>1</sup>, at least 10<sup>2</sup>, at least 10<sup>3</sup>, at least 10<sup>4</sup>, at least 10<sup>5</sup>, at least 10<sup>6</sup>, at least 10<sup>7</sup>, at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, at least 10<sup>12</sup>, at least 10<sup>13</sup>, at least 10<sup>14</sup>, or at least 10<sup>15</sup>. In some embodiments, y is less than 10<sup>2</sup>, less than 10<sup>3</sup>, less than 10<sup>4</sup>, less than 10<sup>5</sup>, less than 10<sup>6</sup>, less than 10<sup>7</sup>, less than 10<sup>8</sup>, less than 10<sup>9</sup>, less than 10<sup>10</sup>, less than 10<sup>11</sup>, less than 10<sup>12</sup>, less than 10<sup>13</sup>, less than 10<sup>14</sup>, or less than 10<sup>15</sup>. The constant region, in some embodiments, is of a length that allows for efficient self-ligation of a single repeat unit. In some embodiments, the constant region is of a length that allows for efficient separation of single repeat units from fragments comprising two or more repeat units. In some embodiments, the constant region is of a length allows for efficient sequencing of a complete repeat unit in one sequencing read. Suitable lengths will be apparent to those of skill in the art. For example, in some embodiments, the constant region is between 5 and 100 base pairs long, for example, about 5 base pairs, about 10 base pairs, about 15 base pairs,<!-- EPO <DP n="44"> --> about 20 base pairs, about 25 base pairs, about 30 base pairs, about 35 base pairs, about 40 base pairs, about 50 base pairs, about 60 base pairs, about 70 base pairs, about 80 base pairs, about 90 base pairs, or about 100 base pairs long. In some embodiments, the constant region is 1, 2, 3, 4, 5, 6, 7, 8, 9, 0, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 base pairs long.</p>
<p id="p0077" num="0077">An LSR site typically comprises a [left-half site]-[spacer sequence]-[right-half site] structure. The lengths of the half-size and the spacer sequence will depend on the specific nuclease to be evaluated. In general, the half-sites will be 6-30 nucleotides long, and preferably 10-18 nucleotides long. For example, each half site individually may be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides long. In some embodiments, an LSR site may be longer than 30 nucleotides. In some embodiments, the left half site and the right half site of an LSR are of the same length. In some embodiments, the left half site and the right half site of an LSR are of different lengths. In some embodiments, the left half site and the right half site of an LSR are of different sequences. In some embodiments, a library is provided that comprises candidate nucleic acids which comprise LSRs that can be cleaved by a FokI cleavage domain, a Zinc Finger Nuclease (ZFN), a Transcription Activator-Like Effector Nuclease (TALEN), a homing endonuclease, or an organic compound (e.g., an enediyne antibiotic such as dynemicin, neocarzinostatin, calicheamicin, and esperamicinl; and bleomycin).</p>
<p id="p0078" num="0078">In some embodiments of this disclosure, a library of candidate nucleic acid molecules is provided that comprises at least 10<sup>5</sup>, at least 10<sup>6</sup>, at least 10<sup>7</sup>, at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, at least 10<sup>12</sup>, at least 10<sup>13</sup>, at least 10<sup>14</sup>, or at least 10<sup>15</sup> different candidate nuclease target sites. In some embodiments, the candidate nucleic acid molecules of the library are concatemers produced from a secularized templates by rolling cycle amplification. In some embodiments, the library comprises nucleic acid molecules, <i>e.g</i>., concatemers, of a molecular weight of at least 5 kDa, at least 6 kDa, at least 7 kDa, at least 8 kDa, at least 9 kDa, at least 10 kDa, at least 12 kDa, or at least 15kDa. In some embodiments, the molecular weight of the nucleic acid molecules within the library may be larger than 15 kDa. In some embodiments, the library comprises nucleic acid molecules within a specific size range, for example, within a range of 5-7 kDa, 5-10 kDa, 8-12 kDa, 10-15 kDa, or 12-15 kDa, or 5-10 kDa or any possible subrange. While some methods suitable for generating nucleic acid concatemers according to some aspects of this disclosure result in<!-- EPO <DP n="45"> --> the generation of nucleic acid molecules of greatly different molecular weights, such mixtures of nucleic acid molecules may be size fractionated to obtain a desired size distribution. Suitable methods for enriching nucleic acid molecules of a desired size or excluding nucleic acid molecules of a desired size are well known to those of skill in the art and the disclosure is not limited in this respect.</p>
<p id="p0079" num="0079">In some embodiments, partially randomized sites differ from the consensus site by no more than 10%, no more than 15%, no more than 20%, no more than 25%, nor more than 30%, no more than 40%, or no more than 50% on average, distributed binomially. For example, in some embodiments partially randomized sites differ from the consensus site by more than 5%, but by no more than 10%; by more than 10%, but by no more than 20%; by more than 20%, but by no more than 25%; by more than 5%, but by no more than 20%, and so on. Using partially randomized nuclease target sites in the library is useful to increase the concentration of library members comprising target sites that are closely related to the consensus site, for example, that differ from the consensus sites in only one, only two, only three, only four, or only five residues. The rationale behind this is that a given nuclease, for example a given ZFN or RNA-programmable nuclease, is likely to cut its intended target site and any closely related target sites, but unlikely to cut a target sites that is vastly different from or completely unrelated to the intended target site. Accordingly, using a library comprising partially randomized target sites can be more efficient than using libraries comprising fully randomized target sites without compromising the sensitivity in detecting any off-target cleavage events for any given nuclease. Thus, the use of partially randomized libraries significantly reduces the cost and effort required to produce a library having a high likelihood of covering virtually all off-target sites of a given nuclease. In some embodiments however it may be desirable to use a fully randomized library of target sites, for example, in embodiments, where the specificity of a given nuclease is to be evaluated in the context of any possible site in a given genome.</p>
<heading id="h0009"><i>Selection and Design of Site-Specific Nucleases</i></heading>
<p id="p0080" num="0080">Some aspects of this disclosure provide methods and strategies for selecting and designing site-specific nucleases that allow the targeted cleavage of a single, unique sites in the context of a complex genome. In some embodiments, a method is provided that comprises providing a plurality of candidate nucleases that are designed or known to cut the same consensus sequence; profiling the target sites actually cleaved by each candidate nuclease, thus detecting any cleaved off-target sites (target sites that differ from the<!-- EPO <DP n="46"> --> consensus target site); and selecting a candidate nuclease based on the off-target site(s) so identified. In some embodiments, this method is used to select the most specific nuclease from a group of candidate nucleases, for example, the nuclease that cleaves the consensus target site with the highest specificity, the nuclease that cleaves the lowest number of off-target sites, the nuclease that cleaves the lowest number of off-target sites in the context of a target genome, or a nuclease that does not cleave any target site other than the consensus target site. In some embodiments, this method is used to select a nuclease that does not cleave any off-target site in the context of the genome of a subject at concentration that is equal to or higher than a therapeutically effective concentration of the nuclease.</p>
<p id="p0081" num="0081">The methods and reagents provided herein can be used, for example, to evaluate a plurality of different nucleases targeting the same intended targets site, for example, a plurality of variations of a given site-specific nuclease, for example a given zinc finger nuclease. Accordingly, such methods may be used as the selection step in evolving or designing a novel site-specific nucleases with improved specificity.</p>
<heading id="h0010"><i>Identifying Unique Nuclease Target Sites within a Genome</i></heading>
<p id="p0082" num="0082">Some embodiments of this disclosure provide a method for selecting a nuclease target site within a genome. As described in more detail elsewhere herein, it was surprisingly discovered that off target sites cleaved by a given nuclease are typically highly similar to the consensus target site, <i>e.g.</i>, differing from the consensus target site in only one, only two, only three, only four, or only five nucleotide residues. Based on this discovery, a nuclease target sites within the genome can be selected to increase the likelihood of a nuclease targeting this site not cleaving any off target sites within the genome. For example, in some embodiments, a method is provided that comprises identifying a candidate nuclease target site; and comparing the candidate nuclease target site to other sequences within the genome. Methods for comparing candidate nuclease target sites to other sequences within the genome are well known to those of skill in the art and include for example sequence alignment methods, for example, using a sequence alignment software or algorithm such as BLAST on a general purpose computer. A suitable unique nuclease target site can then be selected based on the results of the sequence comparison. In some embodiments, if the candidate nuclease target site differs from any other sequence within the genome by at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 nucleotides, the nuclease target site is selected as a unique site within the genome, whereas if the site does not fulfill this criteria, the site may be discarded. In some embodiments, once a site is selected<!-- EPO <DP n="47"> --> based on the sequence comparison, as outlined above, a site-specific nuclease targeting the selected site is designed. For example, a zinc finger nuclease may be designed to target any selected nuclease target site by constructing a zinc finger array binding the target site, and conjugating the zinc finger array to a DNA cleavage domain. In embodiments where the DNA cleavage domain needs to dimerize in order to cleave DNA, to zinc finger arrays will be designed, each binding a half site of the nuclease target site, and each conjugated to a cleavage domain. In some embodiments, nuclease designing and/or generating is done by recombinant technology. Suitable recombinant technologies are well known to those of skill in the art, and the disclosure is not limited in this respect.</p>
<p id="p0083" num="0083">In some embodiments, a site-specific nuclease designed or generated according to aspects of this disclosure is isolated and/or purified. The methods and strategies for designing site-specific nucleases according to aspects of this disclosure can be applied to design or generate any site-specific nuclease, including, but not limited to Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases (TALENs), a homing endonuclease, an organic compound nuclease, or an enediyne antibiotic (e.g., dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin).</p>
<heading id="h0011"><i>Isolated Nucleases</i></heading>
<p id="p0084" num="0084">Some aspects of this disclosure provide isolated site-specific nucleases with enhanced specificity that are designed using the methods and strategies described herein. Some embodiments of this disclosure provide nucleic acids encoding such nucleases. Some embodiments of this disclosure provide expression constructs comprising such encoding nucleic acids. For example, in some embodiments an isolated nuclease is provided that has been engineered to cleave a desired target site within a genome, and has been evaluated according to a method provided herein to cut less than 1, less than 2, less than 3, less than 4, less than 5, less than 6, less than 7, less than 8, less than 9 or less than 10 off-target sites at a concentration effective for the nuclease to cut its intended target site. In some embodiments an isolated nuclease is provided that has been engineered to cleave a desired unique target site that has been selected to differ from any other site within a genome by at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 nucleotide residues. In some embodiments, the isolated nuclease is an RNA-programmable nuclease, such as a Cas9 nuclease; a Zinc Finger Nuclease (ZFN); or a Transcription Activator-Like Effector Nuclease (TALEN), a homing endonuclease, an organic compound nuclease, or an enediyne antibiotic (e.g., dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin). In some<!-- EPO <DP n="48"> --> embodiments, the isolated nuclease cleaves a target site within an allele that is associated with a disease or disorder. In some embodiments, the isolated nuclease cleaves a target site the cleavage of which results in treatment or prevention of a disease or disorder. In some embodiments, the disease is HIV/AIDS, or a proliferative disease. In some embodiments, the allele is a CCR5 (for treating HIV/AIDS) or a VEGFA allele (for treating a proliferative disease).</p>
<p id="p0085" num="0085">In some embodiments of the disclosure, the isolated nuclease is provided as part of a pharmaceutical composition. For example, some embodiments provide pharmaceutical compositions comprising a nuclease as provided herein, or a nucleic acid encoding such a nuclease, and a pharmaceutically acceptable excipient. Pharmaceutical compositions may optionally comprise one or more additional therapeutically active substances.</p>
<p id="p0086" num="0086">In some embodiments of the disclosure, compositions provided herein are administered to a subject, for example, to a human subject, in order to effect a targeted genomic modification within the subject. In some embodiments of the disclosure, cells are obtained from the subject and contacted with a nuclease or a nuclease-encoding nucleic acid ex vivo, and re-administered to the subject after the desired genomic modification has been effected or detected in the cells. Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions is contemplated include, but are not limited to, humans and/or other primates; mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, dogs, mice, and/or rats; and/or birds, including commercially relevant birds such as chickens, ducks, geese, and/or turkeys.</p>
<p id="p0087" num="0087">Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with an excipient and/or one or more other accessory ingredients, and then, if<!-- EPO <DP n="49"> --> necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.</p>
<p id="p0088" num="0088">Pharmaceutical formulations may additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. <nplcit id="ncit0044" npl-type="b"><text>Remington's The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro (Lippincott, Williams &amp; Wilkins, Baltimore, MD, 2006</text></nplcit>) discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation thereof. See also PCT application <patcit id="pcit0004" dnum="US2010055131W" dnum-type="L"><text>PCT/US2010/055131</text></patcit> for additional suitable methods, reagents, excipients and solvents for producing pharmaceutical compositions comprising a nuclease. Except insofar as any conventional excipient medium is incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this disclosure.</p>
<p id="p0089" num="0089">The function and advantage of these and other embodiments of the present invention will be more fully understood from the Examples below. The following Examples are intended to illustrate the benefits of the present invention and to describe particular embodiments, but are not intended to exemplify the full scope of the invention. Accordingly, it will be understood that the Examples are not meant to limit the scope of the invention.</p>
<heading id="h0012"><b>EXAMPLES</b></heading>
<heading id="h0013"><i>Materials and Methods</i></heading>
<p id="p0090" num="0090"><i>Oligonucleotides.</i> All oligonucleotides used in this study were purchased from Integrated DNA Technologies. Oligonucleotide sequences are listed in Table 9.</p>
<p id="p0091" num="0091"><i>Expression and Purification of S. pyogenes Cas9. E. coli</i> Rosetta (DE3) cells were transformed with plasmid pMJ806<sup>11</sup>, encoding the <i>S. pyogenes cas9</i> gene fused to an N-terminal 6xHis-tag/maltose binding protein. The resulting expression strain was inoculated in Luria-Bertani (LB) broth containing 100 µg/mL of ampicillin and 30 µg/mL of chloramphenicol at 37 °C overnight. The cells were diluted 1:100 into the same growth medium and grown at 37 °C to OD<sub>600</sub> ∼0.6. The culture was incubated at 18 °C for 30 min, and isopropyl β-D-1-thiogalactopyranoside (IPTG) was added at 0.2 mM to induce Cas9<!-- EPO <DP n="50"> --> expression. After ∼17 h, the cells were collected by centrifugation at 8,000 g and resuspended in lysis buffer (20 mM tris(hydroxymethyl)-aminomethane (Tris)-HCl, pH 8.0, 1 M KCl, 20 % glycerol, 1 mM tris (2-carboxyethyl)phosphine (TCEP)). The cells were lysed by sonication (10 sec pulse-on and 30 sec pulse-off for 10 min total at 6 W output) and the soluble lysate was obtained by centrifugation at 20,000 g for 30 min. The cell lysate was incubated with nickel-nitriloacetic acid (nickel-NTA) resin (Qiagen) at 4 °C for 20 min to capture His-tagged Cas9. The resin was transferred to a 20-mL column and washed with 20 column volumes of lysis buffer. Cas9 was eluted in 20 mM Tris-HCl (pH 8), 0.1 M KCl, 20 % glycerol, 1 mM TCEP, and 250 mM imidazole, and concentrated by Amicon ultra centrifugal filter (Millipore, 30-kDa molecular weight cut-off) to -50 mg/mL. The 6xHis tag and maltose-binding protein were removed by TEV protease treatment at 4 °C for 20 h and captured by a second Ni-affinity purification step. The eluent, containing Cas9, was injected into a HiTrap SP FF column (GE Healthcare) in purification buffer containing 20 mM Tris-HCl (pH 8), 0.1 M KCl, 20 % glycerol, and 1 mM TCEP. Cas9 was eluted with purification buffer containing a linear KCl gradient from 0.1 M to 1 M over five column volumes. The eluted Cas9 was further purified by a HiLoad Superdex 200 column in purification buffer, snap-frozen in liquid nitrogen, and stored in aliquots at -80 °C.</p>
<p id="p0092" num="0092"><i>In Vitro RNA Transcription.</i> 100 pmol CLTA(#) v2.1 fwd and v2.1 template rev were incubated at 95 °C and cooled at 0.1 °C/s to 37 °C in NEBuffer2 (50 mM sodium chloride, 10 mM Tris-HCl, 10 mM magnesium chloride, 1 mM dithiothreitol, pH 7.9) supplemented with 10 µM dNTP mix (Bio-Rad). 10 U of Klenow Fragment (3'→5' exo<sup>-</sup>) (NEB) were added to the reaction mixture and a double-stranded CLTA(#) v2.1 template was obtained by overlap extension for 1 h at 37 °C. 200 nM CLTA(#) v2.1 template alone or 100 nM CLTA(#) template with 100 nM T7 promoter oligo was incubated overnight at 37 °C with 0.16 U/µL of T7 RNA Polymerase (NEB) in NEB RNAPol Buffer (40 mM Tris-HCl, pH 7.9, 6 mM magnesium chloride, 10 mM dithiothreitol, 2 mM spermidine) supplemented with 1 mM rNTP mix (1 mM rATP, 1 mM rCTP, 1 mM rGTP, 1 mM rUTP). <i>In vitro</i> transcribed RNA was precipitated with ethanol and purified by gel electrophoresis on a Criterion 10% polyacrylamide TBE-Urea gel (Bio-Rad). Gel-purified sgRNA was precipitated with ethanol and redissolved in water.</p>
<p id="p0093" num="0093"><i>In Vitro Library Construction.</i> 10 pmol of CLTA(#) lib oligonucleotides were separately circularized by incubation with 100 units of CircLigase II ssDNA Ligase (Epicentre) in 1x CircLigase II Reaction Buffer (33 mM Tris-acetate, 66 mM potassium acetate, 0.5 mM dithiothreitol, pH 7.5) supplemented with 2.5 mM manganese chloride in a<!-- EPO <DP n="51"> --> total reaction volume of 20 µL for 16 hours at 60 °C. The reaction mixture was incubated for 10 minutes at 85 °C to inactivate the enzyme. 5 µL (5 pmol) of the crude circular single-stranded DNA were converted into the concatemeric pre-selection libraries with the illustra TempliPhi Amplification Kit (GE Healthcare) according to the manufacturer's protocol. Concatemeric pre-selection libraries were quantified with the Quant-it PicoGreen dsDNA Assay Kit (Invitrogen).</p>
<p id="p0094" num="0094"><i>In Vitro Cleavage of On-Target and Off-Target Substrates.</i> Plasmid templates for PCR were constructed by ligation of annealed oligonucleotides CLTA(#) site fwd/rev into <i>Hin</i>dIII/<i>Xba</i>I double-digested pUC19 (NEB). On-target substrate DNAs were generated by PCR with the plasmid templates and test fwd and test rev primers, then purified with the QIAquick PCR Purification Kit (Qiagen). Off-target substrate DNAs were generated by primer extension. 100 pmol off-target (#) fwd and off-target (#) rev primers were incubated at 95 °C and cooled at 0.1 °C/s to 37 °C in NEBuffer2 (50 mM sodium chloride, 10 mM Tris-HCl, 10 mM magnesium chloride, 1 mM dithiothreitol, pH 7.9) supplemented with 10 µM dNTP mix (Bio-Rad). 10 U of Klenow Fragment (3'→5' exo-) (NEB) were added to the reaction mixture and double-stranded off-target templates were obtained by overlap extension for 1 h at 37 °C followed by enzyme inactivation for 20 min at 75 °C, then purified with the QIAquick PCR Purification Kit (Qiagen). 200 nM substrate DNAs were incubated with 100 nM Cas9 and 100 nM (v1.0 or v2.1) sgRNA or 1000 nM Cas9 and 1000 nM (v1.0 or v2.1) sgRNA in Cas9 cleavage buffer (200 mM HEPES, pH 7.5, 1.5 M potassium chloride, 100 mM magnesium chloride, 1 mM EDTA, 5 mM dithiothreitol) for 10 min at 37 °C. On-target cleavage reactions were purified with the QIAquick PCR Purification Kit (Qiagen), and off-target cleavage reactions were purified with the QIAquick Nucleotide Removal Kit (Qiagen) before electrophoresis in a Criterion 5% polyacrylamide TBE gel (Bio-Rad).</p>
<p id="p0095" num="0095"><i>In Vitro Selection.</i> 200 nM concatemeric pre-selection libraries were incubated with 100 nM Cas9 and 100 nM sgRNA or 1000 nM Cas9 and 1000 nM sgRNA in Cas9 cleavage buffer (200 mM HEPES, pH 7.5, 1.5 M potassium chloride, 100 mM magnesium chloride, 1 mM EDTA, 5 mM dithiothreitol) for 10 min at 37 °C. Pre-selection libraries were also separately incubated with 2 U of BspMI restriction endonuclease (NEB) in NEBuffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol, pH 7.9) for 1 h at 37 °C. Blunt-ended post-selection library members or sticky-ended pre-selection library members were purified with the QIAQuick PCR Purification Kit (Qiagen) and ligated to 10 pmol adapter1/2(AACA) (Cas9:v2.1 sgRNA, 100 nM), adapter1/2(TTCA) (Cas9:v2.1 sgRNA, 1000 nM), adapter1/2 (Cas9:v2.1 sgRNA, 1000 nM), or lib adapter1/CLTA(#) lib<!-- EPO <DP n="52"> --> adapter 2 (pre-selection) with 1,000 U of T4 DNA Ligase (NEB) in NEB T4 DNA Ligase Reaction Buffer (50 mM Tris-HCl, pH 7.5, 10 mM magnesium chloride, 1 mM ATP, 10 mM dithiothreitol) overnight (&gt; 10 h) at room temperature. Adapter-ligated DNA was purified with the QIAquick PCR Purification Kit and PCR-amplified for 10-13 cycles with Phusion Hot Start Flex DNA Polymerase (NEB) in Buffer HF (NEB) and primers CLTA(#) sel PCR/PE2 short (post-selection) or CLTA(#) lib seq PCR/lib fwd PCR (pre-selection). Amplified DNAs were gel purified, quantified with the KAPA Library Quantification Kit-Illumina (KAPA Biosystems), and subjected to single-read sequencing on an Illumina MiSeq or Rapid Run single-read sequencing on an Illumina HiSeq 2500 (Harvard University FAS Center for Systems Biology Core facility, Cambridge, MA).</p>
<p id="p0096" num="0096"><i>Selection Analysis.</i> Pre-selection and post-selection sequencing data were analyzed as previously described<sup>21</sup>, with modification (Algorithms) using scripts written in C++. Raw sequence data is not shown; see Table 2 for a curated summary. Specificity scores were calculated with the formulae: positive specificity score = (frequency of base pair at position[post-selection] - frequency of base pair at position[pre-selection]) / (1 - frequency of base pair at position[pre-selection]) and negative specificity score = (frequency of base pair at position[post-selection] - frequency of base pair at position[pre-selection]) / (frequency of base pair at position[pre-selection]). Normalization for sequence logos was performed as previously described<sup>22</sup>.</p>
<p id="p0097" num="0097"><i>Cellular Cleavage Assays.</i> HEK293T cells were split at a density of 0.8x10<sup>5</sup> per well (6-well plate) before transcription and maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in a 37°C humidified incubator with 5% CO<sub>2</sub>. After 1 day, cells were transiently transfected using Lipofectamine 2000 (Invitrogen) following the manufacturer's protocols. HEK293T cells were transfected at 70% confluency in each well of 6-well plate with 1.0 µg of the Cas9 expression plasmid (Cas9-HA-2xNLS-GFP-NLS) and 2.5 µg of the single-strand RNA expression plasmid pSiliencer-CLTA (version 1.0 or 2.1). The transfection efficiencies were estimated to be ∼70%, based on the fraction of GFP-positive cells observed by fluorescence microscopy. 48 h after transfection, cells were washed with phosphate buffered saline (PBS), pelleted and frozen at -80 °C. Genomic DNA was isolated from 200 µL cell lysate using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer's protocol.</p>
<p id="p0098" num="0098"><i>Off-Target Site Sequence Determination.</i> 100 ng genomic DNA isolated from cells treated with Cas9 expression plasmid and single-strand RNA expression plasmid (treated cells) or Cas9 expression plasmid alone (control cells) were amplified by PCR with<!-- EPO <DP n="53"> --> 10 s 72°C extension for 35 cycles with primers CLTA(#)-(#)-(#) fwd and CLTA(#)-(#)-(#) rev and Phusion Hot Start Flex DNA Polymerase (NEB) in Buffer GC (NEB), supplemented with 3% DMSO. Relative amounts of crude PCR products were quantified by gel, and Cas9-treated (control) and Cas9:sgRNA-treated PCRs were separately pooled in equimolar concentrations before purification with the QIAquick PCR Purification Kit (Qiagen). Purified DNA was amplified by PCR with primers PE1-barcode# and PE2-barcode# for 7 cycles with Phusion Hot Start Flex DNA Polymerase (NEB) in Buffer HF (NEB). Amplified control and treated DNA pools were purified with the QIAquick PCR Purification Kit (Qiagen), followed by purification with Agencourt AMPure XP (Beckman Coulter). Purified control and treated DNAs were quantified with the KAPA Library Quantification Kit-Illumina (KAPA Biosystems), pooled in a 1:1 ratio, and subjected to paired-end sequencing on an Illumina MiSeq.</p>
<p id="p0099" num="0099"><i>Statistical Analysis.</i> Statistical analysis was performed as previously described<sup>21</sup>. P-values in Table 1 and Table 6 were calculated for a one-sided Fisher exact test.</p>
<heading id="h0014"><i>Algorithms</i></heading>
<p id="p0100" num="0100">All scripts were written in C++. Algorithms used in this study are as previous reported (reference) with modification.</p>
<p id="p0101" num="0101"><i>Sequence binning.</i> 1) designate sequence pairs starting with the barcode <i>"AACA"</i> or "TTCA" as post-selection library members. 2) for post-selection library members (with illustrated example):<br/>
example read:
<img id="ib0004" file="imgb0004.tif" wi="160" he="20" img-content="dna" img-format="tif"/>
<ol id="ol0001" ol-style="">
<li>i) search both paired reads for the positions, pos1 and pos2, of the constant sequence "<b>CTCGGCAGGT</b>" (SEQ ID NO:43). ii) keep only sequences that have <u style="double">identical sequences</u> between the barcode and pos1 and preceding pos2. iii) keep the region between the two instances of the constant sequence (the region between the barcode and pos1 contains a cut half-site; the region that is between the two instances of the constant sequence contains a full site)<br/>
<!-- EPO <DP n="54"> -->example: ACTTGCAGATGTAGTCTTTCCA<u style="double">CATGGGTCGACACAAACACAA</u> (SEQ ID NO:44)</li>
<li>ii) search the sequence for a selection barcode ("<u style="single">TGTGTTTGTGTT</u>" (SEQ ID NO:45) for CLTA1,<br/>
"<u style="single">AGAAGAAGAAGA</u>" (SEQ ID NO:46) for CLTA2, "<u style="single">TTCTCTTTCTCT</u>" (SEQ ID NO:47) for CLTA3, "<u style="single">ACACAAACACAA</u>" (SEQ ID NO:48) for CLTA4)<br/>
example: ACTTGCAGATGTAGTCTTTCCACATGGGTCG<u style="single">ACACAAACACAA</u> (SEQ ID NO:49) - CLTA4</li>
<li>iii) the sequence before the barcode is the full post-selection library member (first four and last four nucleotides are fully randomized flanking sequence)<br/>
example: ACTT GCAGATGTAGTCTTTCCACATGG GTCG (SEQ ID NO:50)</li>
<li>iv) parse the quality scores for the positions corresponding to the 23 nucleotide post-selection library member<br/>
example read:
<img id="ib0005" file="imgb0005.tif" wi="163" he="22" img-content="dna" img-format="tif"/>
<img id="ib0006" file="imgb0006.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>v) keep sequences only if the corresponding quality score string (underlined) FASTQ quality characters for the sequence are '?' or higher in ASCII code (Phred quality score &gt;= 30)</li>
</ol></p>
<heading id="h0015"><i>NHEJ sequence calling</i></heading>
<p id="p0102" num="0102">
<ul id="ul0002" list-style="none" compact="compact">
<li>example read:
<img id="ib0007" file="imgb0007.tif" wi="161" he="12" img-content="dna" img-format="tif"/><!-- EPO <DP n="55"> -->
<img id="ib0008" file="imgb0008.tif" wi="153" he="13" img-content="dna" img-format="tif"/></li>
<li>example quality scores:
<img id="ib0009" file="imgb0009.tif" wi="161" he="26" img-content="dna" img-format="tif"/>
<ul id="ul0003" list-style="none">
<li>1) identify the <u style="single">20 base pairs flanking both sides</u> of <b>20 base pair target site</b> + <b>three base pair PAM</b> for each target site<br/>
example flanking sequences:
<ul id="ul0004" list-style="none" compact="compact">
<li><u style="single">GCTGGTGCACTGAAGAGCCA</u> (SEQ ID NO:53)</li>
<li><u style="single">AATATCTTAATCCTACTCAG</u> (SEQ ID NO:54)</li>
</ul></li>
<li>2) search all sequence reads for the flanking sequences to identify the potential off-target site (the sequence between the flanking sequences)<br/>
example potential off-target site: <b>CCCTGTGAAACACTACATCTGC</b> (SEQ ID NO:55)</li>
<li>3) if the potential off-target site contains indels (length is less than 23), keep sequence as potential off-target site if all corresponding FASTQ quality characters for the sequence are '?' or higher in ASCII code (Phred quality score &gt;= 30)<br/>
example potential off-target site length = 22 example corresponding FASTQ quality characters: HHGHHHHHHHHHHHHHHHHHHH</li>
<li>4) bin and manually inspect all sequences that pass steps 2 and 3 and keep sequences as potential modified sequences if they have at least one deletion involving position 16, 17, or 18 (of 20 counting from the non-PAM end) of if they have an insertion between position 17 and 18, consistent with the most frequent modifications observed for the intended target site (<figref idref="f0006 f0007 f0008"><b>Figure 3</b></figref>)<br/>
<!-- EPO <DP n="56"> -->example potential off-target site (reverse complement, with positions labeled) with reference sequence:<br/>
11111111112222<br/>
non-PAM end 12345678901234567890123 PAM end
<ul id="ul0005" list-style="none" compact="compact">
<li>GCAGATGTAGTGTTTC-ACAGGG (SEQ ID NO:56)</li>
<li>GCAGATGTAGTGTTTCCACAGGG (SEQ ID NO:57)</li>
</ul></li>
<li>4) repeat steps 1-3 for read2 and keep only if the sequence is the same</li>
<li>5) compare overall counts in Cas9+sgRNA treated sample to Cas9 alone sample to identify modified sites</li>
</ul></li>
</ul></p>
<heading id="h0016"><i>Filter based on cleavage site (for post-selection sequences)</i></heading>
<p id="p0103" num="0103">
<ol id="ol0002" compact="compact" ol-style="">
<li>1) tabulate the cleavage site locations across the recognition site by identifying the first position in the full sequenced recognition site (between the two constant sequences) that is identical to the first position in the sequencing read after the barcode (before the first constant sequence).</li>
<li>2) after tabulation, repeat step 1, keeping only sequences with cleavage site locations that are present in at least 5% of the sequencing reads.</li>
</ol></p>
<heading id="h0017"><i>Results</i></heading>
<heading id="h0018"><b><i>Broad off-target DNA cleavage profiling reveals RNA-programmed Cas9 nuclease specificity.</i></b></heading>
<p id="p0104" num="0104">Sequence-specific endonucleases including zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) have become important tools to modify genes in induced pluripotent stem cells (iPSCs),<sup>1-3</sup> in multi-cellular organisms,<sup>4-8</sup> and in <i>ex vivo</i> gene therapy clinical trials.<sup>9,10</sup> Although ZFNs and TALENs have proved effective for such genetic manipulation, a new ZFN or TALEN protein must be generated for each DNA target site. In contrast, the RNA-guided Cas9 endonuclease uses RNA:DNA hybridization to determine target DNA cleavage sites, enabling a single monomeric protein to cleave, in principle, any sequence specified by the guide RNA.<sup>11</sup></p>
<p id="p0105" num="0105">Previous studies<sup>12-17</sup> demonstrated that Cas9 mediates genome editing at sites complementary to a 20-nucleotide sequence in a bound guide RNA. In addition, target sites<!-- EPO <DP n="57"> --> must include a protospacer adjacent motif (PAM) at the 3' end adjacent to the 20-nucleotide target site; for <i>Streptococcus pyogenes</i> Cas9, the PAM sequence is NGG. Cas9-mediated DNA cleavage specificity both <i>in vitro</i> and in cells has been inferred previously based on assays against small collections of potential single-mutation off-target sites. These studies suggested that perfect complementarity between guide RNA and target DNA is required in the 7-12 base pairs adjacent to the PAM end of the target site (3' end of the guide RNA) and mismatches are tolerated at the non-PAM end (5' end of the guide RNA).<sup>11, 12, 17-19</sup></p>
<p id="p0106" num="0106">Although such a limited number of nucleotides specifying Cas9:guide RNA target recognition would predict multiple sites of DNA cleavage in genomes of moderate to large size (&gt; ∼10<sup>7</sup> bp), Cas9:guide RNA complexes have been successfully used to modify both cells<sup>12, 13, 15</sup> and organisms.<sup>14</sup> A study using Cas9:guide RNA complexes to modify zebrafish embryos observed toxicity at a rate similar to that of ZFNs and TALENs.<sup>14</sup> A recent, broad study of the specificity of DNA binding (transcriptional repression) in <i>E. coli</i> of a catalytically inactive Cas9 mutant using high-throughput sequencing found no detectable off-target transcriptional repression in the relatively small <i>E. coli</i> transcriptome.<sup>20</sup> While these studies have substantially advanced our basic understanding of Cas9, a systematic and comprehensive profile of Cas9:guide RNA-mediated DNA cleavage specificity generated from measurements of Cas9 cleavage on a large number of related mutant target sites has not been described. Such a specificity profile is needed to understand and improve the potential of Cas9:guide RNA complexes as research tools and future therapeutic agents.</p>
<p id="p0107" num="0107">We modified our previously published <i>in vitro</i> selection,<sup>21</sup> adapted to process the blunt-ended cleavage products produced by Cas9 compared to the overhang-containing products of ZFN cleavage, to determine the off-target DNA cleavage profiles of Cas9: single guide RNA (sgRNA)<sup>11</sup> complexes. Each selection experiment used DNA substrate libraries containing ∼10<sup>12</sup> sequences, a size sufficiently large to include ten-fold coverage of all sequences with eight or fewer mutations relative to each 22-base pair target sequence (including the two-base pair PAM) (<figref idref="f0001 f0002">FIG. 1</figref>). We used partially randomized nucleotide mixtures at all 22 target-site base pairs to create a binomially distributed library of mutant target sites with an expected mean of 4.62 mutations per target site. In addition, target site library members were flanked by four fully randomized base pairs on each side to test for specificity patterns beyond those imposed by the canonical 20-base pair target site and PAM</p>
<p id="p0108" num="0108">Pre-selection libraries of 10<sup>12</sup> individual potential off-target sites were generated for each of four different target sequences in the human clathrin light chain A (<i>CLTA</i>) gene (<figref idref="f0006 f0007 f0008">FIG. 3</figref>). Synthetic 5'-phosphorylated 53-base oligonucleotides were self-ligated<!-- EPO <DP n="58"> --> into circular single-stranded DNA <i>in vitro</i>, then converted into concatemeric 53-base pair repeats through rolling-circle amplification. The resulting pre-selection libraries were incubated with their corresponding Cas9:sgRNA complexes. Cleaved library members containing free 5' phosphates were separated from intact library members through the 5' phosphate-dependent ligation of non-phosphorylated double-stranded sequencing adapters. The ligation-tagged post-selection libraries were amplified by PCR. The PCR step generated a mixture of post-selection DNA fragments containing 0.5, 1.5, or 2.5, etc. repeats of library members cleaved by Cas9, resulting from amplification of an adapter-ligated cut half-site with or without one or more adjacent corresponding full sites (<figref idref="f0001 f0002">FIG. 1</figref>). Post-selection library members with 1.5 target-sequence repeats were isolated by gel purification and analyzed by high-throughput sequencing. In a final computational selection step to minimize the impact of errors during DNA amplification or sequencing, only sequences with two identical copies of the repeated cut half-site were analyzed.</p>
<p id="p0109" num="0109">Pre-selection libraries were incubated under enzyme-limiting conditions (200 nM target site library, 100 nM Cas9:sgRNA v2.1) or enzyme-saturating conditions (200 nM target site library, 1000 nM Cas9:sgRNA v2.1) for each of the four guide RNAs targets tested (CLTA1, CLTA2, CLTA3, and CLTA4) (<figref idref="f0007">FIG. 3C</figref> and <figref idref="f0008">3D</figref>). A second guide RNA construct, sgRNA v1.0, which is less active than sgRNA v2.1, was assayed under enzyme-saturating conditions alone for each of the four guide RNA targets tested (200 nM target site library, 1000 nM Cas9:sgRNA v1.0). The two guide RNA constructs differ in their length (<figref idref="f0006 f0007 f0008">FIG. 3</figref>) and in their DNA cleavage activity level under the selection conditions, consistent with previous reports<sup>15</sup> (<figref idref="f0009">FIG. 4</figref>). Both pre-selection and post-selection libraries were characterized by high-throughput DNA sequencing and computational analysis. As expected, library members with fewer mutations were significantly enriched in post-selection libraries relative to pre-selection libraries (<figref idref="f0010 f0011 f0012">FIG. 5</figref>).</p>
<p id="p0110" num="0110"><i>Pre- and Post-Selection Library Composition.</i> The pre-selection libraries for CLTA1, CLTA2, CLTA3, and CLTA4 had observed mean mutation rates of 4.82 (n = 1,129,593), 5.06 (n = 847,618), 4.66 (n = 692,997), and 5.00 (n = 951,503) mutations per 22-base pair target site, including the two-base pair PAM, respectively. The post-selection libraries treated under enzyme-limiting conditions with Cas9 plus CLTA1, CLTA2, CLTA3, or CLTA4 v.2.1 sgRNAs contained means of 1.14 (n= 1,206,268), 1.21 (n = 668,312), 0.91 (n = 1,138,568), and 1.82 (n= 560,758) mutations per 22-base pair target site. Under enzyme-excess conditions, the mean number of mutations among sequences surviving selection increased to 1.61 (n= 640,391), 1.86 (n = 399,560), 1.46 (n = 936,414), and 2.24<!-- EPO <DP n="59"> --> (n= 506,179) mutations per 22-base pair target site, respectively, for CLTA1, CLTA2, CLTA3, or CLTA4 v2.1 sgRNAs. These results reveal that the selection significantly enriched library members with fewer mutations for all Cas9:sgRNA complexes tested, and that enzyme-excess conditions resulted in the putative cleavage of more highly mutated library members compared with enzyme-limiting conditions (<figref idref="f0010 f0011 f0012">FIG. 5</figref>).</p>
<p id="p0111" num="0111">We calculated specificity scores to quantify the enrichment level of each base pair at each position in the post-selection library relative to the pre-selection library, normalized to the maximum possible enrichment of that base pair. Positive specificity scores indicate base pairs that were enriched in the post-selection library and negative specificity scores indicate base pairs that were de-enriched in the post-selection library. For example, a score of +0.5 indicates that a base pair is enriched to 50% of the maximum enrichment value, while a score of -0.5 indicates that a base pair is de-enriched to 50% of the maximum deenrichment value.</p>
<p id="p0112" num="0112">In addition to the two base pairs specified by the PAM, all 20 base pairs targeted by the guide RNA were enriched in the sequences from the CLTA1 and CLTA2 selections (<figref idref="f0003 f0004 f0005">FIG. 2</figref>, <figref idref="f0013 f0014">FIG. 6</figref> and <figref idref="f0019">9</figref>, and Table 2). For the CLTA3 and CLTA4 selections (<figref idref="f0015 f0016">FIG. 7</figref> and <figref idref="f0017 f0018">8</figref>, and Table 2), guide RNA-specified base pairs were enriched at all positions except for the two most distal base pairs from the PAM (5' end of the guide RNA), respectively. At these non-specified positions farthest from the PAM, at least two of the three alternate base pairs were nearly as enriched as the specified base pair. Our finding that the entire 20 base-pair target site and two base pair PAM can contribute to Cas9:sgRNA DNA cleavage specificity contrasts with the results from previous single-substrate assays suggesting that only 7-12 base pairs and two base pair PAM are specified.<sup>11, 12, 15</sup></p>
<p id="p0113" num="0113">All single-mutant pre-selection (n ≥ 14,569) and post-selection library members (<i>n</i> ≥ 103,660) were computationally analyzed to provide a selection enrichment value for every possible single-mutant sequence. The results of this analysis (<figref idref="f0003 f0004 f0005">FIG. 2</figref> and <figref idref="f0013 f0014">FIG. 6</figref> and <figref idref="f0017">8</figref>) show that when only single-mutant sequences are considered, the six to eight base pairs closest to the PAM are generally highly specified and the non-PAM end is poorly specified under enzyme-limiting conditions, consistent with previous findings.<sup>11, 12, 17-19</sup> Under enzyme-saturating conditions, however, single mutations even in the six to eight base pairs most proximal to the PAM are tolerated, suggesting that the high specificity at the PAM end of the DNA target site can be compromised when enzyme concentrations are high relative to substrate (<figref idref="f0003 f0004 f0005">FIG. 2</figref>). The observation of high specificity against single mutations close to the PAM only applies to sequences with a single mutation and the selection results<!-- EPO <DP n="60"> --> do not support a model in which any combination of mutations is tolerated in the region of the target site farthest from the PAM (<figref idref="f0021 f0022 f0023 f0024 f0025 f0026 f0027 f0028 f0029 f0030 f0031">FIG. 10-15</figref>). Analyses of pre- and post-selection library composition are described elsewhere herein, position-dependent specificity patterns are illustrated in <figref idref="f0037 f0038 f0039 f0040 f0041">FIGs 18-20</figref>, PAM nucleotide specificity is illustrated in <figref idref="f0043 f0044 f0045 f0046 f0047 f0048 f0049">FIGs 21-24</figref>, and more detailed effects of Cas9:sgRNA concentration on specificity are described in <figref idref="f0005">FIG. 2G</figref> and <figref idref="f0050 f0051">FIG. 25</figref>).</p>
<p id="p0114" num="0114"><i>Specificity at the Non-PAM End of the Target Site.</i> To assess the ability of Cas9:v2.1 sgRNA under enzyme-excess conditions to tolerate multiple mutations distal to the PAM, we calculated maximum specificity scores at each position for sequences that contained mutations only in the region of one to 12 base pairs at the end of the target site most distal from the PAM (<figref idref="f0021 f0022 f0023 f0024 f0025 f0026 f0027 f0028 f0029 f0030 f0031 f0032 f0033 f0034 f0035">FIG. 10-17</figref>).</p>
<p id="p0115" num="0115">The results of this analysis show no selection (maximum specificity score ∼ 0) against sequences with up to three mutations, depending on the target site, at the end of the molecule farthest from the PAM when the rest of the sequence contains no mutations. For example, when only the three base pairs farthest from the PAM are allowed to vary (indicated by dark bars in <figref idref="f0022">FIG. 11C</figref>) in the CLTA2 target site, the maximum specificity scores at each of the three variable positions are close to zero, indicating that there was no selection for any of the four possible base pairs at each of the three variable positions. However, when the eight base pairs farthest from the PAM are allowed to vary (<figref idref="f0023">FIG. 11H</figref>), the maximum specificity scores at positions 4-8 are all greater than +0.4, indicating that the Cas9:sgRNA has a sequence preference at these positions even when the rest of the substrate contains preferred, on-target base pairs.</p>
<p id="p0116" num="0116">We also calculated the distribution of mutations (<figref idref="f0031 f0032 f0033 f0034 f0035">FIG. 15-17</figref>), in both pre-selection and v2.1 sgRNA-treated post-selection libraries under enzyme-excess conditions, when only the first 1-12 base pairs of the target site are allowed to vary. There is significant overlap between the pre-selection and post-selection libraries for only a subset of the data (<figref idref="f0031 f0032 f0033 f0034 f0035">FIG. 15-17</figref>, a-c), demonstrating minimal to no selection in the post-selection library for sequences with mutations only in the first three base pairs of the target site. These results collectively show that Cas9:sgRNA can tolerate a small number of mutations (∼one to three) at the end of the sequence farthest from the PAM when provided with maximal sgRNA:DNA interactions in the rest of the target site.</p>
<p id="p0117" num="0117"><i>Specificity at the PAM End of the Target Site.</i> We plotted positional specificity as the sum of the magnitudes of the specificity scores for all four base pairs at each position of each target site, normalized to the same sum for the most highly specified position (<figref idref="f0037 f0038 f0039 f0040 f0041">FIG.<!-- EPO <DP n="61"> --> 18-20</figref>). Under both enzyme-limiting and enzyme-excess conditions, the PAM end of the target site is highly specified. Under enzyme-limiting conditions, the PAM end of the molecule is almost absolutely specified (specificity score ≥ +0.9 for guide RNA-specified base pairs) by CLTA1, CTLA2, and CLTA3 guide RNAs (<figref idref="f0003 f0004 f0005">FIG. 2</figref> and <figref idref="f0013 f0019">FIG. 6-9</figref>), and highly specified by CLTA4 guide RNA (specificity score of +0.7 to +0.9). Within this region of high specificity, specific single mutations, consistent with wobble pairing between the guide RNA and target DNA, that are tolerated. For example, under enzyme-limiting conditions for single-mutant sequences, a dA:dT off-target base pair and a guide RNA-specified dG:dC base pair are equally tolerated at position 17 out of 20 (relative to the non-PAM end of the target site) of the CLTA3 target site. At this position, an rG:dT wobble RNA:DNA base pair may be formed, with minimal apparent loss of cleavage activity.</p>
<p id="p0118" num="0118">Importantly, the selection results also reveal that the choice of guide RNA hairpin affects specificity. The shorter, less-active sgRNA v1.0 constructs are more specific than the longer, more-active sgRNA v2.1 constructs when assayed under identical, enzyme-saturating conditions that reflect an excess of enzyme relative to substrate in a cellular context (<figref idref="f0003 f0004 f0005">FIG. 2</figref> and <figref idref="f0010 f0017">FIGs. 5-8</figref>). The higher specificity of sgRNA v1.0 over sgRNA v2.1 is greater for CLTA1 and CLTA2 (∼40-90% difference) than for CLTA3 and CLTA4 (&lt; 40% difference). Interestingly, this specificity difference is localized to different regions of the target site for each target sequence (<figref idref="f0005">FIGs. 2H</figref> and <figref idref="f0052 f0053">26</figref>). Collectively, these results indicate that different guide RNA architectures result in different DNA cleavage specificities, and that guide RNA-dependent changes in specificity do not affect all positions in the target site equally. Given the inverse relationship between Cas9:sgRNA concentration and specificity described above, we speculate that the differences in specificity between guide RNA architectures arises from differences in their overall level of DNA-cleavage activities.</p>
<p id="p0119" num="0119"><i>Effects of Cas9:sgRNA Concentration on DNA Cleavage Specificity.</i> To assess the effect of enzyme concentration on patterns of specificity for the four target sites tested, we calculated the concentration-dependent difference in positional specificity and compared it to the maximal possible change in positional specificity (<figref idref="f0050 f0051">FIG. 25</figref>). In general, specificity was higher under enzyme-limiting conditions than enzyme-excess conditions. A change from enzyme-excess to enzyme-limiting conditions generally increased the specificity at the PAM end of the target by ≥ 80% of the maximum possible change in specificity. Although a decrease in enzyme concentration generally induces small (∼30%) increases in specificity at the end of the target sites farthest from the PAM, concentration decreases induce much larger increases in specificity at the end of the target site nearest the PAM. For<!-- EPO <DP n="62"> --> CLTA4, a decrease in enzyme concentration is accompanied by a small (∼30%) decrease in specificity at some base pairs near the end of the target site farthest from the PAM</p>
<p id="p0120" num="0120"><i>Specificity of PAM Nucleotides.</i> To assess the contribution of the PAM to specificity, we calculated the abundance of all 16 possible PAM dinucleotides in the pre-selection and post-selection libraries, considering all observed post-selection target site sequences (<figref idref="f0042 f0043">FIG. 21</figref>) or considering only post-selection target site sequences that contained no mutations in the 20 base pairs specified by the guide RNA (<figref idref="f0044 f0045">FIG. 22</figref>). Considering all observed post-selection target site sequences, under enzyme-limiting conditions, GG dinucleotides represented 99.8%, 99.9%, 99.8%, and 98.5% of the post-selection PAM dinucleotides for selections with CLTA1, CLTA2, CLTA3, and CLTA4 v2.1 sgRNAs, respectively. In contrast, under enzyme-excess conditions, GG dinucleotides represented 97.7%, 98.3%, 95.7%, and 87.0% of the post-selection PAM dinucleotides for selections with CLTA1, CLTA2, CLTA3, and CLTA4 v2.1 sgRNAs, respectively. These data demonstrate that an increase in enzyme concentration leads to increased cleavage of substrates containing non-canonical PAM dinucleotides.</p>
<p id="p0121" num="0121">To account for the pre-selection library distribution of PAM dinucleotides, we calculated specificity scores for the PAM dinucleotides (<figref idref="f0046 f0047">FIG. 23</figref>). When only on-target post-selection sequences are considered under enzyme-excess conditions (<figref idref="f0048 f0049">FIG. 24</figref>), non-canonical PAM dinucleotides with a single G rather than two Gs are relatively tolerated. Under enzyme-excess conditions, Cas9:CLTA4 sgRNA 2.1 exhibited the highest tolerance of non-canonical PAM dinucleotides of all the Cas9:sgRNA combinations tested. AG and GA dinucleotides were the most tolerated, followed by GT, TG, and CG PAM dinucleotides. In selections with Cas9:CLTA1, 2, or 3 sgRNA 2.1 under enzyme-excess conditions, AG was the predominate non-canonical PAM (<figref idref="f0046 f0047">FIG. 23</figref> and <figref idref="f0048 f0049">24</figref>). Our results are consistent with another recent study of PAM specificity, which shows that Cas9:sgRNA can recognize AG PAM dinucleotides<sup>23</sup>. In addition, our results show that under enzyme-limiting conditions, GG PAM dinucleotides are highly specified, and under enzyme-excess conditions, non-canonical PAM dinucleotides containing a single G can be tolerated, depending on the guide RNA context.</p>
<p id="p0122" num="0122">To confirm that the <i>in vitro</i> selection results accurately reflect the cleavage behavior of Cas9 <i>in vitro</i>, we performed discrete cleavage assays of six CLTA4 off-target substrates containing one to three mutations in the target site. We calculated enrichment values for all sequences in the post-selection libraries for the Cas9:CLTA4 v2.1 sgRNA under enzyme-saturating conditions by dividing the abundance of each sequence in the post-selection<!-- EPO <DP n="63"> --> library by the calculated abundance in the pre-selection library. Under enzyme-saturating conditions, the single one, two, and three mutation sequences with the highest enrichment values (27.5, 43.9, and 95.9) were cleaved to ≥ 71% completion (<figref idref="f0054">FIG. 27</figref>). A two-mutation sequence with an enrichment value of 1.0 was cleaved to 35%, and a two-mutation sequence with an enrichment value near zero (0.064) was not cleaved. The three-mutation sequence, which was cleaved to 77% by CLTA4 v2.1 sgRNA, was cleaved to a lower efficiency of 53% by CLTA4 v1.0 sgRNA (<figref idref="f0055">FIG. 28</figref>). These results indicate that the selection enrichment values of individual sequences are predictive of <i>in vitro</i> cleavage efficiencies.</p>
<p id="p0123" num="0123">To determine if results of the <i>in vitro</i> selection and <i>in vitro</i> cleavage assays pertain to Cas9:guide RNA activity in human cells, we identified 51 off-target sites (19 for CLTA1 and 32 for CLTA4) containing up to eight mutations that were both enriched in the <i>in vitro</i> selection and present in the human genome (Tables 3-5). We expressed Cas9:CLTA1 sgRNA v1.0, Cas9:CLTA1 sgRNA v2.1, Cas9:CLTA4 sgRNA v1.0, Cas9:CLTA4 sgRNA v2.1, or Cas9 without sgRNA in HEK293T cells by transient transfection and used genomic PCR and high-throughput DNA sequencing to look for evidence of Cas9:sgRNA modification at 46 of the 51 off-target sites as well as at the on-target loci; no specific amplified DNA was obtained for five of the 51 predicted off-target sites (three for CLTA1 and two for CLTA4).</p>
<p id="p0124" num="0124">Deep sequencing of genomic DNA isolated from HEK293T cells treated with Cas9:CLTA1 sgRNA or Cas9:CLTA4 sgRNA identified sequences evident of non-homologous end-joining (NHEJ) at the on-target sites and at five of the 49 tested off-target sites (CLTA1-1-1, CLTA1-2-2, CLTA4-3-1, CLTA4-3-3, and CLTA4-4-8) (Tables 1 and 6-8). The CLTA4 target site was modified by Cas9:CLTA4 v2.1 sgRNA at a frequency of 76%, while off-target sites, CLTA4-3-1 CLTA4-3-3, and CLTA4-4-8, were modified at frequencies of 24%, 0.47% and 0.73%, respectively. The CLTA1 target site was modified by Cas9:CLTA1 v2.1 sgRNA at a frequency of 0.34%, while off-target sites, CLTA1-1-1 and CLTA1-2-2, were modified at frequencies of 0.09% and 0.16%, respectively.</p>
<p id="p0125" num="0125">Under enzyme-saturating conditions with the v2.1 sgRNA, the two verified CLTA1 off-target sites, CLTA1-1-1 and CLTA1-2-2, were two of the three most highly enriched sequences identified in the <i>in vitro</i> selection. CLTA4-3-1 and CLTA4-3-3 were the highest and third-highest enriched sequences of the seven CLTA4 three-mutation sequences enriched in the <i>in vitro</i> selection that are also present in the genome. The <i>in vitro</i> selection enrichment values of the four-mutation sequences were not calculated, since 12 out of the 14<!-- EPO <DP n="64"> --> CLTA4 sequences in the genome containing four mutations, including CLTA4-4-8, were observed at a level of only one sequence count in the post-selection library. Taken together, these results confirm that several of the off-target substrates identified in the <i>in vitro</i> selection that are present in the human genome are indeed cleaved by Cas9:sgRNA complexes in human cells, and also suggest that the most highly enriched genomic off-target sequences in the selection are modified in cells to the greatest extent.</p>
<p id="p0126" num="0126">The off-target sites we identified in cells were among the most-highly enriched in our <i>in vitro</i> selection and contain up to four mutations relative to the intended target sites. While it is possible that heterochromatin or covalent DNA modifications could diminish the ability of a Cas9:guide RNA complex to access genomic off-target sites in cells, the identification of five out of 49 tested cellular off-target sites in this study, rather than zero or many, strongly suggests that Cas9-mediated DNA cleavage is not limited to specific targeting of only a 7-12-base pair target sequence, as suggested in recent studies.<sup>11, 12, 19</sup></p>
<p id="p0127" num="0127">The cellular genome modification data are also consistent with the increase in specificity of sgRNA v1.0 compared to sgRNA v2.1 sgRNAs observed in the <i>in vitro</i> selection data and discrete assays. Although the CLTA1-2-2, CLTA 4-3-3, and CLTA 4-4-8 sites were modified by the Cas9-sgRNA v2.1 complexes, no evidence of modification at any of these three sites was detected in Cas9:sgRNA v1.0-treated cells. The CLTA4-3-1 site, which was modified at 32% of the frequency of on-target CLTA4 site modification in Cas9:v2.1 sgRNA-treated cells, was modified at only 0.5% of the on-target modification frequency in v1.0 sgRNA-treated cells, representing a 62-fold change in selectivity. Taken together, these results demonstrate that guide RNA architecture can have a significant influence on Cas9 specificity in cells. Our specificity profiling findings present an important caveat to recent and ongoing efforts to improve the overall DNA modification activity of Cas9:guide RNA complexes through guide RNA engineering.<sup>11, 15</sup></p>
<p id="p0128" num="0128">Overall, the off-target DNA cleavage profiling of Cas9 and subsequent analyses show that (<i>i</i>) Cas9:guide RNA recognition extends to 18-20 specified target site base pairs and a two-base pair PAM for the four target sites tested; (<i>ii</i>) increasing Cas9:guide RNA concentrations can decrease DNA-cleaving specificity <i>in vitro</i>; (<i>iii</i>) using more active sgRNA architectures can increase DNA-cleavage specificity both <i>in vitro</i> and in cells but impair DNA-cleavage specificity both <i>in vitro</i> and in cells; and (<i>iv</i>) as predicted by our <i>in vitro</i> results, Cas9:guide RNA can modify off-target sites in cells with up to four mutations relative to the on-target site. Our findings provide key insights to our understanding of RNA-programmed Cas9 specificity, and reveal a previously unknown role for sgRNA architecture<!-- EPO <DP n="65"> --> in DNA-cleavage specificity. The principles revealed in this study may also apply to Cas9-based effectors engineered to mediate functions beyond DNA cleavage.</p>
<heading id="h0019"><b>EQUIVALENTS AND SCOPE</b></heading>
<p id="p0129" num="0129">Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above description, but rather is as set forth in the appended claims.</p>
<p id="p0130" num="0130">In the claims articles such as "a," "an," and "the" may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.</p>
<p id="p0131" num="0131">Furthermore, it is to be understood that the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, <i>etc.</i>, from one or more of the claims or from relevant portions of the description is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.</p>
<p id="p0132" num="0132">Where elements are presented as lists, <i>e.g.</i>, in Markush group format, it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It is also noted that the term "comprising" is intended to be open and permits the inclusion of additional elements or steps. It should be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, steps, <i>etc.</i>, certain embodiments of the invention or aspects of<!-- EPO <DP n="66"> --> the invention consist such elements, features, steps, <i>etc.</i> For purposes of simplicity those embodiments have not been specifically set forth <i>in haec verba</i> herein. Thus for each embodiment of the invention that comprises one or more elements, features, steps, <i>etc.</i>, the invention also provides embodiments that consist of those elements, features, steps, <i>etc.</i></p>
<p id="p0133" num="0133">Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. It is also to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.</p>
<p id="p0134" num="0134">In addition, it is to be understood that any particular embodiment of the present disclosure may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may explicitly be excluded from any one or more of the claims. Any embodiment, element, feature, application, or aspect of the compositions and/or methods of the disclosure can be excluded from any one or more claims. For purposes of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects is excluded are not set forth explicitly herein.<!-- EPO <DP n="67"> --></p>
<heading id="h0020">TABLES</heading>
<p id="p0135" num="0135"><br/>
<b>Table 1. Cellular modification induced by Cas9:CLTA4 sgRNA.</b> 33 human genomic DNA sequences were identified that were enriched in the Cas9:CLTA4 v2.1 sgRNA <i>in vitro</i> selections under enzyme-limiting or enzyme-saturating conditions. Sites shown with underline contain insertions or deletions (indels) that are consistent with significant Cas9:sgRNA-mediated modification in HEK293T cells. <i>In vitro</i> enrichment values for selections with Cas9:CLTA4 v1.0 sgRNA or Cas9:CLTA4 v2.1 sgRNA are shown for sequences with three or fewer mutations. Enrichment values were not calculated for sequences with four or more mutations due to low numbers of <i>in vitro</i> selection sequence counts. Modification frequencies (number of sequences with indels divided by total number of sequences) in HEK293T cells treated with Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA4 v1.0 sgRNA, or Cas9 with CLTA4 v2.1 sgRNA. P-values are listed for those sites that show significant modification in v1.0 sgRNA- or v2.1 sgRNA-treated cells compared to cells treated with Cas9 without sgRNA. "Not tested (n.t.)" indicates that PCR of the genomic sequence failed to provide specific amplification products.<br/>
<b>Table 2: Raw selection sequence counts.</b> Positions -4 to -1 are the four nucleotides preceding the 20-base pair target site. PAM1, PAM2, and PAM3 are the PAM positions immediately following the target site. Positions +4 to +7 are the four nucleotides immediately following the PAM<br/>
<b>Table 3: CLTA1 genomic off-target sequences.</b> 20 human genomic DNA sequences were identified that were enriched in the Cas9:CLTA1 v2.1 sgRNA <i>in vitro</i> selections under enzyme-limiting or enzyme-excess conditions. "m" refers to number of mutations from on-target sequence with mutations shown in lower case. Sites shown with underline contain insertions or deletions (indels) that are consistent with significant Cas9:sgRNA-mediated modification in HEK293T cells. Human genome coordinates are shown for each site (assembly GRCh37). CLTA1-0-1 is present at two loci, and sequence counts were pooled from both loci. Sequence counts are shown for amplified and sequenced DNA for each site from HEK293T cells treated with Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA1 v1.0 sgRNA, or Cas9 with CLTA1 v2.1 sgRNA.<br/>
<b>Table 4: CLTA4 genomic off-target sequences.</b> 33 human genomic DNA sequences were identified that were enriched in the Cas9:CLTA4 v2.1 sgRNA <i>in vitro</i> selections under enzyme-limiting or enzyme-excess conditions. "m" refers to number of mutations from on-target sequence with mutations shown in lower case. Sites shown with underline contain insertions or deletions (indels) that are consistent with significant<!-- EPO <DP n="68"> --> Cas9:sgRNA-mediated modification in HEK293T cells. Human genome coordinates are shown for each site (assembly GRCh37). Sequence counts are shown for amplified and sequenced DNA for each site from HEK293T cells treated with Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA4 v1.0 sgRNA, or Cas9 with CLTA4 v2.1 sgRNA.<br/>
<b>Table 5: Genomic coordinates of CLTA1 and CLTA4 off-target sites.</b> 54 human genomic DNA sequences were identified that were enriched in the Cas9:CLTA1 v2.1 sgRNA and Cas9:CLTA4 v2.1 sgRNA <i>in vitro</i> selections under enzyme-limiting or enzyme-excess conditions. Human genome coordinates are shown for each site (assembly GRCh37).<br/>
<b>Table 6: Cellular modification induced by Cas9:CLTA1 sgRNA.</b> 20 human genomic DNA sequences were identified that were enriched in the Cas9:CLTA1 v2.1 sgRNA <i>in vitro</i> selections under enzyme-limiting or enzyme-excess conditions. Sites shown with underline contain insertions or deletions (indels) that are consistent with significant Cas9:sgRNA-mediated modification in HEK293T cells. <i>In vitro</i> enrichment values for selections with Cas9:CLTA1 v1.0 sgRNA or Cas9:CLTA1 v2.1 sgRNA are shown for sequences with three or fewer mutations. Enrichment values were not calculated for sequences with four or more mutations due to low numbers of <i>in vitro</i> selection sequence counts. Modification frequencies (number of sequences with indels divided by total number of sequences) in HEK293T cells treated with Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA1 v1.0 sgRNA, or Cas9 with CLTA1 v2.1 sgRNA. P-values of sites that show significant modification in v1.0 sgRNA- or v2.1 sgRNA-treated cells compared to cells treated with Cas9 without sgRNA were 1.1E-05 (v1.0) and 6.9E-55 (v2.1) for CLTA1-0-1, 2.6E-03 (v1.0) and 2.0E-10 (v2.1) for CLTA1-1-1, and 4.6E-08 (v2.1) for CLTA1-2-2. P-values were calculated using a one-sided Fisher exact test. "Not tested (n.t.)" indicates that the site was not tested or PCR of the genomic sequence failed to provide specific amplification products.<br/>
<b>Table 7: CLTA1 genomic off-target indel sequences.</b> Insertion and deletion-containing sequences from cells treated with amplified and sequenced DNA for the on-target genomic sequence (CLTA1-0-1) and each modified off-target site from HEK293T cells treated with Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA1 v1.0 sgRNA, or Cas9 with CLTA1 v2.1 sgRNA. "ref' refers to the human genome reference sequence for each site, and the modified sites are listed below. Mutations relative to the on-target genomic sequence are shown in lowercase letters. Insertions and deletions are shown in underlined bold letters or dashes, respectively. Modification percentages are shown for those conditions<!-- EPO <DP n="69"> --> (v1.0 sgRNA or v2.1 sgRNA) that show statistically significant enrichment of modified sequences compared to the control (no sgRNA).<br/>
<b>Table 8: CLTA4 genomic off-target indel sequences.</b> Insertion and deletion-containing sequences from cells treated with amplified and sequenced DNA for the on-target genomic sequence (CLTA4-0-1) and each modified off-target site from HEK293T cells treated with Cas9 without sgRNA ("no sgRNA"), Cas9 with CLTA4 v1.0 sgRNA, or Cas9 with CLTA4 v2.1 sgRNA. "ref' refers to the human genome reference sequence for each site, and the modified sites are listed below. Mutations relative to the on-target genomic sequence are shown in lowercase letters. Insertions and deletions are shown in underlined bold letters or dashes, respectively. Modification percentages are shown for those conditions (v1.0 sgRNA or v2.1 sgRNA) that show statistically significant enrichment of modified sequences compared to the control (no sgRNA).<br/>
<b>Table 9: Oligonucleotides used in this study.</b> All oligonucleotides were purchased from Integrated DNA Technologies. An asterisk (*) indicates that the preceding nucleotide was incorporated as a hand mix of phosphoramidites consisting of 79 mol% of the phosphoramidite corresponding to the preceding nucleotide and 4 mol% of each of the other three canonical phosphoramidites. "/5Phos/" denotes a 5' phosphate group installed during synthesis.<!-- EPO <DP n="70"> -->
<tables id="tabl0001" num="0001">
<table frame="all">
<title><b>Table 1</b></title>
<tgroup cols="12">
<colspec colnum="1" colname="col1" colwidth="23mm"/>
<colspec colnum="2" colname="col2" colwidth="24mm"/>
<colspec colnum="3" colname="col3" colwidth="43mm"/>
<colspec colnum="4" colname="col4" colwidth="13mm"/>
<colspec colnum="5" colname="col5" colwidth="22mm"/>
<colspec colnum="6" colname="col6" colwidth="14mm"/>
<colspec colnum="7" colname="col7" colwidth="14mm"/>
<colspec colnum="8" colname="col8" colwidth="19mm"/>
<colspec colnum="9" colname="col9" colwidth="20mm"/>
<colspec colnum="10" colname="col10" colwidth="19mm"/>
<colspec colnum="11" colname="col11" colwidth="16mm"/>
<colspec colnum="12" colname="col12" colwidth="18mm"/>
<thead>
<row>
<entry align="center"/>
<entry align="center"/>
<entry align="center"/>
<entry align="center"/>
<entry align="center"/>
<entry namest="col6" nameend="col7" align="center"><i>in vitro</i> enrichment</entry>
<entry namest="col8" nameend="col10" align="center">modification frequency in HEK293T cells</entry>
<entry namest="col11" nameend="col12" align="center">P-value</entry></row>
<row>
<entry align="center"/>
<entry align="center"># of Mutations</entry>
<entry align="center">sequence</entry>
<entry align="center">SEQ ID NO.</entry>
<entry align="center">gene</entry>
<entry align="center">v1.0</entry>
<entry align="center">v2.1</entry>
<entry align="center">no sgRNA</entry>
<entry align="center">v1.0</entry>
<entry align="center">v2.1</entry>
<entry align="center">v1.0</entry>
<entry align="center">v2.1</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="bottom"><u style="single">CLTA4-0-1</u></entry>
<entry align="center" valign="bottom">0</entry>
<entry align="center" valign="bottom"><u style="single">GCAGATGTAGTGTTTCCACAGGG</u></entry>
<entry valign="bottom">SEQ ID NO:58</entry>
<entry align="center" valign="bottom"><u style="single">CLTA</u></entry>
<entry align="center" valign="bottom"><u style="single">20</u></entry>
<entry align="center" valign="bottom"><u style="single">7.95</u></entry>
<entry align="center" valign="bottom"><u style="single">0.021%</u></entry>
<entry align="center" valign="bottom"><u style="single">11%</u></entry>
<entry align="center" valign="bottom"><u style="single">76%</u></entry>
<entry align="center" valign="bottom"><u style="single">&lt;1E-55</u></entry>
<entry align="center" valign="bottom"><u style="single">&lt;1E-55</u></entry></row>
<row>
<entry align="center" valign="bottom"><u style="single">CLTA4-3-1</u></entry>
<entry align="center" valign="bottom">3</entry>
<entry align="center" valign="bottom"><u style="single">aCAtATGTAGTaTTTCCACAGGG</u></entry>
<entry valign="bottom">SEQ ID NO:59</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"><u style="single">16.5</u></entry>
<entry align="center" valign="bottom"><u style="single">12.5</u></entry>
<entry align="center" valign="bottom"><u style="single">0.006%</u></entry>
<entry align="center" valign="bottom"><u style="single">0.055%</u></entry>
<entry align="center" valign="bottom"><u style="single">24%</u></entry>
<entry align="center" valign="bottom"><u style="single">6.0E-04</u></entry>
<entry align="center" valign="bottom"><u style="single">&lt;1E-55</u></entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-2</entry>
<entry align="center" valign="bottom">3</entry>
<entry align="center" valign="bottom">GCAtATGTAGTGTTTCCAaATGt</entry>
<entry valign="bottom">SEQ ID NO:60</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">2.99</entry>
<entry align="center" valign="bottom">6.97</entry>
<entry align="center" valign="bottom">0.017%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.014%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom"><u style="single">CLTA4-3-3</u></entry>
<entry align="center" valign="bottom">3</entry>
<entry align="center" valign="bottom"><u style="single">cCAGATGTAGTaTTcCCACAGGG</u></entry>
<entry valign="bottom">SEQ ID NO:61</entry>
<entry align="center" valign="bottom"><u style="single">CELF1</u></entry>
<entry align="center" valign="bottom"><u style="single">1.00</u></entry>
<entry align="center" valign="bottom"><u style="single">4.95</u></entry>
<entry align="center" valign="bottom"><u style="single">0%</u></entry>
<entry align="center" valign="bottom"><u style="single">0%</u></entry>
<entry align="center" valign="bottom"><u style="single">0.469%</u></entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"><u style="single">2.5E-21</u></entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-4</entry>
<entry align="center" valign="bottom">3</entry>
<entry align="center" valign="bottom">GCAGtTtTAGTGTTTtCACAGGG</entry>
<entry valign="bottom">SEQ ID NO:62</entry>
<entry align="center" valign="bottom">BC073807</entry>
<entry align="center" valign="bottom">0.79</entry>
<entry align="center" valign="bottom">3.12</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-5</entry>
<entry align="center" valign="bottom">3</entry>
<entry align="center" valign="bottom">GCAGAgtTAGTGTTTCCACACaG</entry>
<entry valign="bottom">SEQ ID NO:63</entry>
<entry align="center" valign="bottom">MPPED2</entry>
<entry align="center" valign="bottom">0</entry>
<entry align="center" valign="bottom">1.22</entry>
<entry align="center" valign="bottom">0.005%</entry>
<entry align="center" valign="bottom">0.015%</entry>
<entry align="center" valign="bottom">0.018%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-6</entry>
<entry align="center" valign="bottom">3</entry>
<entry align="center" valign="bottom">GCAGATGgAGgGTTTtCACAGGG</entry>
<entry valign="bottom">SEQ ID NO:64</entry>
<entry align="center" valign="bottom">DCHS2</entry>
<entry align="center" valign="bottom">1.57</entry>
<entry align="center" valign="bottom">1.17</entry>
<entry align="center" valign="bottom">0.015%</entry>
<entry align="center" valign="bottom">0.023%</entry>
<entry align="center" valign="bottom">0.021 %</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-7</entry>
<entry align="center" valign="bottom">3</entry>
<entry align="center" valign="bottom">GgAaATtTAGTGTTTCCACAGGG</entry>
<entry valign="bottom">SEQ ID NO:65</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.43</entry>
<entry align="center" valign="bottom">0.42</entry>
<entry align="center" valign="bottom">0.005%</entry>
<entry align="center" valign="bottom">0.012%</entry>
<entry align="center" valign="bottom">0.003%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-1</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">aaAGAaGTAGTaTTTCCACATGG</entry>
<entry valign="bottom">SEQ ID NO:66</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-2</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">aaAGATGTAGTcaTTCCACAAGG</entry>
<entry valign="bottom">SEQ ID NO:67</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.005%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-3</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">aaAtATGTAGTcTTTCCACAGGG</entry>
<entry valign="bottom">SEQ ID NO:68</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom">0.009%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-4</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">atAGATGTAGTGTTTCCAaAGGa</entry>
<entry valign="bottom">SEQ ID NO:69</entry>
<entry align="center" valign="bottom">NR1H4</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.032%</entry>
<entry align="center" valign="bottom">0.006%</entry>
<entry align="center" valign="bottom">0.052%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-5</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">cCAGAgGTAGTGcTcCCACAGGG</entry>
<entry valign="bottom">SEQ ID NO:70</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.005%</entry>
<entry align="center" valign="bottom">0.006%</entry>
<entry align="center" valign="bottom">0.007%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-6</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">cCAGATGTgagGTTTCCACAAGG</entry>
<entry valign="bottom">SEQ ID NO:71</entry>
<entry align="center" valign="bottom">XKR6</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.018%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.007%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-7</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">ctAcATGTAGTGTTTCCAtATGG</entry>
<entry valign="bottom">SEQ ID NO:72</entry>
<entry align="center" valign="bottom">HKR1</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.006%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.008%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom"><u style="single">CLTA4-4-8</u></entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">ctAGATGaAGTGcTTCCACATGG</entry>
<entry valign="bottom">SEQ ID NO:73</entry>
<entry align="center" valign="bottom"><u style="single">CDK8</u></entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"><u style="single">0.009%</u></entry>
<entry align="center" valign="bottom"><u style="single">0.0.13%</u></entry>
<entry align="center" valign="bottom"><u style="single">0.730%</u></entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"><u style="single">9.70E-21</u></entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-9</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">GaAaATGgAGTGTTTaCACATGG</entry>
<entry valign="bottom">SEQ ID NO:74</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-10</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">GCAaATGaAGTGTcaCCACAAGG</entry>
<entry valign="bottom">SEQ ID NO:75</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-11</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">GCAaATGTAtTaTTTCCACtAGG</entry>
<entry valign="bottom">SEQ ID NO:76</entry>
<entry align="center" valign="bottom">NOV</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-12</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">GCAGATGTAGctTTTgtACATGG</entry>
<entry valign="bottom">SEQ ID NO:77</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-13</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">GCAGcTtaAGTGTTTtCACATGG</entry>
<entry valign="bottom">SEQ ID NO:78</entry>
<entry align="center" valign="bottom">GRHL2</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.020%</entry>
<entry align="center" valign="bottom">0.02%</entry>
<entry align="center" valign="bottom">0.030%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-14</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">ttAcATGTAGTGTTTaCACACGG</entry>
<entry valign="bottom">SEQ ID NO:79</entry>
<entry align="center" valign="bottom">LINC00535</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-1</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">GaAGAgGaAGTGTTTgCcCAGGG</entry>
<entry valign="bottom">SEQ ID NO:80</entry>
<entry align="center" valign="bottom">RNH1</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom">0.01%</entry>
<entry align="center" valign="bottom">0.006%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-2</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">GaAGATGTgGaGTTgaCACATGG</entry>
<entry valign="bottom">SEQ ID NO:81</entry>
<entry align="center" valign="bottom">FZD3</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-3</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">GCAGAaGTAcTGTTgttACAAGG</entry>
<entry valign="bottom">SEQ ID NO:82</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.002%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0.003%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-4</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">GCAGATGTgGaaTTaCaACAGGG</entry>
<entry valign="bottom">SEQ ID NO:83</entry>
<entry align="center" valign="bottom">SLC9A2</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-5</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">GCAGtcaTAGTGTaTaCACATGG</entry>
<entry valign="bottom">SEQ ID NO:84</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0.005%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-6</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">taAGATGTAGTaTTTCCAaAAGt</entry>
<entry valign="bottom">SEQ ID NO:85</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.007%</entry>
<entry align="center" valign="bottom">0.01%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-6-1</entry>
<entry align="center" valign="bottom">6</entry>
<entry align="center" valign="bottom">GCAGcTGgcaTtTcTCCACACGG</entry>
<entry valign="bottom">SEQ ID NO:86</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-6-2</entry>
<entry align="center" valign="bottom">6</entry>
<entry align="center" valign="bottom">GgAGATcTgaTGgTTCtACAAGG</entry>
<entry valign="bottom">SEQ ID NO:87</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.007%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0.009%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-6-3</entry>
<entry align="center" valign="bottom">6</entry>
<entry align="center" valign="bottom">taAaATGcAGTGTaTCCAtATGG</entry>
<entry valign="bottom">SEQ ID NO:88</entry>
<entry align="center" valign="bottom">SMA4</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.015%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-7-1</entry>
<entry align="center" valign="bottom">7</entry>
<entry align="center" valign="bottom">GCcagaaTAGTtTTTCaACAAGG</entry>
<entry valign="bottom">SEQ ID NO:89</entry>
<entry align="center" valign="bottom">SEPHS2</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0.007%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row>
<row>
<entry align="center" valign="bottom">CLTA4-7-2</entry>
<entry align="center" valign="bottom">8</entry>
<entry align="center" valign="bottom">ttgtATtTAGaGaTTgCACAAGG</entry>
<entry valign="bottom">SEQ ID NO:90</entry>
<entry align="center" valign="bottom">RORB</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.00%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="71"> -->
<img id="ib0010" file="imgb0010.tif" wi="94" he="233" img-content="table" img-format="tif"/><!-- EPO <DP n="72"> -->
<img id="ib0011" file="imgb0011.tif" wi="94" he="233" img-content="table" img-format="tif"/><!-- EPO <DP n="73"> -->
<img id="ib0012" file="imgb0012.tif" wi="158" he="219" img-content="table" img-format="tif"/><!-- EPO <DP n="74"> -->
<img id="ib0013" file="imgb0013.tif" wi="161" he="233" img-content="table" img-format="tif"/><!-- EPO <DP n="75"> -->
<img id="ib0014" file="imgb0014.tif" wi="165" he="80" img-content="table" img-format="tif"/><!-- EPO <DP n="76"> -->
<tables id="tabl0002" num="0002">
<table frame="all">
<title><b>Table 5</b></title>
<tgroup cols="2">
<colspec colnum="1" colname="col1" colwidth="26mm"/>
<colspec colnum="2" colname="col2" colwidth="50mm"/>
<thead>
<row>
<entry align="center">Off-target site</entry>
<entry align="center">Human genome coordinates</entry></row></thead>
<tbody>
<row>
<entry morerows="1" align="center" valign="bottom">CLTA1-0-1</entry>
<entry rowsep="0" align="center" valign="bottom">9(+): 36,211,732-36,211,754</entry></row>
<row>
<entry align="center" valign="bottom">12(+): 7,759,893-7,759,915</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-1-1</entry>
<entry align="center" valign="bottom">8(-): 15,546,437-15,546,459</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-2-1</entry>
<entry align="center" valign="bottom">3(-): 54,223,111-54,223,133</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-2-2</entry>
<entry align="center" valign="bottom">15(+): 89,388,670-89,388,692</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-2-3</entry>
<entry align="center" valign="bottom">5(+): 88716920-88,716,942</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-3-1</entry>
<entry align="center" valign="bottom">21(+): 27,972,462-27,972,484</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-3-2</entry>
<entry align="center" valign="bottom">4(-): 17,179,924-17,179,946</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-1</entry>
<entry align="center" valign="bottom">1(+): 147,288,742-147,288,764</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-2</entry>
<entry align="center" valign="bottom">10(+): 97,544,444-97,544,466</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-3</entry>
<entry align="center" valign="bottom">2(-): 161,873,870-161,873,892</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-4</entry>
<entry align="center" valign="bottom">1(+): 196,172,702-196,172,724</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-5</entry>
<entry align="center" valign="bottom">13(+): 56,574,636-56,574,658</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-6</entry>
<entry align="center" valign="bottom">2(+): 241,357,827-241,357,849</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-7</entry>
<entry align="center" valign="bottom">3(+): 121,248,627-121,248,649</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-8</entry>
<entry align="center" valign="bottom">12(+): 132,937,319-132,937,341</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-5-1</entry>
<entry align="center" valign="bottom">9(-): 80,930,919 -80,930,941</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-5-2</entry>
<entry align="center" valign="bottom">2(+): 140,901,875-14,0901,897</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-5-3</entry>
<entry align="center" valign="bottom">3(+): 45,016,841-45,016,863</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-5-4</entry>
<entry align="center" valign="bottom">X(+): 40,775,684-40,775,706</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-5-5</entry>
<entry align="center" valign="bottom">2(-): 185,151,622-185,151,644</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-6-1</entry>
<entry align="center" valign="bottom">X(+): 150,655,097-150,655,119</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-0-1</entry>
<entry align="center" valign="bottom">9(-): 36,211,779-36,211,801</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-1</entry>
<entry align="center" valign="bottom">12(-): 50,679,419-50,679,441</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-2</entry>
<entry align="center" valign="bottom">X(-): 143,939,483-143,939,505</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-3</entry>
<entry align="center" valign="bottom">11(-): 47,492,611-47,492,633</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-4</entry>
<entry align="center" valign="bottom">3(-): 162,523,715-162,523,737</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-5</entry>
<entry align="center" valign="bottom">11(+): 30,592,975-30,592,997</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-6</entry>
<entry align="center" valign="bottom">4(-): 155,252,699-155,252,721</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-3-7</entry>
<entry align="center" valign="bottom">18(+): 39,209,441-39,209,463</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-1</entry>
<entry align="center" valign="bottom">17(-): 36,785,650-36,785,672</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-2</entry>
<entry align="center" valign="bottom">1(-): 241,537,119-241,537,141</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-3</entry>
<entry align="center" valign="bottom">8(-): 120,432,103-120,432,125</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-4</entry>
<entry align="center" valign="bottom">6(-): 106,204,600-106,204,622</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-5</entry>
<entry align="center" valign="bottom">8(+): 102,527,804-102,527,826</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-6</entry>
<entry align="center" valign="bottom">8(-): 94,685,538-94,685,560</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-7</entry>
<entry align="center" valign="bottom">2(+): 35,820,054-35,820,076</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-8</entry>
<entry align="center" valign="bottom">3(-): 36,590,352-36,590,374</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-9</entry>
<entry align="center" valign="bottom">12(+): 100,915,498-100,915,520</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-10</entry>
<entry align="center" valign="bottom">21(+): 33,557,705-33,557,727</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-11</entry>
<entry align="center" valign="bottom">8(+): 10,764,183-10,764,205</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-12</entry>
<entry align="center" valign="bottom">19(+): 37,811,645-37,811,667</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-13</entry>
<entry align="center" valign="bottom">13(-): 26,832,673-26,832,695</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-4-14</entry>
<entry align="center" valign="bottom">6(+): 19,349,572-19,349,594</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-1</entry>
<entry align="center" valign="bottom">11 (-): 502,300-502,322</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-2</entry>
<entry align="center" valign="bottom">8(-): 28,389,683-28,389,705</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-3</entry>
<entry align="center" valign="bottom">2(-): 118,557,405-118,557,427</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-4</entry>
<entry align="center" valign="bottom">2(-): 103,248,360-103,248,382</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-5</entry>
<entry align="center" valign="bottom">21(-): 42,929,085-42,929,107</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-5-6</entry>
<entry align="center" valign="bottom">13(-): 83,097,278-83,097,300</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-6-1</entry>
<entry align="center" valign="bottom">2(+): 43,078,423-43,078,445</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-6-2</entry>
<entry align="center" valign="bottom">7(-): 11,909,384-11,909,406</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-6-3</entry>
<entry align="center" valign="bottom">5(-): 69,775,482-69,775,504</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-7-1</entry>
<entry align="center" valign="bottom">16(+): 30,454,945-30,454,967</entry></row>
<row>
<entry align="center" valign="bottom">CLTA4-7-2</entry>
<entry align="center" valign="bottom">9(-): 77,211,328-77,211,350</entry></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="77"> -->
<tables id="tabl0003" num="0003">
<table frame="all">
<title><b>Table 6</b></title>
<tgroup cols="9">
<colspec colnum="1" colname="col1" colwidth="19mm"/>
<colspec colnum="2" colname="col2" colwidth="32mm"/>
<colspec colnum="3" colname="col3" colwidth="79mm"/>
<colspec colnum="4" colname="col4" colwidth="31mm"/>
<colspec colnum="5" colname="col5" colwidth="12mm"/>
<colspec colnum="6" colname="col6" colwidth="13mm"/>
<colspec colnum="7" colname="col7" colwidth="19mm"/>
<colspec colnum="8" colname="col8" colwidth="19mm"/>
<colspec colnum="9" colname="col9" colwidth="19mm"/>
<thead>
<row>
<entry align="center"/>
<entry align="center"/>
<entry align="center"/>
<entry align="center"/>
<entry namest="col5" nameend="col6" align="center"><i>in vitro</i> enrichment</entry>
<entry namest="col7" nameend="col9" align="center">modification frequency in HEK293T cells</entry></row>
<row>
<entry align="center"/>
<entry align="center">number of mutations</entry>
<entry align="center">sequence</entry>
<entry align="center">gene</entry>
<entry align="center">v1.0</entry>
<entry align="center">v2.1</entry>
<entry align="center">no sgRNA</entry>
<entry align="center">v1.0</entry>
<entry align="center">v2.1</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="bottom"><u style="single">CLTA1-0-1</u></entry>
<entry align="center" valign="bottom"><u style="single">0</u></entry>
<entry align="center" valign="bottom"><u style="double">AGTCCTCATCTCCCTCAAGCAGG</u> (SEQ ID NO:145)</entry>
<entry align="center" valign="bottom"><u style="double">CLTA</u></entry>
<entry align="center" valign="middle"><u style="double">41.4</u></entry>
<entry align="center" valign="bottom"><u style="single">2.3.3</u></entry>
<entry align="center" valign="bottom"><u style="single">0.003%</u></entry>
<entry align="center" valign="bottom"><u style="single">0,042%</u></entry>
<entry align="center" valign="bottom"><u style="single">0.337%</u></entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-1-1</entry>
<entry align="center" valign="bottom">1</entry>
<entry align="center" valign="bottom"><u style="double">AGTCCTCAaCTCCCTCAAGCAGG</u> (SEQ ID NO:146)</entry>
<entry align="center" valign="bottom"><u style="single">TUSC3</u></entry>
<entry align="center" valign="middle"><u style="single">25.9</u></entry>
<entry align="center" valign="bottom"><u style="single">14</u></entry>
<entry align="center" valign="bottom"><u style="single">0.003%</u></entry>
<entry align="center" valign="bottom"><u style="single">0.031%</u></entry>
<entry align="center" valign="bottom"><u style="single">0.091%</u></entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-2-1</entry>
<entry align="center" valign="bottom">2</entry>
<entry align="center" valign="bottom">AGcCCTCATtTCCCTCAAGCAGG (SEQ ID NO:147)</entry>
<entry align="center" valign="bottom">CACNA2D3</entry>
<entry align="center" valign="middle">15.4</entry>
<entry align="center" valign="bottom">26.2</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry></row>
<row>
<entry align="center" valign="bottom"><u style="single">CLTA1-2-2</u></entry>
<entry align="center" valign="bottom">2</entry>
<entry align="center" valign="bottom"><u style="double">AcTCCTCATCcCCCTCAAGCCGG</u> (SEQ ID NO:148)</entry>
<entry align="center" valign="bottom"><u style="single">ACAN</u></entry>
<entry align="center" valign="middle"><u style="single">29.2</u></entry>
<entry align="center" valign="bottom"><u style="single">18.8</u></entry>
<entry align="center" valign="bottom"><u style="single">0.014%</u></entry>
<entry align="center" valign="bottom"><u style="single">0.005%</u></entry>
<entry align="center" valign="bottom"><u style="single">0.146%</u></entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-2-3</entry>
<entry align="center" valign="bottom">2</entry>
<entry align="center" valign="bottom">AGTCaTCATCTCCCTCAAGCAGa (SEQ ID NO:149)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="middle">0.06</entry>
<entry align="center" valign="bottom">1.27</entry>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-3-1</entry>
<entry align="center" valign="bottom">3</entry>
<entry align="center" valign="bottom">cGTCCTCcTCTCCCcCAAGCAGG (SEQ ID NO:150)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="bottom">2.07</entry>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-3-2</entry>
<entry align="center" valign="bottom">3</entry>
<entry align="center" valign="bottom">tGTCCTCtTCTCCCTCAAGCAGa (SEQ ID NO:151)</entry>
<entry align="center" valign="bottom">BC029598</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="bottom">1.47</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-1</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">AagCtTCATCTCtCTCAAGCTGG (SEQ ID NO:152)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.006%</entry>
<entry align="center" valign="bottom">0%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-2</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">AGTaCTCtTtTCCCTCAgGCTGG (SEQ ID NO:153)</entry>
<entry align="center" valign="bottom">ENTPD1</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.007%</entry>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom">0.015%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-3</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">AGTCtTaAatTCCCTCAAGCAGG (SEQ ID NO:154)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.003%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.001 %</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-4</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">AGTgCTCATCTaCCagAAGCTGG (SEQ ID NO:155)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.008%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-5</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">ccTCCTCATCTCCCTgcAGCAGG (SEQ ID NO:156)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.013%</entry>
<entry align="center" valign="bottom">0.004%</entry>
<entry align="center" valign="bottom">0%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-6</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">ctaCaTCATCTCCCTCAAGCTGG (SEQ ID NO:157)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.008%</entry>
<entry align="center" valign="bottom">0.016%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-7</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">gGTCCTCATCTCCCTaAAaCAGa (SEQ ID NO:158)</entry>
<entry align="center" valign="bottom">POLQ (coding)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.011%</entry>
<entry align="center" valign="bottom">0.037%</entry>
<entry align="center" valign="bottom">0%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-4-8</entry>
<entry align="center" valign="bottom">4</entry>
<entry align="center" valign="bottom">tGTCCTCATCggCCTCAgGCAGG (SEQ ID NO:159)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.016%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-5-1</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">AGaCacCATCTCCCTtgAGCTGG (SEQ ID NO:160)</entry>
<entry align="center" valign="bottom">PSAT1</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.003%</entry>
<entry align="center" valign="bottom">0.006%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-5-2</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">AGgCaTCATCTaCaTCAAGtTGG (SEQ ID NO:161)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry></row><!-- EPO <DP n="78"> -->
<row>
<entry align="center" valign="bottom">CLTA1-5-3</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">AGTaaTCActTCCaTCAAGCCGG (SEQ ID NO:162)</entry>
<entry align="center" valign="bottom">ZDHHC3, EXOSC7</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry>
<entry align="center" valign="bottom">n.t.</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-5-4</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">tccCCTCAcCTCCCTaAAGCAGG (SEQ ID NO:163)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0.008%</entry>
<entry align="center" valign="bottom">0.029%</entry>
<entry align="center" valign="bottom">0.004%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-5-5</entry>
<entry align="center" valign="bottom">5</entry>
<entry align="center" valign="bottom">tGTCtTtATtTCCCTCtAGCTGG (SEQ ID NO:164)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0.009%</entry></row>
<row>
<entry align="center" valign="bottom">CLTA1-6-1</entry>
<entry align="center" valign="bottom">6</entry>
<entry align="center" valign="bottom">AGTCCTCATCTCCCTCAAGCAGG (SEQ ID NO:165)</entry>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom"/>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry>
<entry align="center" valign="bottom">0%</entry></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="79"> -->
<tables id="tabl0004" num="0004">
<table frame="all">
<title><b>Table 7</b></title>
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="14mm"/>
<colspec colnum="2" colname="col2" colwidth="85mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="22mm"/>
<colspec colnum="5" colname="col5" colwidth="23mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="middle"><b>CLTA1-0-1</b></entry>
<entry namest="col3" nameend="col5" align="center" valign="middle"># of sequences</entry></row>
<row>
<entry valign="middle"/>
<entry align="center" valign="middle">sequence</entry>
<entry align="center" valign="middle">no sgRNA</entry>
<entry align="center" valign="middle">v1.0 sgRNA</entry>
<entry align="center" valign="middle">v2.1 sgRNA</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">ref</entry>
<entry valign="middle">AGTCCTCATCTCCCTCAAGCAGG (SEQ ID NO:166)</entry>
<entry align="center" valign="middle">58,887</entry>
<entry align="center" valign="middle">42,665</entry>
<entry align="center" valign="middle">52,667</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCATCTCCCTCA<b><u style="double">A</u></b>AGCAGG (SEQ ID NO:167)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">66</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCATCTCCCTC-AGCAGG (SEQ ID NO:168)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry>
<entry align="center" valign="middle">28</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCAT--------------</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">13</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCATCTCCCTCA<b><u style="double">T</u></b>AGCAGG (SEQ ID NO:169)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">11</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCAT--------AGCAGG (SEQ ID NO:170)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">9</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCATCT------AGCAGG (SEQ ID NO:171)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">8</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCA---------AGCAGG (SEQ ID NO:172)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">6</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle"><img id="ib0015" file="imgb0015.tif" wi="71" he="12" img-content="dna" img-format="tif"/></entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">4</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCATCTCCCTCA<b><u style="double">TT</u></b>AGCAGG (SEQ ID NO:174)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">4</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle"><img id="ib0016" file="imgb0016.tif" wi="71" he="12" img-content="dna" img-format="tif"/></entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">3</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCATCTCCCT-AGCAGG (SEQ ID NO:176)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">11</entry>
<entry align="center" valign="middle">0</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCATCCCTC-AAGCAGG (SEQ ID NO:177)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">3</entry>
<entry align="center" valign="middle">0</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCATCTCCCT-AAGCAGG (SEQ ID NO:178)</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">2</entry>
<entry align="center" valign="middle">0</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">other</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">26</entry></row>
<row rowsep="0">
<entry valign="middle"/>
<entry valign="middle">modified total</entry>
<entry align="center" valign="middle">2</entry>
<entry align="center" valign="middle">18 (0.042%)</entry>
<entry align="center" valign="middle">178 (0.34%)</entry></row></tbody></tgroup>
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="14mm"/>
<colspec colnum="2" colname="col2" colwidth="85mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="22mm"/>
<colspec colnum="5" colname="col5" colwidth="23mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="middle"><b>CLTA1-1-1</b></entry>
<entry namest="col3" nameend="col5" align="center" valign="middle"># of sequences</entry></row>
<row>
<entry valign="middle"/>
<entry align="center" valign="middle">sequence</entry>
<entry align="center" valign="middle">no sgRNA</entry>
<entry align="center" valign="middle">v1.0 sgRNA</entry>
<entry align="center" valign="middle">v2.1 sgRNA</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">ref</entry>
<entry valign="middle">AGTCCTCAaCTCCCTCAAGCAGG (SEQ ID NO:179)</entry>
<entry align="center" valign="middle">39,803</entry>
<entry align="center" valign="middle">28,991</entry>
<entry align="center" valign="middle">40,551</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCAaCTCCCTCA<b><u style="double">A</u></b>AGCAGG (SEQ ID NO:180)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">4</entry>
<entry align="center" valign="middle">13</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCAaCTCCCTCA------ (SEQ ID NO:181)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">12</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCAaCTCCCTC-AGCAGG (SEQ ID NO:182)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry>
<entry align="center" valign="middle">4</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle"><img id="ib0017" file="imgb0017.tif" wi="72" he="12" img-content="dna" img-format="tif"/></entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">3</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle"><img id="ib0018" file="imgb0018.tif" wi="72" he="12" img-content="dna" img-format="tif"/></entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCAaCTCCCT-AAGCAGG (SEQ ID NO:185)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">3</entry>
<entry align="center" valign="middle">1</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle"><img id="ib0019" file="imgb0019.tif" wi="72" he="13" img-content="dna" img-format="tif"/></entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">1</entry></row>
<row rowsep="0">
<entry valign="middle"/>
<entry valign="middle"><img id="ib0020" file="imgb0020.tif" wi="71" he="8" img-content="dna" img-format="tif"/></entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">1</entry></row><!-- EPO <DP n="80"> -->
<row>
<entry valign="middle"/>
<entry valign="middle"><img id="ib0021" file="imgb0021.tif" wi="30" he="5" img-content="dna" img-format="tif"/></entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle"/></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AGTCCTCAaCTCCC-AAGCAGG (SEQ ID NO:188)</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry></row>
<row>
<entry valign="middle"/>
<entry align="center" valign="middle">modified total</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">9 (0.031 %)</entry>
<entry align="center" valign="middle">37 (0.091 %)</entry></row></tbody></tgroup>
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="14mm"/>
<colspec colnum="2" colname="col2" colwidth="85mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="22mm"/>
<colspec colnum="5" colname="col5" colwidth="23mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="middle"><b>CLTA1-2-2</b></entry>
<entry namest="col3" nameend="col5" align="center" valign="middle"># of sequences</entry></row>
<row>
<entry valign="middle"/>
<entry align="center" valign="middle">sequence</entry>
<entry align="center" valign="middle">no sgRNA</entry>
<entry align="center" valign="middle">v1.0 sgRNA</entry>
<entry align="center" valign="middle">v2.1 sgRNA</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">ref</entry>
<entry valign="middle">AcTCCTCATCcCCCTCAAGCCGG (SEQ ID NO:189)</entry>
<entry align="center" valign="middle">21,264</entry>
<entry align="center" valign="middle">20,041</entry>
<entry align="center" valign="middle">22,546</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCATCcCCCTCA<b><u style="double">A</u></b>AGCCGG (SEQ ID NO:190)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">8</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCATCcCCCTCA<b><u style="double">G</u></b>AGCCGG (SEQ ID NO:191)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">7</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTC-----------AGCCGG (SEQ ID NO:192)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">5</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCATCcCCCTCA<b><u style="double">AA</u></b>AGCCGG (SEQ ID NO:193)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCATCcCCCTCA<b><u style="double">GC</u></b>AGCCGG (SEQ ID NO:194)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCATCcCCCTCA<b><u style="double">T</u></b>AGCCGG (SEQ ID NO:195)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCATCcCCCTCA<b><u style="double">TCC</u></b>CCGG (SEQ ID NO:196)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCATCcC-----AGCCGG (SEQ ID NO:197)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCATCcCCCTA-AGCCGG (SEQ ID NO:198)</entry>
<entry align="center" valign="middle">3</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">1</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCATCcCCCTCA<b><u style="double">AT</u></b>AGCCGG (SEQ ID NO:199)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">1</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">AcTCCTCACCcCCCTCA<b><u style="double">GC</u></b>AGCCGG (SEQ ID NO:200)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">1</entry></row>
<row>
<entry valign="middle"/>
<entry align="center">modified total</entry>
<entry align="center">3</entry>
<entry align="center">1</entry>
<entry align="center">33 (0.15%)</entry></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="81"> -->
<tables id="tabl0005" num="0005">
<table frame="all">
<title><b>Table 8</b></title>
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="14mm"/>
<colspec colnum="2" colname="col2" colwidth="87mm"/>
<colspec colnum="3" colname="col3" colwidth="15mm"/>
<colspec colnum="4" colname="col4" colwidth="22mm"/>
<colspec colnum="5" colname="col5" colwidth="24mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="middle"><b>CLTA4-0-1</b></entry>
<entry namest="col3" nameend="col5" align="center" valign="middle"># of sequences</entry></row>
<row>
<entry valign="middle"/>
<entry align="center" valign="middle">sequence</entry>
<entry align="center" valign="middle">control</entry>
<entry align="center" valign="middle">v1.0 sqRNA</entry>
<entry align="center" valign="middle">v2.1 sqRNA</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">ref</entry>
<entry valign="middle">GCAGATGTAGTGTTTCCACAGGG (SEQ ID NO:201)</entry>
<entry align="center" valign="middle">29,185</entry>
<entry align="center" valign="middle">16,635</entry>
<entry align="center" valign="middle">17,555</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGTAGTGTTTC-ACAGGG (SEQ ID NO:202)</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">891</entry>
<entry align="center" valign="middle">5,937</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGTAGTGTTTCC<b><u style="double">C</u></b>ACAGGG (SEQ ID NO:203)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">809</entry>
<entry align="center" valign="middle">5,044</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGTAGTG----CACAGGG (SEQ ID NO:204)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">14</entry>
<entry align="center" valign="middle">400</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGTAGTGTTTCC-CAGGG (SEQ ID NO:205)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">19</entry>
<entry align="center" valign="middle">269</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGTAC-------ACAGGG (SEQ ID NO:206)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">17</entry>
<entry align="center" valign="middle">262</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGTAGTGTCA---CAGGG (SEQ ID NO:207)</entry>
<entry align="center" valign="middle">2</entry>
<entry align="center" valign="middle">6</entry>
<entry align="center" valign="middle">254</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGTAGTGTTCA-CAGGG (SEQ ID NO:208)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">21</entry>
<entry align="center" valign="middle">229</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGTAGTGTTTC-CAGGG (SEQ ID NO:209)</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">14</entry>
<entry align="center" valign="middle">188</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGTAGT-----CACAGGG (SEQ ID NO:210)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">152</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">GCAGATGT-----------AGGG (SEQ ID NO:211)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">6</entry>
<entry align="center" valign="middle">129</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">other</entry>
<entry align="center" valign="middle">2</entry>
<entry align="center" valign="middle">208</entry>
<entry align="center" valign="middle">2,106</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">modified total</entry>
<entry align="center" valign="middle">6</entry>
<entry align="center" valign="middle">2,005 (11 %)</entry>
<entry align="center" valign="middle">14,970 (76%)</entry></row></tbody></tgroup>
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="14mm"/>
<colspec colnum="2" colname="col2" colwidth="87mm"/>
<colspec colnum="3" colname="col3" colwidth="15mm"/>
<colspec colnum="4" colname="col4" colwidth="22mm"/>
<colspec colnum="5" colname="col5" colwidth="24mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="middle"><b>CLTA4-3-1</b></entry>
<entry namest="col3" nameend="col5" align="center" valign="middle"># of sequences</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">sequence</entry>
<entry align="center" valign="middle">control</entry>
<entry align="center" valign="middle">v1.0 sqRNA</entry>
<entry align="center" valign="middle">v2.1 sqRNA</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">ref</entry>
<entry valign="middle">aCAtATGTAGTaTTTCCACAGGG (SEQ ID NO:212)</entry>
<entry align="center" valign="middle">34,163</entry>
<entry align="center" valign="middle">20,007</entry>
<entry align="center" valign="middle">12,208</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">a CAtATGTAGTaTTTCC<b><u style="double">C</u></b>ACAGGG (SEQ ID NO:213)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">8</entry>
<entry align="center" valign="middle">1779</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">aCAtATGTAGTaTTTCA-CAGGG (SEQ ID NO:214)</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">293</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">aCAtATGTAGTaTTTC-CAGGG (SEQ ID NO:215)</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">227</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">aCAtAT----------CACAGGG (SEQ ID NO:216)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">117</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">a-----------------CAGGG</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">96</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">aCAt------------CACAGGG (SEQ ID NO:217)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">78</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">aCAtATGTAGT-----CACAGGG (SEQ ID NO:218)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">77</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">aCAtATGTAGTaTTTCC-(SEQ ID NO:219)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">76</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">aCAtATGT-----------AGGG (SEQ ID NO:220)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">68</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry valign="middle">aCAtATGTAG------CACAGGG (SEQ ID NO:221)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">64</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">other</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">3</entry>
<entry align="center" valign="middle">999</entry></row>
<row>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">modified total</entry>
<entry align="center" valign="middle">2</entry>
<entry align="center" valign="middle">11 (0.055%)</entry>
<entry align="center" valign="middle">3874 (24%)</entry></row></tbody></tgroup><!-- EPO <DP n="82"> -->
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="14mm"/>
<colspec colnum="2" colname="col2" colwidth="87mm"/>
<colspec colnum="3" colname="col3" colwidth="15mm"/>
<colspec colnum="4" colname="col4" colwidth="22mm"/>
<colspec colnum="5" colname="col5" colwidth="24mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="middle"><b>CLTA4-3-3</b></entry>
<entry namest="col3" nameend="col5" align="center" valign="middle"># of sequences</entry></row>
<row>
<entry valign="middle"/>
<entry align="center" valign="middle">sequence</entry>
<entry align="center" valign="middle">control</entry>
<entry align="center" valign="middle">v1.0 sqRNA</entry>
<entry align="center" valign="middle">v2.1 sqRNA</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">ref</entry>
<entry valign="middle">cCAGATGTAGTaTTcCCACAGGG (SEQ ID NO:222)</entry>
<entry align="center" valign="middle">16,559</entry>
<entry align="center" valign="middle">12,007</entry>
<entry align="center" valign="middle">11,030</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">cCAGATGTAGTaTTcCC<b><u style="double">C</u></b>ACAGGG (SEQ ID NO:223)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">35</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">cCAGATGTAGTaT----ACAGGG (SEQ ID NO:224)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">5</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">cCAGATGTAGTaT---CACAGGG (SEQ ID NO:225)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">3</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">cCAGATGTAGTaTTcCC<b><u style="double">AAC</u></b>ACAGGG (SEQ ID NO:226)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">cCAGATGTAGTaTT-CACAGGG (SEQ ID NO:227)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">cCAGATGTAGTaTTcC-CAGGG (SEQ ID NO:228)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">cCAGATGTA--------------</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">cCAGATGTAGTaTTcC-ACAGGG (SEQ ID NO:229)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">1</entry></row>
<row>
<entry valign="middle"/>
<entry align="center" valign="middle">modified total</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">52 (0.47%)</entry></row></tbody></tgroup>
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="14mm"/>
<colspec colnum="2" colname="col2" colwidth="87mm"/>
<colspec colnum="3" colname="col3" colwidth="15mm"/>
<colspec colnum="4" colname="col4" colwidth="22mm"/>
<colspec colnum="5" colname="col5" colwidth="24mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="middle"><b>CLTA4-4-8</b></entry>
<entry namest="col3" nameend="col5" align="center" valign="middle"># of sequences</entry></row>
<row>
<entry valign="middle"/>
<entry align="center" valign="middle">sequence</entry>
<entry align="center" valign="middle">control</entry>
<entry align="center" valign="middle">v1.0 sqRNA</entry>
<entry align="center" valign="middle">v2.1 sqRNA</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">ref</entry>
<entry valign="middle">ctAGATGaAGTGcTTCCACATGG (SEQ ID NO:230)</entry>
<entry align="center" valign="middle">10,691</entry>
<entry align="center" valign="middle">7,608</entry>
<entry align="center" valign="middle">8,018</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">ctAGATGaAGTGcTTCC<b><u style="double">C</u></b>ACATGG (SEQ ID NO:231)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">49</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">ctAGATGaAGTGcTTC-ACATGG (SEQ ID NO:232)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">6</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">ctAGATGaAGTG-(SEQ ID NO:233)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">2</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">ctAGATGaAGTGcTTCC<b><u style="double">AC</u></b>ACATGG (SEQ ID NO:234)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">1</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">ctAGATGaAGTGcTTC-CATGG (SEQ ID NO:235)</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">0</entry></row>
<row>
<entry valign="middle"/>
<entry valign="middle">ctAGATGaAGTGcTTCC-CATGG (SEQ ID NO:236)</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">0</entry></row>
<row>
<entry valign="middle"/>
<entry align="center" valign="middle">modified total</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">1</entry>
<entry align="center" valign="middle">59 (0.73%)</entry></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="83"> -->
<tables id="tabl0006" num="0006">
<table frame="all">
<title><b>Table 9</b></title>
<tgroup cols="2">
<colspec colnum="1" colname="col1" colwidth="40mm"/>
<colspec colnum="2" colname="col2" colwidth="126mm"/>
<thead>
<row>
<entry valign="middle"><b>oligonucleotide name</b></entry>
<entry valign="middle"><b>oligonucleotide sequence (5'-&gt;3')</b></entry></row></thead>
<tbody>
<row>
<entry valign="middle">CLTA1 v2.1 template fwd</entry>
<entry valign="middle">TAA TAC GAC TCA CTA TAG GAG TCC TCA TCT CCC TCA AGC GTT TTA GAG CTA TGC TG (SEQ ID NO:237)</entry></row>
<row>
<entry valign="middle">CLTA2 v2.1 template fwd</entry>
<entry valign="middle">TAA TAC GAC TCA CTA TAG GCT CCC TCA AGC AGG CCC CGC GTT TTA GAG CTA TGC TG (SEQ ID NO:238)</entry></row>
<row>
<entry valign="middle">CLTA3 v2.1 template fwd</entry>
<entry valign="middle">TAA TAC GAC TCA CTA TAG GTG TGA AGA GCT TCA CTG AGT GTT TTA GAG CTA TGC TG (SEQ ID NO:239)</entry></row>
<row>
<entry valign="middle">CLTA4 v2.1 template fwd</entry>
<entry valign="middle">TAA TAC GAC TCA CTA TAG GGC AGA TGT AGT GTT TCC ACA GTT TTA GAG CTA TGC TG (SEQ ID NO:240)</entry></row>
<row>
<entry valign="middle">v2.1 template rev</entry>
<entry valign="middle">GAT AAC GGA CTA GCC TTA TTT TAA CTT GCT ATG CTT TTC AGC ATA GCT CTA AAA C (SEQ ID NO:241)</entry></row>
<row>
<entry valign="middle">CLTA1 v1.0 template</entry>
<entry valign="middle">CGG ACT AGC CTT ATT TTA ACT TGC TAT TTC TAG CTC TAA AAC GCT TGA GGG AGA TGA GGA CTC CTA TAG TGA GTC GTA TTA (SEQ ID NO:242)</entry></row>
<row>
<entry valign="middle">CLTA2 v1.0 template</entry>
<entry valign="middle">CGG ACT AGC CTT ATT TTA ACT TGC TAT TTC TAG CTC TAA AAC GCG GGG CCT GCT TGA GGG AGC CTA TAG TGA GTC GTA TTA (SEQ ID NO:243)</entry></row>
<row>
<entry valign="middle">CLTA3 v1.0 template</entry>
<entry valign="middle">CGG ACT AGC CTT ATT TTA ACT TGC TAT TTC TAG CTC TAA AAC ACT CAG TGA AGC TCT TCA CAC CTA TAG TGA GTC GTA TTA (SEQ ID NO:244)</entry></row>
<row>
<entry valign="middle">CLTA4 v1.0 template</entry>
<entry valign="middle">CGG ACT AGC CTT ATT TTA ACT TGC TAT TTC TAG CTC TAA AAC TGT GGA AAC ACT ACA TCT GCC CTA TAG TGA GTC GTA TTA (SEQ ID NO:245)</entry></row>
<row>
<entry valign="middle">T7 promoter oligo</entry>
<entry valign="middle">TAA TAC GAC TCA CTA TAG G (SEQ ID NO:246)</entry></row>
<row>
<entry valign="middle">CLTA1 lib</entry>
<entry valign="middle">/5Phos/AAC ACA NNN NC*C* NG*C* T*T*G* A*G*G* G*A*G* A*T*G* A*G*G* A*C*T* NNN NAC CTG CCG AGA ACA CA (SEQ ID NO:247)</entry></row>
<row>
<entry valign="middle">CLTA2 lib</entry>
<entry valign="middle">/5Phos/TCT TCT NNN NC*C* NG*C* G*G*G* G*C*C* T*G*C* T*T*G* A*G*G* G*A*G* NNN NAC CTG CCG AGT CTT CT (SEQ ID NO:248)</entry></row>
<row>
<entry valign="middle">CLTA3 lib</entry>
<entry valign="middle">/5Phos/AGA GAA NNN NC*C* NA*C* T*C*A* G*T*G* A*A*G* C*T*C* T*T*C* A*C*A* NNN NAC CTG CCG AGA GAG AA (SEQ ID NO:249)</entry></row>
<row>
<entry valign="middle">CLTA4 lib</entry>
<entry valign="middle">/5Phos/TTG TGT NNN NC*C* NT*G* T*G*G* A*A*A* C*A*C* T*A*C* A*T*C* T*G*C* NNN NAC CTG CCG AGT TGT GT (SEQ ID NO:250)</entry></row>
<row>
<entry valign="middle">CLTA1 site fwd</entry>
<entry valign="middle">CTA GCA GTC CTC ATC TCC CTC AAG CAG GC (SEQ ID NO:251)</entry></row>
<row>
<entry valign="middle">CLTA1 site rev</entry>
<entry valign="middle">AGC TGC CTG CTT GAG GGA GAT GAG GAC TG (SEQ ID NO:252)</entry></row>
<row>
<entry valign="middle">CLTA2 site fwd</entry>
<entry valign="middle">CTA GTC TCC CTC AAG CAG GCC CCG CTG GT (SEQ ID NO:253)</entry></row>
<row>
<entry valign="middle">CLTA2 site rev</entry>
<entry valign="middle">AGC TAC CAG CGG GGC CTG CTT GAG GGA GA (SEQ ID NO:254)</entry></row>
<row>
<entry valign="middle">CLTA3 site fwd</entry>
<entry valign="middle">CTA GCT GTG AAG AGC TTC ACT GAG TAG GA (SEQ ID NO:255)</entry></row>
<row>
<entry valign="middle">CLTA3 site rev</entry>
<entry valign="middle">AGC TTC CTA CTC AGT GAA GCT CTT CAC AG (SEQ ID NO:256)</entry></row>
<row>
<entry valign="middle">CLTA4 site fwd</entry>
<entry valign="middle">CTA GTG CAG ATG TAG TGT TTC CAC AGG GT (SEQ ID NO:257)</entry></row>
<row>
<entry valign="middle">CLTA4 site rev</entry>
<entry valign="middle">AGC TAC CCT GTG GAA ACA CTA CAT CTG CA (SEQ ID NO:258)</entry></row>
<row>
<entry valign="middle">test fwd</entry>
<entry valign="middle">GCG ACA CGG AAA TGT TGA ATA CTC AT (SEQ ID NO:259)</entry></row>
<row>
<entry valign="middle">test rev</entry>
<entry valign="middle">GGA GTC AGG CAA CTA TGG ATG AAC G (SEQ ID NO:260)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-0 fwd</entry>
<entry valign="middle">ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GCA GAT GTA GTG TTT CCA CAG GGT (SEQ ID NO:261)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-1 fwd</entry>
<entry valign="middle">ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GAA GAT GTA GTG TTT CCA CAG GGT (SEQ ID NO:262)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-2a fwd</entry>
<entry valign="middle">ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GAA GAT GTA GTG TTT CCA CTG GGT (SEQ ID NO:263)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-2b fwd</entry>
<entry valign="middle">ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GCA GAT GGA GGG TTT CCA CAG GGT (SEQ ID NO:264)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-2c fwd</entry>
<entry valign="middle">ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GCA GAT GTA GTG TTA CCA GAG GGT (SEQ ID NO:265)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-3 fwd</entry>
<entry valign="middle">ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GGG GAT GTA GTG TTT CCA CTG GGT (SEQ ID NO:266)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-0 rev</entry>
<entry valign="middle">TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CTG TGG AAA CAC TAC ATC TGC (SEQ ID NO:267)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-1 rev</entry>
<entry valign="middle">TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CTG TGG AAA CAC TAC ATC TTC (SEQ ID NO:268)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-2a rev</entry>
<entry valign="middle">TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CAG TGG AAA CAC TAC ATC TTC (SEQ ID NO:269)</entry></row><!-- EPO <DP n="84"> -->
<row>
<entry valign="middle">off-target CLTA4-2b rev</entry>
<entry valign="middle">TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CTG TGG AAA CCC TCC ATC TGC (SEQ ID NO:270)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-2c rev</entry>
<entry valign="middle">TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CTC TGG TAA CAC TAC ATC TGC (SEQ ID NO:271)</entry></row>
<row>
<entry valign="middle">off-target CLTA4-3 rev</entry>
<entry valign="middle">TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CAG TGG AAA CAC TAC ATC CCC (SEQ ID NO:272)</entry></row>
<row>
<entry valign="middle">adapter1 (AACA)</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TAA CA (SEQ ID NO:273)</entry></row>
<row>
<entry valign="middle">adapter2(AACA)</entry>
<entry valign="middle">TGT TAG ATC GGA AGA GCG TCG TGT AGG GAA AGA GTG TAG ATC TCG GTG G (SEQ ID NO:274)</entry></row>
<row>
<entry valign="middle">adapter1 (TTCA)</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TTT CA (SEQ ID NO:275)</entry></row>
<row>
<entry valign="middle">adapter2(TTCA)</entry>
<entry valign="middle">TGA AAG ATC GGA AGA GCG TCG TGT AGG GAA AGA GTG TAG ATC TCG GTG G (SEQ ID NO:276)</entry></row>
<row>
<entry valign="middle">adapter1</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC T (SEQ ID NO:277)</entry></row>
<row>
<entry valign="middle">adapter2</entry>
<entry valign="middle">AGA TCG GAA GAG CGT CGT GTA GGG AAA GAG TGT AGA TCT CGG TGG (SEQ ID NO:278)</entry></row>
<row>
<entry valign="middle">lib adapter1</entry>
<entry valign="middle">GAC GGC ATA CGA GAT (SEQ ID NO:279)</entry></row>
<row>
<entry valign="middle">CLTA1 lib adapter2</entry>
<entry valign="middle">AAC AAT CTC GTA TGC CGT CTT CTG CTT G (SEQ ID NO:280)</entry></row>
<row>
<entry valign="middle">CLTA2 lib adapter2</entry>
<entry valign="middle">TCT TAT CTC GTA TGC CGT CTT CTG CTT G (SEQ ID NO:281)</entry></row>
<row>
<entry valign="middle">CLTA3 lib adapter2</entry>
<entry valign="middle">AGA GAT CTC GTA TGC CGT CTT CTG CTT G (SEQ ID NO:282)</entry></row>
<row>
<entry valign="middle">CLTA4 lib adapter2</entry>
<entry valign="middle">TTG TAT CTC GTA TGC CGT CTT CTG CTT G (SEQ ID NO:283)</entry></row>
<row>
<entry valign="middle">CLTA1 sel PCR</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT TGT GTT CTC GGC AGG T (SEQ ID NO:284)</entry></row>
<row>
<entry valign="middle">CLTA2 sel PCR</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT AGA AGA CTC GGC AGG T (SEQ ID NO:285)</entry></row>
<row>
<entry valign="middle">CLTA3 sel PCR</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT TTC TCT CTC GGC AGG T (SEQ ID NO:286)</entry></row>
<row>
<entry valign="middle">CLTA4 sel PCR</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT ACA CAA CTC GGC AGG T (SEQ ID NO:287)</entry></row>
<row>
<entry valign="middle">PE2 short</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GA (SEQ ID NO:288)</entry></row>
<row>
<entry valign="middle">CLTA1 lib seq PCR</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN NNA CCT ACC TGC CGA GAA CAC A (SEQ ID NO:289)</entry></row>
<row>
<entry valign="middle">CLTA2 lib seq PCR</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN NNA CCT ACC TGC CGA GTC TTC T (SEQ ID NO:290)</entry></row>
<row>
<entry valign="middle">CLTA3 lib seq PCR</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN NNA CCT ACC TGC CGA GAG AGA A (SEQ ID NO:291)</entry></row>
<row>
<entry valign="middle">CLTA4 lib seq PCR</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN NNA CCT ACC TGC CGA GTT GTG T (SEQ ID NO:292)</entry></row>
<row>
<entry valign="middle">lib fwd PCR</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT (SEQ ID NO:293)</entry></row>
<row>
<entry valign="middle">CLTA1-0-1 (Chr. 9) fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CAA GTC TAG CAA GCA GGC CA (SEQ ID NO:294)</entry></row>
<row>
<entry valign="middle">CLTA1-0-1 (Chr. 12) fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CAG GCA CTG AGT GGG AAA GT (SEQ ID NO:295)</entry></row>
<row>
<entry valign="middle">CLTA1-1-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TAA CCC CAA GTC AGC AAG CA (SEQ ID NO:296)</entry></row>
<row>
<entry valign="middle">CLTA1-2-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTG CTG GTC AAT ACC CTG GC (SEQ ID NO:297)</entry></row>
<row>
<entry valign="middle">CLTA1-2-2 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGA GTA CCC CTG AAA TGG GC (SEQ ID NO:298)</entry></row>
<row>
<entry valign="middle">CLTA1-3-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCG CTA CCA ATC AGG GCT TT (SEQ ID NO:299)</entry></row>
<row>
<entry valign="middle">CLTA1-3-2 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCA TTG CCA CTT GTT TGC AT (SEQ ID NO:300)</entry></row>
<row>
<entry valign="middle">CLTA1-4-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCT ACC CCC ACA ACT TTG CT (SEQ ID NO:301)</entry></row>
<row>
<entry valign="middle">CLTA1-4-2 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GTG TAC ATC CAG TGC ACC CA (SEQ ID NO:302)</entry></row><!-- EPO <DP n="85"> -->
<row>
<entry valign="middle">CLTA1-4-3 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCG GAA AGG ACT TTG AAT ACT TGT (SEQ ID NO:303)</entry></row>
<row>
<entry valign="middle">CLTA1-4-4 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CGG CCC AAG ACC TCA TTC AC (SEQ ID NO:304)</entry></row>
<row>
<entry valign="middle">CLTA1-4-5 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GTC CTC TCT GGG GCA GAA GT (SEQ ID NO:305)</entry></row>
<row>
<entry valign="middle">CLTA1-4-6 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AGC TGA GTC ATG AGT TGT CTC C (SEQ ID NO:306)</entry></row>
<row>
<entry valign="middle">CLTA1-4-7 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CTG CCA GCT TCT CAC ACC AT (SEQ ID NO:307)</entry></row>
<row>
<entry valign="middle">CLTA1-4-8 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CTG AAG GAC AAA GGC GGG AA (SEQ ID NO:308)</entry></row>
<row>
<entry valign="middle">CLTA1-5-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AAG GTG CTA AAG GCT CCA CG (SEQ ID NO:309)</entry></row>
<row>
<entry valign="middle">CLTA1-5-2 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GAC CAT TGG TGA GCC CAG AG (SEQ ID NO:310)</entry></row>
<row>
<entry valign="middle">CLTA1-5-3 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTT TTC GGG CAA CTG CTC AC (SEQ ID NO:311)</entry></row>
<row>
<entry valign="middle">CLTA1-5-4 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GCA AGC CTT CTC TCC TCA GA (SEQ ID NO:312)</entry></row>
<row>
<entry valign="middle">CLTA1-5-5 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ACA CAA ACT TCC CTG AGA CCC (SEQ ID NO:313)</entry></row>
<row>
<entry valign="middle">CLTA1-6-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGA GTT AGC CCT GCT GTT CA (SEQ ID NO:314)</entry></row>
<row>
<entry valign="middle">CLTA4-0-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGA AGA GCT TCA CTG AGT AGG A (SEQ ID NO:315)</entry></row>
<row>
<entry valign="middle">CLTA4-3-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCC CCT TAC AGC CAA TTT CGT (SEQ ID NO:316)</entry></row>
<row>
<entry valign="middle">CLTA4-3-2 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGC TGA TGA AAT GCA ATT AAG AGG T (SEQ ID NO:317)</entry></row>
<row>
<entry valign="middle">CLTA4-3-3 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GGT CCC TGC AAG CCA GTA TG (SEQ ID NO:318)</entry></row>
<row>
<entry valign="middle">CLTA4-3-4 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ATC AAA GCC TTG TAT CAC AGT T (SEQ ID NO:319)</entry></row>
<row>
<entry valign="middle">CLTA4-3-5 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCC AAA TAA TGC AGG AGC CAA (SEQ ID NO:320)</entry></row>
<row>
<entry valign="middle">CLTA4-3-6 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CTG CCT TTA GTG GGA CAG ACT T (SEQ ID NO:321)</entry></row>
<row>
<entry valign="middle">CLTA4-3-7 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AGT AAC CCT AGT AGC CCT CCA (SEQ ID NO:322)</entry></row>
<row>
<entry valign="middle">CLTA4-4-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CAT TGC AGT GAG CCG AGA TTG (SEQ ID NO:323)</entry></row>
<row>
<entry valign="middle">CLTA4-4-2 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGG CAA AGT TCA CTT CCA TGT (SEQ ID NO:324)</entry></row>
<row>
<entry valign="middle">CLTA4-4-3 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGC TCT GTG ATG TCT GCC AC (SEQ ID NO:325)</entry></row>
<row>
<entry valign="middle">CLTA4-4-4 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGT GTA GGA TTG TGA ACC AGC A (SEQ ID NO:326)</entry></row>
<row>
<entry valign="middle">CLTA4-4-5 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCC CAG CCC AGC ATT TTT CT (SEQ ID NO:327)</entry></row>
<row>
<entry valign="middle">CLTA4-4-6 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AGG TTG CTT TGT GCA CAG TC (SEQ ID NO:328)</entry></row>
<row>
<entry valign="middle">CLTA4-4-7 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCT GGC TTG GGA TGT TGG AA (SEQ ID NO:329)</entry></row>
<row>
<entry valign="middle">CLTA4-4-8 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTG CCC AAG GTC ATA CTG CT (SEQ ID NO:330)</entry></row>
<row>
<entry valign="middle">CLTA4-4-9 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ACC CAC TAG GTA GCC ATA ATC CA (SEQ ID NO:331)</entry></row>
<row>
<entry valign="middle">CLTA4-4-10 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CGG TCA TGT CGC TTG GAA GA (SEQ ID NO:332)</entry></row>
<row>
<entry valign="middle">CLTA4-4-11 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTG GCC CAT ATT GCT TTA TGC TG (SEQ ID NO:333)</entry></row>
<row>
<entry valign="middle">CLTA4-4-12 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ATT AGG GGT TGG CTG CAT GA (SEQ ID NO:334)</entry></row>
<row>
<entry valign="middle">CLTA4-4-13 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCA AGA CGT GTT GCA TGC TG (SEQ ID NO:335)</entry></row>
<row>
<entry valign="middle">CLTA4-4-14 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGG GAG GTG ATA AAT TCC CTA AAT (SEQ ID NO:336)</entry></row>
<row>
<entry valign="middle">CLTA4-5-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCA GAG ACA AAG GTG GGG AG (SEQ ID NO:337)</entry></row>
<row>
<entry valign="middle">CLTA4-5-2 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCA TAC AGA AGA GCA AAG TAC CA (SEQ ID NO:338)</entry></row>
<row>
<entry valign="middle">CLTA4-5-3 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CAA AGA GGG GTA TCG GGA GC (SEQ ID NO:339)</entry></row><!-- EPO <DP n="86"> -->
<row>
<entry valign="middle">CLTA4-5-4 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AAA TGG AAG AAC CAA GTA GAT GAA (SEQ ID NO:340)</entry></row>
<row>
<entry valign="middle">CLTA4-5-5 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTT TGG TTG ACA GAT GGC CAC A (SEQ ID NO:341)</entry></row>
<row>
<entry valign="middle">CLTA4-5-6 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCT TAC TTG TGT GAT TTT AGA ACA A (SEQ ID NO:342)</entry></row>
<row>
<entry valign="middle">CLTA4-6-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GAT GGT TCA TGC AGA GGG CT (SEQ ID NO:343)</entry></row>
<row>
<entry valign="middle">CLTA4-6-2 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GCT GGT CTT TCC TGA GCT GT (SEQ ID NO:344)</entry></row>
<row>
<entry valign="middle">CLTA4-6-3 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CTC CAT CAG ATA CCT GTA CCC A (SEQ ID NO:345)</entry></row>
<row>
<entry valign="middle">CLTA4-7-1 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GGG AAA ACA CTC TCT CTC TGC T (SEQ ID NO:346)</entry></row>
<row>
<entry valign="middle">CLTA4-7-2 fwd</entry>
<entry valign="middle">ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GGA GGC CAC GAC ACA CAA TA (SEQ ID NO:347)</entry></row>
<row>
<entry valign="middle">CLTA1-0-1 (Chr. 9) rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAC AGG GTG GCT CTT CAG TG (SEQ ID NO:348)</entry></row>
<row>
<entry valign="middle">CLTA1-0-1 (Chr. 12) rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGC ACA TGT TTC CAC AGG GT (SEQ ID NO:349)</entry></row>
<row>
<entry valign="middle">CLTA1-1-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGT GTT TCC AGG AGC GGT TT (SEQ ID NO:350)</entry></row>
<row>
<entry valign="middle">CLTA1-2-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AAG CCT CAG GCA CAA CTC TG (SEQ ID NO:351)</entry></row>
<row>
<entry valign="middle">CLTA1-2-2 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TAG GGG AGG GGC AAA GAC A (SEQ ID NO:352)</entry></row>
<row>
<entry valign="middle">CLTA1-3-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGG AAC AGT GGT ATG CTG GT (SEQ ID NO:353)</entry></row>
<row>
<entry valign="middle">CLTA1-3-2 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGT GTG GAC ACT GAC AAG GAA (SEQ ID NO:354)</entry></row>
<row>
<entry valign="middle">CLTA1-4-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TCA CTG CCT GGG TGC TTT AG (SEQ ID NO:355)</entry></row>
<row>
<entry valign="middle">CLTA1-4-2 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TAC CCC AGC CTC CAG CTT TA (SEQ ID NO:356)</entry></row>
<row>
<entry valign="middle">CLTA1-4-3 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGA CTA CTG GGG AGC GAT GA (SEQ ID NO:357)</entry></row>
<row>
<entry valign="middle">CLTA1-4-4 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGG CTG TTA TGC AGG AAA GGA A (SEQ ID NO:358)</entry></row>
<row>
<entry valign="middle">CLTA1-4-5 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GCG GTT GAG GTG GAT GGA AG (SEQ ID NO:359)</entry></row>
<row>
<entry valign="middle">CLTA1-4-6 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGC AGC ATC CCT TAC ATC CT (SEQ ID NO:360)</entry></row>
<row>
<entry valign="middle">CLTA1-4-7 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGA AAA AGC TTC CCC AGA AAG GA (SEQ ID NO:361)</entry></row>
<row>
<entry valign="middle">CLTA1-4-8 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CTG CAC CAA CCT CTA CGT CC (SEQ ID NO:362)</entry></row>
<row>
<entry valign="middle">CLTA1-5-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CTG GAG AGG GCA TAG TTG GC (SEQ ID NO:363)</entry></row>
<row>
<entry valign="middle">CLTA1-5-2 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG AAG GCT CTT TGT GGG TT (SEQ ID NO:364)</entry></row>
<row>
<entry valign="middle">CLTA1-5-3 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTC CTA GCG GGA ACT GGA AA (SEQ ID NO:365)</entry></row>
<row>
<entry valign="middle">CLTA1-5-4 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGG CTA ATG GGG TAG GGG AT (SEQ ID NO:366)</entry></row>
<row>
<entry valign="middle">CLTA1-5-5 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGT CCA TGT TGG CTG AGG TG (SEQ ID NO:367)</entry></row>
<row>
<entry valign="middle">CLTA1-6-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAG GCC AAC CTT GAC AAC TT (SEQ ID NO:368)</entry></row>
<row>
<entry valign="middle">CLTA4-0-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGC AGG CCA AAG ATG TCT CC (SEQ ID NO:369)</entry></row>
<row>
<entry valign="middle">CLTA4-3-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TCT GCT CTT GAG GTT ATT TGT CC (SEQ ID NO:370)</entry></row>
<row>
<entry valign="middle">CLTA4-3-2 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGG ACC AAT TTG CTA CTC ATG G (SEQ ID NO:371)</entry></row>
<row>
<entry valign="middle">CLTA4-3-3 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG AGG CTG TAA ACG TCC TG (SEQ ID NO:372)</entry></row>
<row>
<entry valign="middle">CLTA4-3-4 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGC TAT GAT TTG CTG AAT TAC TCC T (SEQ ID NO:373)</entry></row>
<row>
<entry valign="middle">CLTA4-3-5 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GCA ATT TTG CAG ACC ACC ATC (SEQ ID NO:374)</entry></row>
<row>
<entry valign="middle">CLTA4-3-6 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGC AGC TTG CAA CCT TCT TG (SEQ ID NO:375)</entry></row>
<row>
<entry valign="middle">CLTA4-3-7 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TCA TGA GAG TTT CCC CAA CA (SEQ ID NO:376)</entry></row><!-- EPO <DP n="87"> -->
<row>
<entry valign="middle">CLTA4-4-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT ACT TGA GGG GGA AAA AGT TTC TTA (SEQ ID NO:377)</entry></row>
<row>
<entry valign="middle">CLTA4-4-2 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG TCC CTG TCT GTC ATT GG (SEQ ID NO:378)</entry></row>
<row>
<entry valign="middle">CLTA4-4-3 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AAG CGA GTG ACT GTC TGG GA (SEQ ID NO:379)</entry></row>
<row>
<entry valign="middle">CLTA4-4-4 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAT GGG TGG GAC ACG TAG TT (SEQ ID NO:380)</entry></row>
<row>
<entry valign="middle">CLTA4-4-5 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGC TTT CCT GGA CAC CCT ATC (SEQ ID NO:381)</entry></row>
<row>
<entry valign="middle">CLTA4-4-6 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGA GCG AGG GAG CGA TGT A (SEQ ID NO:382)</entry></row>
<row>
<entry valign="middle">CLTA4-4-7 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTG TGG ACC ACT GCT TAG TGC (SEQ ID NO:383)</entry></row>
<row>
<entry valign="middle">CLTA4-4-8 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAA CTA CCC TGA GGC CAC C (SEQ ID NO:384)</entry></row>
<row>
<entry valign="middle">CLTA4-4-9 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGT CAG CAC TCC TCA GCT TT (SEQ ID NO:385)</entry></row>
<row>
<entry valign="middle">CLTA4-4-10 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG AGG ATG CAT GCC ACA TT (SEQ ID NO:386)</entry></row>
<row>
<entry valign="middle">CLTA4-4-11 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CCC AGC CTC TTT GAC CCT TC (SEQ ID NO:387)</entry></row>
<row>
<entry valign="middle">CLTA4-4-12 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CCC ACA CCA GGC TGT AAG G (SEQ ID NO:388)</entry></row>
<row>
<entry valign="middle">CLTA4-4-13 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TAG ATA TAT GGG TGT GTC TGT ACG (SEQ ID NO:389)</entry></row>
<row>
<entry valign="middle">CLTA4-4-14 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTC CAA AGT GGC TGA ACC AT (SEQ ID NO:390)</entry></row>
<row>
<entry valign="middle">CLTA4-5-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CCC ACA GGG CTG ATG TTT CA (SEQ ID NO:391)</entry></row>
<row>
<entry valign="middle">CLTA4-5-2 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTG TAA TGC AAC CTC TGT CAT GC (SEQ ID NO:392)</entry></row>
<row>
<entry valign="middle">CLTA4-5-3 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CCA GCT CCA GCA ATC CAT GA (SEQ ID NO:393)</entry></row>
<row>
<entry valign="middle">CLTA4-5-4 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTT GGG AAA GAT AGC CCT GGA (SEQ ID NO:394)</entry></row>
<row>
<entry valign="middle">CLTA4-5-5 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAA TGA AAC AGC GGG GAG GT (SEQ ID NO:395)</entry></row>
<row>
<entry valign="middle">CLTA4-5-6 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT ACA ATC ACG TGT CCT TCA CT (SEQ ID NO:396)</entry></row>
<row>
<entry valign="middle">CLTA4-6-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAG ATC CCT CCT GGG CAA TG (SEQ ID NO:397)</entry></row>
<row>
<entry valign="middle">CLTA4-6-2 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GTC AGG AGG CAA GGA GGA AC (SEQ ID NO:398)</entry></row>
<row>
<entry valign="middle">CLTA4-6-3 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT ACT TCC TTC CTT TTG AGA CCA AGT (SEQ ID NO:399)</entry></row>
<row>
<entry valign="middle">CLTA4-7-1 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GCG GCA GAT TCC TGG TGA TT (SEQ ID NO:400)</entry></row>
<row>
<entry valign="middle">CLTA4-7-2 rev</entry>
<entry valign="middle">GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGT CAC CAT CAG CAC AGT CA (SEQ ID NO:401)</entry></row>
<row>
<entry valign="middle">PE1-barcode1</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT ATA TCA GTG TGA CTG GAG TTC AGA CGT GTG CT (SEQ ID NO:402)</entry></row>
<row>
<entry valign="middle">PE 1-barcode2</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT TTT CAC CGG TGA CTG GAG TTC AGA CGT GTG CT (SEQ ID NO:403)</entry></row>
<row>
<entry valign="middle">PE1-barcode3</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT CCA CTC ATG TGA CTG GAG TTC AGA CGT GTG CT (SEQ ID NO:404)</entry></row>
<row>
<entry valign="middle">PE1-barcode4</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT TAC GTA CGG TGA CTG GAG TTC AGA CGT GTG CT (SEQ ID NO:405)</entry></row>
<row>
<entry valign="middle">PE1-barcode5</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT CGA AAC TCG TGA CTG GAG TTC AGA CGT GTG CT (SEQ ID NO:406)</entry></row>
<row>
<entry valign="middle">PE 1-barcode6</entry>
<entry valign="middle">CAA GCA GAA GAC GGC ATA CGA GAT ATC AGT ATG TGA CTG GAG TTC AGA CGT GTG CT (SEQ ID NO:407)</entry></row>
<row>
<entry valign="middle">PE2-barcode1</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACA TTA CTC GAC ACT CTT TCC CTA CAC GAC (SEQ ID NO:408)</entry></row>
<row>
<entry valign="middle">PE2-barcode2</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CCG GAG AAC ACT CTT TCC CTA CAC GAC (SEQ ID NO:409)</entry></row>
<row>
<entry valign="middle">PE2-barcode3</entry>
<entry valign="middle">AAT GAT ACG GCG ACC ACC GAG ATC TAC ACC GCT CAT TAC ACT CTT TCC CTA CAC GAC (SEQ ID NO:410)</entry></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="88"> --></p>
<heading id="h0021"><b>REFERENCES</b></heading>
<p id="p0136" num="0136">
<ol id="ol0003" compact="compact" ol-style="">
<li>1. <nplcit id="ncit0045" npl-type="s"><text>Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nature biotechnology 29, 731-734 (2011</text></nplcit>).</li>
<li>2. <nplcit id="ncit0046" npl-type="s"><text>Zou, J. et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell stem cell 5, 97-110 (2009</text></nplcit>).</li>
<li>3. <nplcit id="ncit0047" npl-type="s"><text>Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nature biotechnology 27, 851-857 (2009</text></nplcit>).</li>
<li>4. <nplcit id="ncit0048" npl-type="s"><text>Doyon, Y. et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nature biotechnology 26, 702-708 (2008</text></nplcit>).</li>
<li>5. <nplcit id="ncit0049" npl-type="s"><text>Meng, X., Noyes, M.B., Zhu, L.J., Lawson, N.D. &amp; Wolfe, S.A. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nature biotechnology 26, 695-701 (2008</text></nplcit>).</li>
<li>6. <nplcit id="ncit0050" npl-type="s"><text>Sander, J.D. et al. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nature biotechnology 29, 697-698 (2011</text></nplcit>).</li>
<li>7. <nplcit id="ncit0051" npl-type="s"><text>Tesson, L. et al. Knockout rats generated by embryo microinjection of TALENs. Nature biotechnology 29, 695-696 (2011</text></nplcit>).</li>
<li>8. <nplcit id="ncit0052" npl-type="s"><text>Cui, X. et al. Targeted integration in rat and mouse embryos with zinc-finger nucleases. Nature biotechnology 29, 64-67 (2011</text></nplcit>).</li>
<li>9. <nplcit id="ncit0053" npl-type="s"><text>Perez, E.E. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nature biotechnology 26, 808-816 (2008</text></nplcit>).</li>
<li>10. NCT00842634, NCT01044654, NCT01252641, NCT01082926.</li>
<li>11. <nplcit id="ncit0054" npl-type="s"><text>Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012</text></nplcit>).</li>
<li>12. <nplcit id="ncit0055" npl-type="s"><text>Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013</text></nplcit>).</li>
<li>13. <nplcit id="ncit0056" npl-type="s"><text>Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013</text></nplcit>).</li>
<li>14. <nplcit id="ncit0057" npl-type="s"><text>Hwang, W.Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013</text></nplcit>).</li>
<li>15. <nplcit id="ncit0058" npl-type="s"><text>Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013</text></nplcit>).</li>
<li>16. <nplcit id="ncit0059" npl-type="s"><text>Dicarlo, J.E. et al. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic acids research (2013</text></nplcit>).<!-- EPO <DP n="89"> --></li>
<li>17. <nplcit id="ncit0060" npl-type="s"><text>Jiang, W., Bikard, D., Cox, D., Zhang, F. &amp; Marraffini, L.A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology 31, 233-239 (2013</text></nplcit>).</li>
<li>18. <nplcit id="ncit0061" npl-type="s"><text>Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic acids research 39, 9275-9282 (2011</text></nplcit>).</li>
<li>19. <nplcit id="ncit0062" npl-type="s"><text>Semenova, E. et al. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proceedings of the National Academy of Sciences of the United States of America 108, 10098-10103 (2011</text></nplcit>).</li>
<li>20. <nplcit id="ncit0063" npl-type="s"><text>Qi, L.S. et al. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. Cell 152, 1173-1183 (2013</text></nplcit>).</li>
<li>21. <nplcit id="ncit0064" npl-type="s"><text>Pattanayak, V., Ramirez, C.L., Joung, J.K. &amp; Liu, D.R. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nature methods 8, 765-770 (2011</text></nplcit>).</li>
<li>22. <nplcit id="ncit0065" npl-type="s"><text>Doyon, J.B., Pattanayak, V., Meyer, C.B. &amp; Liu, D.R. Directed evolution and substrate specificity profile of homing endonuclease I-SceI. Journal of the American Chemical Society 128, 2477-2484 (2006</text></nplcit>).</li>
<li>23. <nplcit id="ncit0066" npl-type="s"><text>Jiang, W., Bikard, D., Cox, D., Zhang, F. &amp; Marraffini, L.A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology 31, 233-239 (2013</text></nplcit>).</li>
<li>24. <nplcit id="ncit0067" npl-type="s"><text>Pattanayak, V., Ramirez, C.L., Joung, J.K. &amp; Liu, D.R. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nature methods 8, 765-770 (2011</text></nplcit>).</li>
<li>25. <nplcit id="ncit0068" npl-type="s"><text>Schneider, T.D. &amp; Stephens, R.M. Sequence logos: a new way to display consensus sequences. Nucleic acids research 18, 6097-6100 (1990</text></nplcit>).</li>
</ol><!-- EPO <DP n="90"> --></p>
<heading id="h0022">SEQUENCE LISTING</heading>
<p id="p0137" num="0137">
<ul id="ul0006" list-style="none">
<li>&lt;110&gt; President and Fellows of Harvard College</li>
<li>&lt;120&gt; NUCLEASE PROFILING SYSTEM</li>
<li>&lt;130&gt; P103019EP1</li>
<li>&lt;140&gt;<br/>
&lt;141&gt; 2014-08-08</li>
<li>&lt;150&gt; <patcit id="pcit0005" dnum="US61864289B"><text>US 61/864,289</text></patcit><br/>
&lt;151&gt; 2013-08-09</li>
<li>&lt;150&gt; <patcit id="pcit0006" dnum="US14320370B"><text>US 14/320,370</text></patcit><br/>
&lt;151&gt; 2014-06-30</li>
<li>&lt;150&gt; <patcit id="pcit0007" dnum="US14320413B"><text>US 14/320,413</text></patcit><br/>
&lt;151&gt; 2013-06-30</li>
<li>&lt;160&gt; 410</li>
<li>&lt;170&gt; PatentIn version 3.5</li>
<li>&lt;210&gt; 1<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Polynucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (21)..(21)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 1<br/>
agtcctcatc tccctcaagc ngg   23</li>
<li>&lt;210&gt; 2<br/>
&lt;211&gt; 48<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 2<br/>
atgtctcccg catgcgctca gtcctcatct ccctcaagca ggccccgc   48</li>
<li>&lt;210&gt; 3<br/>
&lt;211&gt; 48<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 3<br/>
<!-- EPO <DP n="91"> -->gcggggcctg cttgagggag atgaggactg agcgcatgcg ggagacat   48</li>
<li>&lt;210&gt; 4<br/>
&lt;211&gt; 48<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 4<br/>
tggtgcactg aagagccacc ctgtggaaac actacatctg caatatct   48</li>
<li>&lt;210&gt; 5<br/>
&lt;211&gt; 48<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 5<br/>
agatattgca gatgtagtgt ttccacaggg tggctcttca gtgcacca   48</li>
<li>&lt;210&gt; 6<br/>
&lt;211&gt; 48<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 6<br/>
taatcctact cagtgaagct cttcacagtc attggattaa ttatgttg   48</li>
<li>&lt;210&gt; 7<br/>
&lt;211&gt; 48<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 7<br/>
caacataatt aatccaatga ctgtgaagag cttcactgag taggatta   48</li>
<li>&lt;210&gt; 8<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 8<br/>
agtcctcatc tccctcaagc agg   23<!-- EPO <DP n="92"> --></li>
<li>&lt;210&gt; 9<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 9<br/>
cctgcttgag ggagatgagg act   23</li>
<li>&lt;210&gt; 10<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; RNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 10<br/>
gaguccucau cucccucaag cguuuuagag cuagaaauag cuuaaaauaa ggcuaguccg   60</li>
<li>&lt;210&gt; 11<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 11<br/>
ctccctcaag caggccccgc tgg   23</li>
<li>&lt;210&gt; 12<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 12<br/>
ccagcggggc ctgcttgagg gag   23</li>
<li>&lt;210&gt; 13<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; RNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 13<br/>
gcucccucaa gcaggccccg cguuuuagag cuagaaauag cuuaaaauaa ggcuaguccg   60</li>
<li>&lt;210&gt; 14<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="93"> -->&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 14<br/>
tgtgaagagc ttcactgagt agg   23</li>
<li>&lt;210&gt; 15<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 15<br/>
cctactcagt gaagctcttc aca   23</li>
<li>&lt;210&gt; 16<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; RNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 16<br/>
gugugaagag cuucacugag uguuuuagag cuagaaauag cuuaaaauaa ggcuaguccg   60</li>
<li>&lt;210&gt; 17<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 17<br/>
gcagatgtag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 18<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 18<br/>
ccctgtggaa acactacatc tgc   23</li>
<li>&lt;210&gt; 19<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; RNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
<!-- EPO <DP n="94"> -->&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 19<br/>
ggcagaugua guguuuccac aguuuuagag cuagaaauag cuuaaaauaa ggcuaguccg   60</li>
<li>&lt;210&gt; 20<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 20<br/>
agtcctcatc tccctcaagc agg   23</li>
<li>&lt;210&gt; 21<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 21<br/>
cctgcttgag ggagatgagg act   23</li>
<li>&lt;210&gt; 22<br/>
&lt;211&gt; 73<br/>
&lt;212&gt; RNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 22
<img id="ib0022" file="imgb0022.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 23<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 23<br/>
ctccctcaag caggccccgc tgg   23</li>
<li>&lt;210&gt; 24<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="95"> --></li>
<li>&lt;400&gt; 24<br/>
ccagcggggc ctgcttgagg gag   23</li>
<li>&lt;210&gt; 25<br/>
&lt;211&gt; 73<br/>
&lt;212&gt; RNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 25
<img id="ib0023" file="imgb0023.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 26<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 26<br/>
tgtgaagagc ttcactgagt agg   23</li>
<li>&lt;210&gt; 27<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 27<br/>
cctactcagt gaagctcttc aca   23</li>
<li>&lt;210&gt; 28<br/>
&lt;211&gt; 73<br/>
&lt;212&gt; RNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 28
<img id="ib0024" file="imgb0024.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 29<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
<!-- EPO <DP n="96"> -->&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 29<br/>
gcagatgtag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 30<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 30<br/>
ccctgtggaa acactacatc tgc   23</li>
<li>&lt;210&gt; 31<br/>
&lt;211&gt; 73<br/>
&lt;212&gt; RNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 31
<img id="ib0025" file="imgb0025.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 32<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (21)..(21)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 32<br/>
ctccctcaag caggccccgc ngg   23</li>
<li>&lt;210&gt; 33<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (21)..(21)<br/>
&lt;223&gt; n is a, c, g, or t<!-- EPO <DP n="97"> --></li>
<li>&lt;400&gt; 33<br/>
gcagatgtag tgtttccaca ngg   23</li>
<li>&lt;210&gt; 34<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 34<br/>
gcagatgtag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 35<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 35<br/>
gaagatgtag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 36<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 36<br/>
gaagatgtag tgtttccact ggg   23</li>
<li>&lt;210&gt; 37<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 37<br/>
gcagatggag ggtttccaca ggg   23</li>
<li>&lt;210&gt; 38<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 38<br/>
gcagatgtag tgttaccaga ggg   23<!-- EPO <DP n="98"> --></li>
<li>&lt;210&gt; 39<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 39<br/>
ggggatgtag tgtttccact ggg   23</li>
<li>&lt;210&gt; 40<br/>
&lt;211&gt; 4104<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 40
<img id="ib0026" file="imgb0026.tif" wi="159" he="152" img-content="dna" img-format="tif"/><!-- EPO <DP n="99"> -->
<img id="ib0027" file="imgb0027.tif" wi="151" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="100"> -->
<img id="ib0028" file="imgb0028.tif" wi="159" he="129" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 41<br/>
&lt;211&gt; 1367<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Polypeptide</li>
<li>&lt;400&gt; 41
<img id="ib0029" file="imgb0029.tif" wi="136" he="66" img-content="dna" img-format="tif"/><!-- EPO <DP n="101"> -->
<img id="ib0030" file="imgb0030.tif" wi="134" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="102"> -->
<img id="ib0031" file="imgb0031.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="103"> -->
<img id="ib0032" file="imgb0032.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="104"> -->
<img id="ib0033" file="imgb0033.tif" wi="138" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="105"> -->
<img id="ib0034" file="imgb0034.tif" wi="132" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="106"> -->
<img id="ib0035" file="imgb0035.tif" wi="133" he="54" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 42<br/>
&lt;211&gt; 100<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 42
<img id="ib0036" file="imgb0036.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 43<br/>
&lt;211&gt; 10<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 43<br/>
ctcggcaggt   10</li>
<li>&lt;210&gt; 44<br/>
&lt;211&gt; 43<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 44<br/>
acttgcagat gtagtctttc cacatgggtc gacacaaaca caa   43</li>
<li>&lt;210&gt; 45<br/>
&lt;211&gt; 12<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 45<br/>
<!-- EPO <DP n="107"> -->tgtgtttgtg tt   12</li>
<li>&lt;210&gt; 46<br/>
&lt;211&gt; 12<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 46<br/>
agaagaagaa ga   12</li>
<li>&lt;210&gt; 47<br/>
&lt;211&gt; 12<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 47<br/>
ttctctttct ct   12</li>
<li>&lt;210&gt; 48<br/>
&lt;211&gt; 12<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 48<br/>
acacaaacac aa   12</li>
<li>&lt;210&gt; 49<br/>
&lt;211&gt; 43<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 49<br/>
acttgcagat gtagtctttc cacatgggtc gacacaaaca caa   43</li>
<li>&lt;210&gt; 50<br/>
&lt;211&gt; 31<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 50<br/>
acttgcagat gtagtctttc cacatgggtc g   31<!-- EPO <DP n="108"> --></li>
<li>&lt;210&gt; 51<br/>
&lt;211&gt; 100<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 51
<img id="ib0037" file="imgb0037.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 52<br/>
&lt;211&gt; 162<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 52
<img id="ib0038" file="imgb0038.tif" wi="159" he="20" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 53<br/>
&lt;211&gt; 20<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 53<br/>
gctggtgcac tgaagagcca   20</li>
<li>&lt;210&gt; 54<br/>
&lt;211&gt; 20<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 54<br/>
aatatcttaa tcctactcag   20</li>
<li>&lt;210&gt; 55<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 55<br/>
<!-- EPO <DP n="109"> -->ccctgtgaaa cactacatct gc   22</li>
<li>&lt;210&gt; 56<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 56<br/>
gcagatgtag tgtttcacag gg   22</li>
<li>&lt;210&gt; 57<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 57<br/>
gcagatgtag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 58<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 58<br/>
gcagatgtag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 59<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 59<br/>
acatatgtag tatttccaca ggg   23</li>
<li>&lt;210&gt; 60<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 60<br/>
gcatatgtag tgtttccaaa tgt   23<!-- EPO <DP n="110"> --></li>
<li>&lt;210&gt; 61<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 61<br/>
ccagatgtag tattcccaca ggg   23</li>
<li>&lt;210&gt; 62<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 62<br/>
gcagttttag tgttttcaca ggg   23</li>
<li>&lt;210&gt; 63<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 63<br/>
gcagagttag tgtttccaca cag   23</li>
<li>&lt;210&gt; 64<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 64<br/>
gcagatggag ggttttcaca ggg   23</li>
<li>&lt;210&gt; 65<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 65<br/>
ggaaatttag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 66<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="111"> -->&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 66<br/>
aaagaagtag tatttccaca tgg   23</li>
<li>&lt;210&gt; 67<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 67<br/>
aaagatgtag tcattccaca agg   23</li>
<li>&lt;210&gt; 68<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 68<br/>
aaatatgtag tctttccaca ggg   23</li>
<li>&lt;210&gt; 69<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 69<br/>
atagatgtag tgtttccaaa gga   23</li>
<li>&lt;210&gt; 70<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 70<br/>
ccagaggtag tgctcccaca ggg   23</li>
<li>&lt;210&gt; 71<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
<!-- EPO <DP n="112"> -->&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 71<br/>
ccagatgtga ggtttccaca agg   23</li>
<li>&lt;210&gt; 72<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 72<br/>
ctacatgtag tgtttccata tgg   23</li>
<li>&lt;210&gt; 73<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 73<br/>
tagatgaagt gcttccacat gg   22</li>
<li>&lt;210&gt; 74<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 74<br/>
gaaaatggag tgtttacaca tgg   23</li>
<li>&lt;210&gt; 75<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 75<br/>
gcaaatgaag tgtcaccaca agg   23</li>
<li>&lt;210&gt; 76<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 76<br/>
<!-- EPO <DP n="113"> -->gcaaatgtat tatttccact agg   23</li>
<li>&lt;210&gt; 77<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 77<br/>
gcagatgtag cttttgtaca tgg   23</li>
<li>&lt;210&gt; 78<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 78<br/>
gcagcttaag tgttttcaca tgg   23</li>
<li>&lt;210&gt; 79<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 79<br/>
ttacatgtag tgtttacaca cgg   23</li>
<li>&lt;210&gt; 80<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 80<br/>
gaagaggaag tgtttgccca ggg   23</li>
<li>&lt;210&gt; 81<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 81<br/>
gaagatgtgg agttgacaca tgg   23<!-- EPO <DP n="114"> --></li>
<li>&lt;210&gt; 82<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 82<br/>
gcagaagtac tgttgttaca agg   23</li>
<li>&lt;210&gt; 83<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 83<br/>
gcagatgtgg aattacaaca ggg   23</li>
<li>&lt;210&gt; 84<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 84<br/>
gcagtcatag tgtatacaca tgg   23</li>
<li>&lt;210&gt; 85<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 85<br/>
taagatgtag tatttccaaa agt   23</li>
<li>&lt;210&gt; 86<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 86<br/>
gcagctggca tttctccaca cgg   23</li>
<li>&lt;210&gt; 87<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="115"> -->&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 87<br/>
ggagatctga tggttctaca agg   23</li>
<li>&lt;210&gt; 88<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 88<br/>
taaaatgcag tgtatccata tgg   23</li>
<li>&lt;210&gt; 89<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 89<br/>
gccagaatag tttttcaaca agg   23</li>
<li>&lt;210&gt; 90<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 90<br/>
ttgtatttag agattgcaca agg   23</li>
<li>&lt;210&gt; 91<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 91<br/>
agtcctcatc tccctcaagc agg   23</li>
<li>&lt;210&gt; 92<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
<!-- EPO <DP n="116"> -->&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 92<br/>
agtcctcaac tccctcaagc agg   23</li>
<li>&lt;210&gt; 93<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 93<br/>
agccctcatt tccctcaagc agg   23</li>
<li>&lt;210&gt; 94<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 94<br/>
actcctcatc cccctcaagc cgg   23</li>
<li>&lt;210&gt; 95<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 95<br/>
agtcatcatc tccctcaagc aga   23</li>
<li>&lt;210&gt; 96<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 96<br/>
cgtcctcctc tcccccaagc agg   23</li>
<li>&lt;210&gt; 97<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 97<br/>
<!-- EPO <DP n="117"> -->tgtcctcttc tccctcaagc aga   23</li>
<li>&lt;210&gt; 98<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 98<br/>
aagcttcatc tctctcaagc tgg   23</li>
<li>&lt;210&gt; 99<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 99<br/>
agtactcttt tccctcaggc tgg   23</li>
<li>&lt;210&gt; 100<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 100<br/>
agtcttaaat tccctcaagc agg   23</li>
<li>&lt;210&gt; 101<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 101<br/>
agtgctcatc taccagaagc tgg   23</li>
<li>&lt;210&gt; 102<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 102<br/>
cctcctcatc tccctgcagc agg   23<!-- EPO <DP n="118"> --></li>
<li>&lt;210&gt; 103<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 103<br/>
ctacatcatc tccctcaagc tgg   23</li>
<li>&lt;210&gt; 104<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 104<br/>
ggtcctcatc tccctaaaac aga   23</li>
<li>&lt;210&gt; 105<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 105<br/>
tgtcctcatc ggcctcaggc agg   23</li>
<li>&lt;210&gt; 106<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 106<br/>
agacaccatc tcccttgagc tgg   23</li>
<li>&lt;210&gt; 107<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 107<br/>
aggcatcatc tacatcaagt tgg   23</li>
<li>&lt;210&gt; 108<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="119"> -->&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 108<br/>
agtaatcact tccatcaagc cgg   23</li>
<li>&lt;210&gt; 109<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 109<br/>
tcccctcacc tccctaaagc agg   23</li>
<li>&lt;210&gt; 110<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 110<br/>
tgtctttatt tccctctagc tgg   23</li>
<li>&lt;210&gt; 111<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 111<br/>
agtcctcatc tccctcaagc agg   23</li>
<li>&lt;210&gt; 112<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 112<br/>
gcagatgtag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 113<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
<!-- EPO <DP n="120"> -->&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 113<br/>
acatatgtag tatttccaca ggg   23</li>
<li>&lt;210&gt; 114<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 114<br/>
gcatatgtag tgtttccaaa tgt   23</li>
<li>&lt;210&gt; 115<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 115<br/>
ccagatgtag tattcccaca ggg   23</li>
<li>&lt;210&gt; 116<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 116<br/>
gcagttttag tgttttcaca ggg   23</li>
<li>&lt;210&gt; 117<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 117<br/>
gcagagttag tgtttccaca cag   23</li>
<li>&lt;210&gt; 118<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 118<br/>
<!-- EPO <DP n="121"> -->gcagatggag ggttttcaca ggg   23</li>
<li>&lt;210&gt; 119<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 119<br/>
ggaaatttag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 120<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 120<br/>
aaagaagtag tatttccaca tgg   23</li>
<li>&lt;210&gt; 121<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 121<br/>
aaagatgtag tcattccaca agg   23</li>
<li>&lt;210&gt; 122<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 122<br/>
aaatatgtag tctttccaca ggg   23</li>
<li>&lt;210&gt; 123<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 123<br/>
atagatgtag tgtttccaaa gga   23<!-- EPO <DP n="122"> --></li>
<li>&lt;210&gt; 124<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 124<br/>
ccagaggtag tgctcccaca ggg   23</li>
<li>&lt;210&gt; 125<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 125<br/>
ccagatgtga ggtttccaca agg   23</li>
<li>&lt;210&gt; 126<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 126<br/>
ctacatgtag tgtttccata tgg   23</li>
<li>&lt;210&gt; 127<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 127<br/>
ctagatgaag tgcttccaca tgg   23</li>
<li>&lt;210&gt; 128<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 128<br/>
gaaaatggag tgtttacaca tgg   23</li>
<li>&lt;210&gt; 129<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="123"> -->&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 129<br/>
gcaaatgaag tgtcaccaca agg   23</li>
<li>&lt;210&gt; 130<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 130<br/>
gcaaatgtat tatttccact agg   23</li>
<li>&lt;210&gt; 131<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 131<br/>
gcagatgtag cttttgtaca tgg   23</li>
<li>&lt;210&gt; 132<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 132<br/>
gcagcttaag tgttttcaca tgg   23</li>
<li>&lt;210&gt; 133<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 133<br/>
ttacatgtag tgtttacaca cgg   23</li>
<li>&lt;210&gt; 134<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
<!-- EPO <DP n="124"> -->&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 134<br/>
gaagaggaag tgtttgccca ggg   23</li>
<li>&lt;210&gt; 135<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 135<br/>
gaagatgtgg agttgacaca tgg   23</li>
<li>&lt;210&gt; 136<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 136<br/>
gcagaagtac tgttgttaca agg   23</li>
<li>&lt;210&gt; 137<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 137<br/>
gcagatgtgg aattacaaca ggg   23</li>
<li>&lt;210&gt; 138<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 138<br/>
gcagtcatag tgtatacaca tgg   23</li>
<li>&lt;210&gt; 139<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 139<br/>
<!-- EPO <DP n="125"> -->taagatgtag tatttccaaa agt   23</li>
<li>&lt;210&gt; 140<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 140<br/>
gcagctggca tttctccaca cgg   23</li>
<li>&lt;210&gt; 141<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 141<br/>
ggagatctga tggttctaca agg   23</li>
<li>&lt;210&gt; 142<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 142<br/>
taaaatgcag tgtatccata tgg   23</li>
<li>&lt;210&gt; 143<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 143<br/>
gccagaatag tttttcaaca agg   23</li>
<li>&lt;210&gt; 144<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 144<br/>
ttgtatttag agattgcaca agg   23<!-- EPO <DP n="126"> --></li>
<li>&lt;210&gt; 145<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 145<br/>
agtcctcatc tccctcaagc agg   23</li>
<li>&lt;210&gt; 146<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 146<br/>
agtcctcaac tccctcaagc agg   23</li>
<li>&lt;210&gt; 147<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 147<br/>
agccctcatt tccctcaagc agg   23</li>
<li>&lt;210&gt; 148<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 148<br/>
actcctcatc cccctcaagc cgg   23</li>
<li>&lt;210&gt; 149<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 149<br/>
agtcatcatc tccctcaagc aga   23</li>
<li>&lt;210&gt; 150<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="127"> -->&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 150<br/>
cgtcctcctc tcccccaagc agg   23</li>
<li>&lt;210&gt; 151<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 151<br/>
tgtcctcttc tccctcaagc aga   23</li>
<li>&lt;210&gt; 152<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 152<br/>
aagcttcatc tctctcaagc tgg   23</li>
<li>&lt;210&gt; 153<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 153<br/>
agtactcttt tccctcaggc tgg   23</li>
<li>&lt;210&gt; 154<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 154<br/>
agtcttaaat tccctcaagc agg   23</li>
<li>&lt;210&gt; 155<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
<!-- EPO <DP n="128"> -->&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 155<br/>
agtgctcatc taccagaagc tgg   23</li>
<li>&lt;210&gt; 156<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 156<br/>
cctcctcatc tccctgcagc agg   23</li>
<li>&lt;210&gt; 157<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 157<br/>
ctacatcatc tccctcaagc tgg   23</li>
<li>&lt;210&gt; 158<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 158<br/>
ggtcctcatc tccctaaaac aga   23</li>
<li>&lt;210&gt; 159<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 159<br/>
tgtcctcatc ggcctcaggc agg   23</li>
<li>&lt;210&gt; 160<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 160<br/>
<!-- EPO <DP n="129"> -->agacaccatc tcccttgagc tgg   23</li>
<li>&lt;210&gt; 161<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 161<br/>
aggcatcatc tacatcaagt tgg   23</li>
<li>&lt;210&gt; 162<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 162<br/>
agtaatcact tccatcaagc cgg   23</li>
<li>&lt;210&gt; 163<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 163<br/>
tcccctcacc tccctaaagc agg   23</li>
<li>&lt;210&gt; 164<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 164<br/>
tgtctttatt tccctctagc tgg   23</li>
<li>&lt;210&gt; 165<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 165<br/>
agtcctcatc tccctcaagc agg   23<!-- EPO <DP n="130"> --></li>
<li>&lt;210&gt; 166<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 166<br/>
agtcctcatc tccctcaagc agg   23</li>
<li>&lt;210&gt; 167<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 167<br/>
agtcctcatc tccctcaaag cagg   24</li>
<li>&lt;210&gt; 168<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 168<br/>
agtcctcatc tccctcagca gg   22</li>
<li>&lt;210&gt; 169<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 169<br/>
agtcctcatc tccctcatag cagg   24</li>
<li>&lt;210&gt; 170<br/>
&lt;211&gt; 15<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 170<br/>
agtcctcata gcagg   15</li>
<li>&lt;210&gt; 171<br/>
&lt;211&gt; 17<br/>
&lt;212&gt; DNA<br/>
<!-- EPO <DP n="131"> -->&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 171<br/>
agtcctcatc tagcagg   17</li>
<li>&lt;210&gt; 172<br/>
&lt;211&gt; 14<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 172<br/>
agtcctcaag cagg   14</li>
<li>&lt;210&gt; 173<br/>
&lt;211&gt; 51<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 173<br/>
agtcctcatc tccctcaaag gcagtgtttg ttacttgagt ttgtcagcag g   51</li>
<li>&lt;210&gt; 174<br/>
&lt;211&gt; 25<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 174<br/>
agtcctcatc tccctcatta gcagg   25</li>
<li>&lt;210&gt; 175<br/>
&lt;211&gt; 65<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 175
<img id="ib0039" file="imgb0039.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 176<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="132"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 176<br/>
agtcctcatc tccctagcag g   21</li>
<li>&lt;210&gt; 177<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 177<br/>
agtcctcatc cctcaagcag g   21</li>
<li>&lt;210&gt; 178<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 178<br/>
agtcctcatc tccctaagca gg   22</li>
<li>&lt;210&gt; 179<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 179<br/>
agtcctcaac tccctcaagc agg   23</li>
<li>&lt;210&gt; 180<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 180<br/>
agtcctcaac tccctcaaag cagg   24</li>
<li>&lt;210&gt; 181<br/>
&lt;211&gt; 17<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="133"> --></li>
<li>&lt;400&gt; 181<br/>
agtcctcaac tccctca   17</li>
<li>&lt;210&gt; 182<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 182<br/>
agtcctcaac tccctcagca gg   22</li>
<li>&lt;210&gt; 183<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 183<br/>
agtcctcaac tccctcaaga aaggtgttga aaatcagaaa gagagaaaca agcagg   56</li>
<li>&lt;210&gt; 184<br/>
&lt;211&gt; 62<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 184
<img id="ib0040" file="imgb0040.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 185<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 185<br/>
agtcctcaac tccctaagca gg   22</li>
<li>&lt;210&gt; 186<br/>
&lt;211&gt; 66<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="134"> --></li>
<li>&lt;400&gt; 186
<img id="ib0041" file="imgb0041.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 187<br/>
&lt;211&gt; 64<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 187
<img id="ib0042" file="imgb0042.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 188<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 188<br/>
agtcctcaac tcccaagcag g   21</li>
<li>&lt;210&gt; 189<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 189<br/>
actcctcatc cccctcaagc cgg   23</li>
<li>&lt;210&gt; 190<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 190<br/>
actcctcatc cccctcaaag ccgg   24</li>
<li>&lt;210&gt; 191<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="135"> --></li>
<li>&lt;400&gt; 191<br/>
actcctcatc cccctcagag ccgg   24</li>
<li>&lt;210&gt; 192<br/>
&lt;211&gt; 13<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 192<br/>
actcctcagc cgg   13</li>
<li>&lt;210&gt; 193<br/>
&lt;211&gt; 25<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 193<br/>
actcctcatc cccctcaaaa gccgg   25</li>
<li>&lt;210&gt; 194<br/>
&lt;211&gt; 25<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 194<br/>
actcctcatc cccctcagca gccgg   25</li>
<li>&lt;210&gt; 195<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 195<br/>
actcctcatc cccctcatag ccgg   24</li>
<li>&lt;210&gt; 196<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 196<br/>
actcctcatc cccctcatcc ccgg   24<!-- EPO <DP n="136"> --></li>
<li>&lt;210&gt; 197<br/>
&lt;211&gt; 18<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 197<br/>
actcctcatc ccagccgg   18</li>
<li>&lt;210&gt; 198<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 198<br/>
actcctcatc cccctaagcc gg   22</li>
<li>&lt;210&gt; 199<br/>
&lt;211&gt; 25<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 199<br/>
actcctcatc cccctcaata gccgg   25</li>
<li>&lt;210&gt; 200<br/>
&lt;211&gt; 25<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 200<br/>
actcctcacc cccctcagca gccgg   25</li>
<li>&lt;210&gt; 201<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 201<br/>
gcagatgtag tgtttccaca ggg   23</li>
<li>&lt;210&gt; 202<br/>
<!-- EPO <DP n="137"> -->&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 202<br/>
gcagatgtag tgtttcacag gg   22</li>
<li>&lt;210&gt; 203<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 203<br/>
gcagatgtag tgtttcccac aggg   24</li>
<li>&lt;210&gt; 204<br/>
&lt;211&gt; 19<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 204<br/>
gcagatgtag tgcacaggg   19</li>
<li>&lt;210&gt; 205<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 205<br/>
gcagatgtag tgtttcccag gg   22</li>
<li>&lt;210&gt; 206<br/>
&lt;211&gt; 16<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 206<br/>
gcagatgtac acaggg   16</li>
<li>&lt;210&gt; 207<br/>
&lt;211&gt; 20<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="138"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 207<br/>
gcagatgtag tgtcacaggg   20</li>
<li>&lt;210&gt; 208<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 208<br/>
gcagatgtag tgttcacagg g   21</li>
<li>&lt;210&gt; 209<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 209<br/>
gcagatgtag tgtttccagg g   21</li>
<li>&lt;210&gt; 210<br/>
&lt;211&gt; 18<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 210<br/>
gcagatgtag tcacaggg   18</li>
<li>&lt;210&gt; 211<br/>
&lt;211&gt; 12<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 211<br/>
gcagatgtag gg   12</li>
<li>&lt;210&gt; 212<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="139"> --></li>
<li>&lt;400&gt; 212<br/>
acatatgtag tatttccaca ggg   23</li>
<li>&lt;210&gt; 213<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 213<br/>
acatatgtag tatttcccac aggg   24</li>
<li>&lt;210&gt; 214<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 214<br/>
acatatgtag tatttcacag gg   22</li>
<li>&lt;210&gt; 215<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 215<br/>
acatatgtag tatttccagg g   21</li>
<li>&lt;210&gt; 216<br/>
&lt;211&gt; 13<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 216<br/>
acatatcaca ggg   13</li>
<li>&lt;210&gt; 217<br/>
&lt;211&gt; 11<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 217<br/>
acatcacagg g   11<!-- EPO <DP n="140"> --></li>
<li>&lt;210&gt; 218<br/>
&lt;211&gt; 18<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 218<br/>
acatatgtag tcacaggg   18</li>
<li>&lt;210&gt; 219<br/>
&lt;211&gt; 17<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 219<br/>
acatatgtag tatttcc   17</li>
<li>&lt;210&gt; 220<br/>
&lt;211&gt; 12<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 220<br/>
acatatgtag gg   12</li>
<li>&lt;210&gt; 221<br/>
&lt;211&gt; 17<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 221<br/>
acatatgtag cacaggg   17</li>
<li>&lt;210&gt; 222<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 222<br/>
ccagatgtag tattcccaca ggg   23</li>
<li>&lt;210&gt; 223<br/>
<!-- EPO <DP n="141"> -->&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 223<br/>
ccagatgtag tattccccac aggg   24</li>
<li>&lt;210&gt; 224<br/>
&lt;211&gt; 19<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 224<br/>
ccagatgtag tatacaggg   19</li>
<li>&lt;210&gt; 225<br/>
&lt;211&gt; 20<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 225<br/>
ccagatgtag tatcacaggg   20</li>
<li>&lt;210&gt; 226<br/>
&lt;211&gt; 26<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 226<br/>
ccagatgtag tattcccaac acaggg   26</li>
<li>&lt;210&gt; 227<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 227<br/>
ccagatgtag tattcacagg g   21</li>
<li>&lt;210&gt; 228<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="142"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 228<br/>
ccagatgtag tattcccagg g   21</li>
<li>&lt;210&gt; 229<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 229<br/>
ccagatgtag tattccacag gg   22</li>
<li>&lt;210&gt; 230<br/>
&lt;211&gt; 23<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 230<br/>
ctagatgaag tgcttccaca tgg   23</li>
<li>&lt;210&gt; 231<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 231<br/>
ctagatgaag tgcttcccac atgg   24</li>
<li>&lt;210&gt; 232<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 232<br/>
ctagatgaag tgcttcacat gg   22</li>
<li>&lt;210&gt; 233<br/>
&lt;211&gt; 12<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="143"> --></li>
<li>&lt;400&gt; 233<br/>
ctagatgaag tg   12</li>
<li>&lt;210&gt; 234<br/>
&lt;211&gt; 25<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 234<br/>
ctagatgaag tgcttccaca catgg   25</li>
<li>&lt;210&gt; 235<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 235<br/>
ctagatgaag tgcttccatg g   21</li>
<li>&lt;210&gt; 236<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 236<br/>
ctagatgaag tgcttcccat gg   22</li>
<li>&lt;210&gt; 237<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 237<br/>
taatacgact cactatagga gtcctcatct ccctcaagcg ttttagagct atgctg   56</li>
<li>&lt;210&gt; 238<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 238<br/>
taatacgact cactataggc tccctcaagc aggccccgcg ttttagagct atgctg   56<!-- EPO <DP n="144"> --></li>
<li>&lt;210&gt; 239<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 239<br/>
taatacgact cactataggt gtgaagagct tcactgagtg ttttagagct atgctg   56</li>
<li>&lt;210&gt; 240<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 240<br/>
taatacgact cactataggg cagatgtagt gtttccacag ttttagagct atgctg   56</li>
<li>&lt;210&gt; 241<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 241<br/>
gataacggac tagccttatt ttaacttgct atgcttttca gcatagctct aaaac   55</li>
<li>&lt;210&gt; 242<br/>
&lt;211&gt; 81<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 242
<img id="ib0043" file="imgb0043.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 243<br/>
&lt;211&gt; 81<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 243
<img id="ib0044" file="imgb0044.tif" wi="159" he="4" img-content="dna" img-format="tif"/><!-- EPO <DP n="145"> -->
<img id="ib0045" file="imgb0045.tif" wi="159" he="4" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 244<br/>
&lt;211&gt; 81<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 244
<img id="ib0046" file="imgb0046.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 245<br/>
&lt;211&gt; 81<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 245
<img id="ib0047" file="imgb0047.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 246<br/>
&lt;211&gt; 19<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 246<br/>
taatacgact cactatagg   19</li>
<li>&lt;210&gt; 247<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (7)..(10)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (13)..(13)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;220&gt;<br/>
<!-- EPO <DP n="146"> -->&lt;221&gt; misc_feature<br/>
&lt;222&gt; (34)..(37)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 247<br/>
aacacannnn ccngcttgag ggagatgagg actnnnnacc tgccgagaac aca   53</li>
<li>&lt;210&gt; 248<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (7)..(10)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (13)..(13)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (34)..(37)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 248<br/>
tcttctnnnn ccngcggggc ctgcttgagg gagnnnnacc tgccgagtct tct   53</li>
<li>&lt;210&gt; 249<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (7)..(10)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (13)..(13)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (34)..(37)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 249<br/>
agagaannnn ccnactcagt gaagctcttc acannnnacc tgccgagaga gaa   53<!-- EPO <DP n="147"> --></li>
<li>&lt;210&gt; 250<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (7)..(10)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (13)..(13)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (34)..(37)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 250<br/>
ttgtgtnnnn ccntgtggaa acactacatc tgcnnnnacc tgccgagttg tgt   53</li>
<li>&lt;210&gt; 251<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 251<br/>
ctagcagtcc tcatctccct caagcaggc   29</li>
<li>&lt;210&gt; 252<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 252<br/>
agctgcctgc ttgagggaga tgaggactg   29</li>
<li>&lt;210&gt; 253<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 253<br/>
ctagtctccc tcaagcaggc cccgctggt   29<!-- EPO <DP n="148"> --></li>
<li>&lt;210&gt; 254<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 254<br/>
agctaccagc ggggcctgct tgagggaga   29</li>
<li>&lt;210&gt; 255<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 255<br/>
ctagctgtga agagcttcac tgagtagga   29</li>
<li>&lt;210&gt; 256<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 256<br/>
agcttcctac tcagtgaagc tcttcacag   29</li>
<li>&lt;210&gt; 257<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 257<br/>
ctagtgcaga tgtagtgttt ccacagggt   29</li>
<li>&lt;210&gt; 258<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 258<br/>
agctaccctg tggaaacact acatctgca   29</li>
<li>&lt;210&gt; 259<br/>
<!-- EPO <DP n="149"> -->&lt;211&gt; 26<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 259<br/>
gcgacacgga aatgttgaat actcat   26</li>
<li>&lt;210&gt; 260<br/>
&lt;211&gt; 25<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 260<br/>
ggagtcaggc aactatggat gaacg   25</li>
<li>&lt;210&gt; 261<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 261<br/>
actgtgaaga gcttcactga gtaggattaa gatattgcag atgtagtgtt tccacagggt   60</li>
<li>&lt;210&gt; 262<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 262<br/>
actgtgaaga gcttcactga gtaggattaa gatattgaag atgtagtgtt tccacagggt   60</li>
<li>&lt;210&gt; 263<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 263<br/>
actgtgaaga gcttcactga gtaggattaa gatattgaag atgtagtgtt tccactgggt   60</li>
<li>&lt;210&gt; 264<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="150"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 264<br/>
actgtgaaga gcttcactga gtaggattaa gatattgcag atggagggtt tccacagggt   60</li>
<li>&lt;210&gt; 265<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 265<br/>
actgtgaaga gcttcactga gtaggattaa gatattgcag atgtagtgtt accagagggt   60</li>
<li>&lt;210&gt; 266<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 266<br/>
actgtgaaga gcttcactga gtaggattaa gatattgggg atgtagtgtt tccactgggt   60</li>
<li>&lt;210&gt; 267<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 267<br/>
tccctcaagc aggccccgct ggtgcactga agagccaccc tgtggaaaca ctacatctgc   60</li>
<li>&lt;210&gt; 268<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 268<br/>
tccctcaagc aggccccgct ggtgcactga agagccaccc tgtggaaaca ctacatcttc   60</li>
<li>&lt;210&gt; 269<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="151"> --></li>
<li>&lt;400&gt; 269<br/>
tccctcaagc aggccccgct ggtgcactga agagccaccc agtggaaaca ctacatcttc   60</li>
<li>&lt;210&gt; 270<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 270<br/>
tccctcaagc aggccccgct ggtgcactga agagccaccc tgtggaaacc ctccatctgc   60</li>
<li>&lt;210&gt; 271<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 271<br/>
tccctcaagc aggccccgct ggtgcactga agagccaccc tctggtaaca ctacatctgc   60</li>
<li>&lt;210&gt; 272<br/>
&lt;211&gt; 60<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 272<br/>
tccctcaagc aggccccgct ggtgcactga agagccaccc agtggaaaca ctacatcccc   60</li>
<li>&lt;210&gt; 273<br/>
&lt;211&gt; 62<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 273<br/>
aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct tccgatctaa   60</li>
<li>ca   62</li>
<li>&lt;210&gt; 274<br/>
&lt;211&gt; 49<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="152"> --></li>
<li>&lt;400&gt; 274<br/>
tgttagatcg gaagagcgtc gtgtagggaa agagtgtaga tctcggtgg   49</li>
<li>&lt;210&gt; 275<br/>
&lt;211&gt; 62<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 275
<img id="ib0048" file="imgb0048.tif" wi="159" he="11" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 276<br/>
&lt;211&gt; 49<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 276<br/>
tgaaagatcg gaagagcgtc gtgtagggaa agagtgtaga tctcggtgg   49</li>
<li>&lt;210&gt; 277<br/>
&lt;211&gt; 58<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 277<br/>
aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct tccgatct   58</li>
<li>&lt;210&gt; 278<br/>
&lt;211&gt; 45<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 278<br/>
agatcggaag agcgtcgtgt agggaaagag tgtagatctc ggtgg   45</li>
<li>&lt;210&gt; 279<br/>
&lt;211&gt; 15<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 279<br/>
<!-- EPO <DP n="153"> -->gacggcatac gagat   15</li>
<li>&lt;210&gt; 280<br/>
&lt;211&gt; 28<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 280<br/>
aacaatctcg tatgccgtct tctgcttg   28</li>
<li>&lt;210&gt; 281<br/>
&lt;211&gt; 28<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 281<br/>
tcttatctcg tatgccgtct tctgcttg   28</li>
<li>&lt;210&gt; 282<br/>
&lt;211&gt; 28<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 282<br/>
agagatctcg tatgccgtct tctgcttg   28</li>
<li>&lt;210&gt; 283<br/>
&lt;211&gt; 28<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 283<br/>
ttgtatctcg tatgccgtct tctgcttg   28</li>
<li>&lt;210&gt; 284<br/>
&lt;211&gt; 40<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 284<br/>
caagcagaag acggcatacg agattgtgtt ctcggcaggt   40<!-- EPO <DP n="154"> --></li>
<li>&lt;210&gt; 285<br/>
&lt;211&gt; 40<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 285<br/>
caagcagaag acggcatacg agatagaaga ctcggcaggt   40</li>
<li>&lt;210&gt; 286<br/>
&lt;211&gt; 40<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 286<br/>
caagcagaag acggcatacg agatttctct ctcggcaggt   40</li>
<li>&lt;210&gt; 287<br/>
&lt;211&gt; 40<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 287<br/>
caagcagaag acggcatacg agatacacaa ctcggcaggt   40</li>
<li>&lt;210&gt; 288<br/>
&lt;211&gt; 20<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 288<br/>
aatgatacgg cgaccaccga   20</li>
<li>&lt;210&gt; 289<br/>
&lt;211&gt; 82<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (59)..(62)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 289<!-- EPO <DP n="155"> -->
<img id="ib0049" file="imgb0049.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 290<br/>
&lt;211&gt; 82<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (59)..(62)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 290
<img id="ib0050" file="imgb0050.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 291<br/>
&lt;211&gt; 82<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (59)..(62)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 291
<img id="ib0051" file="imgb0051.tif" wi="159" he="12" img-content="dna" img-format="tif"/></li>
<li>&lt;210&gt; 292<br/>
&lt;211&gt; 82<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;222&gt; (59)..(62)<br/>
&lt;223&gt; n is a, c, g, or t</li>
<li>&lt;400&gt; 292
<img id="ib0052" file="imgb0052.tif" wi="159" he="12" img-content="dna" img-format="tif"/><!-- EPO <DP n="156"> --></li>
<li>&lt;210&gt; 293<br/>
&lt;211&gt; 24<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 293<br/>
caagcagaag acggcatacg agat   24</li>
<li>&lt;210&gt; 294<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 294<br/>
acactctttc cctacacgac gctcttccga tctcaagtct agcaagcagg cca   53</li>
<li>&lt;210&gt; 295<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 295<br/>
acactctttc cctacacgac gctcttccga tctcaggcac tgagtgggaa agt   53</li>
<li>&lt;210&gt; 296<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 296<br/>
acactctttc cctacacgac gctcttccga tcttaacccc aagtcagcaa gca   53</li>
<li>&lt;210&gt; 297<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 297<br/>
acactctttc cctacacgac gctcttccga tctttgctgg tcaataccct ggc   53</li>
<li>&lt;210&gt; 298<br/>
<!-- EPO <DP n="157"> -->&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 298<br/>
acactctttc cctacacgac gctcttccga tcttgagtac ccctgaaatg ggc   53</li>
<li>&lt;210&gt; 299<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 299<br/>
acactctttc cctacacgac gctcttccga tcttcgctac caatcagggc ttt   53</li>
<li>&lt;210&gt; 300<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 300<br/>
acactctttc cctacacgac gctcttccga tctccattgc cacttgtttg cat   53</li>
<li>&lt;210&gt; 301<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 301<br/>
acactctttc cctacacgac gctcttccga tctcctaccc ccacaacttt gct   53</li>
<li>&lt;210&gt; 302<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 302<br/>
acactctttc cctacacgac gctcttccga tctgtgtaca tccagtgcac cca   53</li>
<li>&lt;210&gt; 303<br/>
&lt;211&gt; 57<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="158"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 303<br/>
acactctttc cctacacgac gctcttccga tcttcggaaa ggactttgaa tacttgt   57</li>
<li>&lt;210&gt; 304<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 304<br/>
acactctttc cctacacgac gctcttccga tctcggccca agacctcatt cac   53</li>
<li>&lt;210&gt; 305<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 305<br/>
acactctttc cctacacgac gctcttccga tctgtcctct ctggggcaga agt   53</li>
<li>&lt;210&gt; 306<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 306<br/>
acactctttc cctacacgac gctcttccga tctagctgag tcatgagttg tctcc   55</li>
<li>&lt;210&gt; 307<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 307<br/>
acactctttc cctacacgac gctcttccga tctctgccag cttctcacac cat   53</li>
<li>&lt;210&gt; 308<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="159"> --></li>
<li>&lt;400&gt; 308<br/>
acactctttc cctacacgac gctcttccga tctctgaagg acaaaggcgg gaa   53</li>
<li>&lt;210&gt; 309<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 309<br/>
acactctttc cctacacgac gctcttccga tctaaggtgc taaaggctcc acg   53</li>
<li>&lt;210&gt; 310<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 310<br/>
acactctttc cctacacgac gctcttccga tctgaccatt ggtgagccca gag   53</li>
<li>&lt;210&gt; 311<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 311<br/>
acactctttc cctacacgac gctcttccga tcttttttcg ggcaactgct cac   53</li>
<li>&lt;210&gt; 312<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 312<br/>
acactctttc cctacacgac gctcttccga tctgcaagcc ttctctcctc aga   53</li>
<li>&lt;210&gt; 313<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 313<br/>
acactctttc cctacacgac gctcttccga tctacacaaa cttccctgag accc   54<!-- EPO <DP n="160"> --></li>
<li>&lt;210&gt; 314<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 314<br/>
acactctttc cctacacgac gctcttccga tcttgagtta gccctgctgt tca   53</li>
<li>&lt;210&gt; 315<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 315<br/>
acactctttc cctacacgac gctcttccga tcttgaagag cttcactgag tagga   55</li>
<li>&lt;210&gt; 316<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 316<br/>
acactctttc cctacacgac gctcttccga tcttcccctt acagccaatt tcgt   54</li>
<li>&lt;210&gt; 317<br/>
&lt;211&gt; 58<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 317<br/>
acactctttc cctacacgac gctcttccga tcttgctgat gaaatgcaat taagaggt   58</li>
<li>&lt;210&gt; 318<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 318<br/>
acactctttc cctacacgac gctcttccga tctggtccct gcaagccagt atg   53</li>
<li>&lt;210&gt; 319<br/>
<!-- EPO <DP n="161"> -->&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 319<br/>
acactctttc cctacacgac gctcttccga tctatcaaag ccttgtatca cagtt   55</li>
<li>&lt;210&gt; 320<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 320<br/>
acactctttc cctacacgac gctcttccga tctcccaaat aatgcaggag ccaa   54</li>
<li>&lt;210&gt; 321<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 321<br/>
acactctttc cctacacgac gctcttccga tctctgcctt tagtgggaca gactt   55</li>
<li>&lt;210&gt; 322<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 322<br/>
acactctttc cctacacgac gctcttccga tctagtaacc ctagtagccc tcca   54</li>
<li>&lt;210&gt; 323<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 323<br/>
acactctttc cctacacgac gctcttccga tctcattgca gtgagccgag attg   54</li>
<li>&lt;210&gt; 324<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="162"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 324<br/>
acactctttc cctacacgac gctcttccga tcttggcaaa gttcacttcc atgt   54</li>
<li>&lt;210&gt; 325<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 325<br/>
acactctttc cctacacgac gctcttccga tcttgctctg tgatgtctgc cac   53</li>
<li>&lt;210&gt; 326<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 326<br/>
acactctttc cctacacgac gctcttccga tcttgtgtag gattgtgaac cagca   55</li>
<li>&lt;210&gt; 327<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 327<br/>
acactctttc cctacacgac gctcttccga tcttcccagc ccagcatttt tct   53</li>
<li>&lt;210&gt; 328<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 328<br/>
acactctttc cctacacgac gctcttccga tctaggttgc tttgtgcaca gtc   53</li>
<li>&lt;210&gt; 329<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="163"> --></li>
<li>&lt;400&gt; 329<br/>
acactctttc cctacacgac gctcttccga tctcctggct tgggatgttg gaa   53</li>
<li>&lt;210&gt; 330<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 330<br/>
acactctttc cctacacgac gctcttccga tctttgccca aggtcatact gct   53</li>
<li>&lt;210&gt; 331<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 331<br/>
acactctttc cctacacgac gctcttccga tctacccact aggtagccat aatcca   56</li>
<li>&lt;210&gt; 332<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 332<br/>
acactctttc cctacacgac gctcttccga tctcggtcat gtcgcttgga aga   53</li>
<li>&lt;210&gt; 333<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 333<br/>
acactctttc cctacacgac gctcttccga tctttggccc atattgcttt atgctg   56</li>
<li>&lt;210&gt; 334<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 334<br/>
acactctttc cctacacgac gctcttccga tctattaggg gttggctgca tga   53<!-- EPO <DP n="164"> --></li>
<li>&lt;210&gt; 335<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 335<br/>
acactctttc cctacacgac gctcttccga tctccaagac gtgttgcatg ctg   53</li>
<li>&lt;210&gt; 336<br/>
&lt;211&gt; 57<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 336<br/>
acactctttc cctacacgac gctcttccga tcttgggagg tgataaattc cctaaat   57</li>
<li>&lt;210&gt; 337<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 337<br/>
acactctttc cctacacgac gctcttccga tctccagaga caaaggtggg gag   53</li>
<li>&lt;210&gt; 338<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 338<br/>
acactctttc cctacacgac gctcttccga tcttcataca gaagagcaaa gtacca   56</li>
<li>&lt;210&gt; 339<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 339<br/>
acactctttc cctacacgac gctcttccga tctcaaagag gggtatcggg agc   53</li>
<li>&lt;210&gt; 340<br/>
<!-- EPO <DP n="165"> -->&lt;211&gt; 57<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 340<br/>
acactctttc cctacacgac gctcttccga tctaaatgga agaaccaagt agatgaa   57</li>
<li>&lt;210&gt; 341<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 341<br/>
acactctttc cctacacgac gctcttccga tctttttggt tgacagatgg ccaca   55</li>
<li>&lt;210&gt; 342<br/>
&lt;211&gt; 58<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 342<br/>
acactctttc cctacacgac gctcttccga tcttcttact tgtgtgattt tagaacaa   58</li>
<li>&lt;210&gt; 343<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 343<br/>
acactctttc cctacacgac gctcttccga tctgatggtt catgcagagg gct   53</li>
<li>&lt;210&gt; 344<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 344<br/>
acactctttc cctacacgac gctcttccga tctgctggtc tttcctgagc tgt   53</li>
<li>&lt;210&gt; 345<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="166"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 345<br/>
acactctttc cctacacgac gctcttccga tctctccatc agatacctgt accca   55</li>
<li>&lt;210&gt; 346<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 346<br/>
acactctttc cctacacgac gctcttccga tctgggaaaa cactctctct ctgct   55</li>
<li>&lt;210&gt; 347<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 347<br/>
acactctttc cctacacgac gctcttccga tctggaggcc acgacacaca ata   53</li>
<li>&lt;210&gt; 348<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 348<br/>
gtgactggag ttcagacgtg tgctcttccg atctcacagg gtggctcttc agtg   54</li>
<li>&lt;210&gt; 349<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 349<br/>
gtgactggag ttcagacgtg tgctcttccg atcttgcaca tgtttccaca gggt   54</li>
<li>&lt;210&gt; 350<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="167"> --></li>
<li>&lt;400&gt; 350<br/>
gtgactggag ttcagacgtg tgctcttccg atctagtgtt tccaggagcg gttt   54</li>
<li>&lt;210&gt; 351<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 351<br/>
gtgactggag ttcagacgtg tgctcttccg atctaagcct caggcacaac tctg   54</li>
<li>&lt;210&gt; 352<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 352<br/>
gtgactggag ttcagacgtg tgctcttccg atcttagggg aggggcaaag aca   53</li>
<li>&lt;210&gt; 353<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 353<br/>
gtgactggag ttcagacgtg tgctcttccg atctgggaac agtggtatgc tggt   54</li>
<li>&lt;210&gt; 354<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 354<br/>
gtgactggag ttcagacgtg tgctcttccg atctagtgtg gacactgaca aggaa   55</li>
<li>&lt;210&gt; 355<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 355<br/>
gtgactggag ttcagacgtg tgctcttccg atcttcactg cctgggtgct ttag   54<!-- EPO <DP n="168"> --></li>
<li>&lt;210&gt; 356<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 356<br/>
gtgactggag ttcagacgtg tgctcttccg atcttacccc agcctccagc ttta   54</li>
<li>&lt;210&gt; 357<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 357<br/>
gtgactggag ttcagacgtg tgctcttccg atcttgacta ctggggagcg atga   54</li>
<li>&lt;210&gt; 358<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 358<br/>
gtgactggag ttcagacgtg tgctcttccg atctaggctg ttatgcagga aaggaa   56</li>
<li>&lt;210&gt; 359<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 359<br/>
gtgactggag ttcagacgtg tgctcttccg atctgcggtt gaggtggatg gaag   54</li>
<li>&lt;210&gt; 360<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 360<br/>
gtgactggag ttcagacgtg tgctcttccg atctggcagc atcccttaca tcct   54</li>
<li>&lt;210&gt; 361<br/>
<!-- EPO <DP n="169"> -->&lt;211&gt; 57<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 361<br/>
gtgactggag ttcagacgtg tgctcttccg atctagaaaa agcttcccca gaaagga   57</li>
<li>&lt;210&gt; 362<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 362<br/>
gtgactggag ttcagacgtg tgctcttccg atctctgcac caacctctac gtcc   54</li>
<li>&lt;210&gt; 363<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 363<br/>
gtgactggag ttcagacgtg tgctcttccg atctctggag agggcatagt tggc   54</li>
<li>&lt;210&gt; 364<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 364<br/>
gtgactggag ttcagacgtg tgctcttccg atcttggaag gctctttgtg ggtt   54</li>
<li>&lt;210&gt; 365<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 365<br/>
gtgactggag ttcagacgtg tgctcttccg atctttccta gcgggaactg gaaa   54</li>
<li>&lt;210&gt; 366<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="170"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 366<br/>
gtgactggag ttcagacgtg tgctcttccg atctaggcta atggggtagg ggat   54</li>
<li>&lt;210&gt; 367<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 367<br/>
gtgactggag ttcagacgtg tgctcttccg atcttgtcca tgttggctga ggtg   54</li>
<li>&lt;210&gt; 368<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 368<br/>
gtgactggag ttcagacgtg tgctcttccg atctcaggcc aaccttgaca actt   54</li>
<li>&lt;210&gt; 369<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 369<br/>
gtgactggag ttcagacgtg tgctcttccg atctagcagg ccaaagatgt ctcc   54</li>
<li>&lt;210&gt; 370<br/>
&lt;211&gt; 57<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 370<br/>
gtgactggag ttcagacgtg tgctcttccg atcttctgct cttgaggtta tttgtcc   57</li>
<li>&lt;210&gt; 371<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="171"> --></li>
<li>&lt;400&gt; 371<br/>
gtgactggag ttcagacgtg tgctcttccg atctgggacc aatttgctac tcatgg   56</li>
<li>&lt;210&gt; 372<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 372<br/>
gtgactggag ttcagacgtg tgctcttccg atcttggagg ctgtaaacgt cctg   54</li>
<li>&lt;210&gt; 373<br/>
&lt;211&gt; 59<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 373<br/>
gtgactggag ttcagacgtg tgctcttccg atcttgctat gatttgctga attactcct   59</li>
<li>&lt;210&gt; 374<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 374<br/>
gtgactggag ttcagacgtg tgctcttccg atctgcaatt ttgcagacca ccatc   55</li>
<li>&lt;210&gt; 375<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 375<br/>
gtgactggag ttcagacgtg tgctcttccg atctggcagc ttgcaacctt cttg   54</li>
<li>&lt;210&gt; 376<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 376<br/>
gtgactggag ttcagacgtg tgctcttccg atcttcatga gagtttcccc aaca   54<!-- EPO <DP n="172"> --></li>
<li>&lt;210&gt; 377<br/>
&lt;211&gt; 58<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 377<br/>
gtgactggag ttcagacgtg tgctcttccg atctacttga gggggaaaaa gtttctta   58</li>
<li>&lt;210&gt; 378<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 378<br/>
gtgactggag ttcagacgtg tgctcttccg atcttggtcc ctgtctgtca ttgg   54</li>
<li>&lt;210&gt; 379<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 379<br/>
gtgactggag ttcagacgtg tgctcttccg atctaagcga gtgactgtct ggga   54</li>
<li>&lt;210&gt; 380<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 380<br/>
gtgactggag ttcagacgtg tgctcttccg atctcatggg tgggacacgt agtt   54</li>
<li>&lt;210&gt; 381<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 381<br/>
gtgactggag ttcagacgtg tgctcttccg atctggcttt cctggacacc ctatc   55</li>
<li>&lt;210&gt; 382<br/>
<!-- EPO <DP n="173"> -->&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 382<br/>
gtgactggag ttcagacgtg tgctcttccg atctagagcg agggagcgat gta   53</li>
<li>&lt;210&gt; 383<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 383<br/>
gtgactggag ttcagacgtg tgctcttccg atctttgtgg accactgctt agtgc   55</li>
<li>&lt;210&gt; 384<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 384<br/>
gtgactggag ttcagacgtg tgctcttccg atctcaacta ccctgaggcc acc   53</li>
<li>&lt;210&gt; 385<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 385<br/>
gtgactggag ttcagacgtg tgctcttccg atctggtcag cactcctcag cttt   54</li>
<li>&lt;210&gt; 386<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 386<br/>
gtgactggag ttcagacgtg tgctcttccg atcttggagg atgcatgcca catt   54</li>
<li>&lt;210&gt; 387<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence<!-- EPO <DP n="174"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 387<br/>
gtgactggag ttcagacgtg tgctcttccg atctcccagc ctctttgacc cttc   54</li>
<li>&lt;210&gt; 388<br/>
&lt;211&gt; 53<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 388<br/>
gtgactggag ttcagacgtg tgctcttccg atctcccaca ccaggctgta agg   53</li>
<li>&lt;210&gt; 389<br/>
&lt;211&gt; 58<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 389<br/>
gtgactggag ttcagacgtg tgctcttccg atcttagata tatgggtgtg tctgtacg   58</li>
<li>&lt;210&gt; 390<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 390<br/>
gtgactggag ttcagacgtg tgctcttccg atctttccaa agtggctgaa ccat   54</li>
<li>&lt;210&gt; 391<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 391<br/>
gtgactggag ttcagacgtg tgctcttccg atctcccaca gggctgatgt ttca   54</li>
<li>&lt;210&gt; 392<br/>
&lt;211&gt; 57<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide<!-- EPO <DP n="175"> --></li>
<li>&lt;400&gt; 392<br/>
gtgactggag ttcagacgtg tgctcttccg atctttgtaa tgcaacctct gtcatgc   57</li>
<li>&lt;210&gt; 393<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 393<br/>
gtgactggag ttcagacgtg tgctcttccg atctccagct ccagcaatcc atga   54</li>
<li>&lt;210&gt; 394<br/>
&lt;211&gt; 55<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 394<br/>
gtgactggag ttcagacgtg tgctcttccg atcttttggg aaagatagcc ctgga   55</li>
<li>&lt;210&gt; 395<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 395<br/>
gtgactggag ttcagacgtg tgctcttccg atctcaatga aacagcgggg aggt   54</li>
<li>&lt;210&gt; 396<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 396<br/>
gtgactggag ttcagacgtg tgctcttccg atctacaatc acgtgtcctt cact   54</li>
<li>&lt;210&gt; 397<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 397<br/>
gtgactggag ttcagacgtg tgctcttccg atctcagatc cctcctgggc aatg   54<!-- EPO <DP n="176"> --></li>
<li>&lt;210&gt; 398<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 398<br/>
gtgactggag ttcagacgtg tgctcttccg atctgtcagg aggcaaggag gaac   54</li>
<li>&lt;210&gt; 399<br/>
&lt;211&gt; 58<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 399<br/>
gtgactggag ttcagacgtg tgctcttccg atctacttcc ttccttttga gaccaagt   58</li>
<li>&lt;210&gt; 400<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 400<br/>
gtgactggag ttcagacgtg tgctcttccg atctgcggca gattcctggt gatt   54</li>
<li>&lt;210&gt; 401<br/>
&lt;211&gt; 54<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 401<br/>
gtgactggag ttcagacgtg tgctcttccg atctggtcac catcagcaca gtca   54</li>
<li>&lt;210&gt; 402<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 402<br/>
caagcagaag acggcatacg agatatatca gtgtgactgg agttcagacg tgtgct   56</li>
<li>&lt;210&gt; 403<br/>
<!-- EPO <DP n="177"> -->&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; <b>Artificial</b> Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 403<br/>
caagcagaag acggcatacg agattttcac cggtgactgg agttcagacg tgtgct   56</li>
<li>&lt;210&gt; 404<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; <b>Artificial</b> Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 404<br/>
caagcagaag acggcatacg agatccactc atgtgactgg agttcagacg tgtgct   56</li>
<li>&lt;210&gt; 405<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; <b>Artificial</b> Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 405<br/>
caagcagaag acggcatacg agattacgta cggtgactgg agttcagacg tgtgct 56</li>
<li>&lt;210&gt; 406<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; <b>Artificial</b> Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 406<br/>
caagcagaag acggcatacg agatcgaaac tcgtgactgg agttcagacg tgtgct   56</li>
<li>&lt;210&gt; 407<br/>
&lt;211&gt; 56<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 407<br/>
caagcagaag acggcatacg agatatcagt atgtgactgg agttcagacg tgtgct   56</li>
<li>&lt;210&gt; 408<br/>
&lt;211&gt; 57<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; <b>Artificial</b> Sequence<!-- EPO <DP n="178"> --></li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 408<br/>
aatgatacgg cgaccaccga gatctacaca ttactcgaca ctctttccct acacgac   57</li>
<li>&lt;210&gt; 409<br/>
&lt;211&gt; 57<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 409<br/>
aatgatacgg cgaccaccga gatctacact ccggagaaca ctctttccct acacgac   57</li>
<li>&lt;210&gt; 410<br/>
&lt;211&gt; 57<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; Synthetic Oligonucleotide</li>
<li>&lt;400&gt; 410<br/>
aatgatacgg cgaccaccga gatctacacc gctcattaca ctctttccct acacgac      57</li>
</ul></p>
</description>
<claims id="claims01" lang="en"><!-- EPO <DP n="179"> -->
<claim id="c-en-01-0001" num="0001">
<claim-text>A method for identifying a target site of a nuclease, the method comprising:
<claim-text>(a) providing a nuclease that cuts a double-stranded nucleic acid target site, wherein cutting of the target site results in cut nucleic acid strands comprising a 5' phosphate moiety;</claim-text>
<claim-text>(b) contacting the nuclease of step (a) with a library of candidate nucleic acid molecules, wherein each nucleic acid molecule comprises a concatemer of a sequence comprising a candidate nuclease target site and a constant insert sequence of at least 10 and not more than 80 nucleotides, under conditions suitable for the nuclease to cut a candidate nucleic acid molecule comprising a target site of the nuclease; and</claim-text>
<claim-text>(c) identifying nuclease target sites cut by the nuclease in step (b) by determining the sequence of an uncut nuclease target site on the nucleic acid strand that was cut by the nuclease in step (b), wherein the determining of step (c) comprises (i) ligating a first nucleic acid adapter to the 5' end of a nucleic acid strand that was cut by the nuclease in step (b) via 5'-phosphate-dependent ligation, and (ii) amplifying a fragment of the concatemer cut by the nuclease that comprises an uncut target site via a PCR reaction using a PCR primer that hybridizes with the adapter and a PCR primer that hybridizes with the constant insert sequence.</claim-text></claim-text></claim>
<claim id="c-en-01-0002" num="0002">
<claim-text>The method of claim 1, wherein the nucleic acid adapter is provided in double-stranded form.</claim-text></claim>
<claim id="c-en-01-0003" num="0003">
<claim-text>The method of claim 1 or claim 2, wherein the 5'-phosphate-dependent ligation is a blunt end ligation.</claim-text></claim>
<claim id="c-en-01-0004" num="0004">
<claim-text>The method of any one of claims 1-3, wherein the method comprises filling in the 5'-overhang before ligating the first nucleic acid adapter to the nucleic acid strand that was cut by the nuclease.</claim-text></claim>
<claim id="c-en-01-0005" num="0005">
<claim-text>The method of any one of claims 1-4, wherein the determining of step (c) further comprises sequencing the fragment obtained by the PCR reaction of step c(ii); and/or
<claim-text>wherein the library of candidate nucleic acid molecules comprises at least 10<sup>8</sup>, at least 10<sup>9</sup>, at least 10<sup>10</sup>, at least 10<sup>11</sup>, or at least 10<sup>12</sup> different candidate nuclease cleavage sites; and/or</claim-text>
<claim-text>wherein the nuclease is a therapeutic nuclease which cuts a specific nuclease target site in<!-- EPO <DP n="180"> --> a gene associated with a disease, optionally wherein the method further comprises determining a maximum concentration of the therapeutic nuclease at which the nuclease cuts the specific nuclease target site, and does not cut more than 10, more than 5, more than 4, more than 3, more than 2, more than 1, or no additional nuclease target sites.</claim-text></claim-text></claim>
<claim id="c-en-01-0006" num="0006">
<claim-text>The method of any one of claims 1-5, wherein the nuclease is an RNA-programmable nuclease that forms a complex with an RNA molecule, and wherein the nuclease:RNA complex specifically binds a nucleic acid sequence complementary to the sequence of the RNA molecule, optionally wherein the RNA molecule is a single-guide RNA (sgRNA), and optionally wherein the nuclease is a Cas9 nuclease.</claim-text></claim>
<claim id="c-en-01-0007" num="0007">
<claim-text>The method of any preceding claim, wherein the nuclease is a Cas9 nuclease in complex with a sgRNA.</claim-text></claim>
<claim id="c-en-01-0008" num="0008">
<claim-text>The method of any preceding claim, wherein the target site comprises a [sgRNA-complementary sequence]-[protospacer adjacent motif (PAM)] structure, and the nuclease cuts the target site within the sgRNA-complementary sequence.</claim-text></claim>
<claim id="c-en-01-0009" num="0009">
<claim-text>The method of any preceding claim, wherein the constant insert sequence comprises not more than 70, not more than 60, or not more than 55 nucleotides.</claim-text></claim>
<claim id="c-en-01-0010" num="0010">
<claim-text>A method of selecting a nuclease that specifically cuts a consensus target site from a plurality of nucleases, the method comprising:
<claim-text>(a) providing a plurality of candidate nucleases that cut the same consensus sequence;</claim-text>
<claim-text>(b) for each of the candidate nucleases of step (a), identifying a nuclease target site cleaved by the candidate nuclease that differs from the consensus target site using the method of any one of claims 1-9; and</claim-text>
<claim-text>(c) selecting a nuclease based on the nuclease target site(s) identified in step (b) which cleaves the consensus target site with the highest specificity.</claim-text></claim-text></claim>
<claim id="c-en-01-0011" num="0011">
<claim-text>The method of claim 10, wherein the nuclease target site comprises a [sgRNA-complementary sequence]-[protospacer adjacent motif (PAM)] structure, and the nuclease cuts the target site within the sgRNA-complementary sequence, optionally wherein the sgRNA-complementary<!-- EPO <DP n="181"> --> sequence comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides.</claim-text></claim>
<claim id="c-en-01-0012" num="0012">
<claim-text>The method of claim 10 or claim 11, wherein the nuclease that cleaves the consensus target site with the highest specificity is one in which
<claim-text>(i) the nuclease cleaves the lowest number of target sites that differ from the consensus site, or</claim-text>
<claim-text>(ii) the nuclease cleaves the lowest number of target sites that are different from the consensus site in the context of a target genome.</claim-text></claim-text></claim>
<claim id="c-en-01-0013" num="0013">
<claim-text>The method of any one of claims 10-12, wherein the nuclease that cleaves the consensus target site with the highest specificity is one which:
<claim-text>(i) does not cleave any target site other than the consensus target site, or</claim-text>
<claim-text>(ii) does not cleave any target site other than the consensus target site within the genome of a subject at a therapeutically effective concentration of the nuclease.</claim-text></claim-text></claim>
<claim id="c-en-01-0014" num="0014">
<claim-text>The method of any one of claims 10-13, wherein the nuclease selected in step (c) cleaves a genome <i>in vitro,</i> optionally wherein the genome is a vertebrate, mammalian, human, non-human primate, rodent, mouse, rat, hamster, goat, sheep, cattle, dog, cat, reptile, amphibian, fish, nematode, insect, or fly genome, and/or wherein the genome is optionally within an in vitro living cell.</claim-text></claim>
<claim id="c-en-01-0015" num="0015">
<claim-text>The method of any one of claims 10-14, wherein the consensus target site is within an allele that is associated with a disease or disorder.</claim-text></claim>
<claim id="c-en-01-0016" num="0016">
<claim-text>The method of claim 15, wherein the disease is HIV/AIDS, and the allele is optionally a CCR5 allele; or wherein the disease is a proliferative disease, and the allele is optionally a VEGFA allele.</claim-text></claim>
</claims>
<claims id="claims02" lang="de"><!-- EPO <DP n="182"> -->
<claim id="c-de-01-0001" num="0001">
<claim-text>Verfahren zur Identifizierung einer Zielstelle einer Nuklease, wobei das Verfahren Folgendes umfasst:
<claim-text>(a) Bereitstellen einer Nuklease, die eine Doppelstrang-Nukleinsäure-Zielstelle schneidet, wobei Schneiden der Zielstelle geschnittene Nukleinsäurestränge ergibt, die eine 5'-Phosphatgruppierung umfassen;</claim-text>
<claim-text>(b) In-Kontakt-Bringen der Nuklease aus Schritt (a) mit einer Bibliothek von Kandidaten-Nukleinsäuremolekülen, wobei jedes Nukleinsäuremolekül ein Concatemer einer Sequenz umfasst, die eine Kandidaten-Nuklease-Zielstelle und eine konstante Insertionssequenz von wenigstens 10 und nicht mehr als 80 Nukleotiden umfasst, unter geeigneten Bedingungen, so dass die Nuklease ein Kandidaten-Nukleinsäuremolekül, das eine Zielstelle der Nuklease umfasst, schneidet; und</claim-text>
<claim-text>(c) Identifizieren von in Schritt (b) von der Nuklease geschnittenen Nuklease-Zielstellen durch Bestimmen der Sequenz einer ungeschnittenen Nuklease-Zielstelle auf dem Nukleinsäurestrang, der von der Nuklease in Schritt (b) geschnitten wurde, wobei das Bestimmen unter Schritt (c) (i) Ligieren eines ersten Nukleinsäureadapters an das 5'-Ende eines Nukleinsäurestrangs, der von der Nuklease in Schritt (b) geschnitten wurde, über 5'-phosphatabhängige<!-- EPO <DP n="183"> --> Ligation und (ii) Amplifizieren eines Fragments des von der Nuklease geschnittenen Concatemers, das eine ungeschnittene Zielstelle umfasst, über eine PCR-Reaktion unter Verwendung eines PCR-Primers, der mit dem Adapter hybridisiert, und eines PCR-Primers, der mit der konstanten Insertionssequenz hybridisiert, umfasst.</claim-text></claim-text></claim>
<claim id="c-de-01-0002" num="0002">
<claim-text>Verfahren nach Anspruch 1, wobei der Nukleinsäureadapter in Doppelstrangform bereitgestellt wird.</claim-text></claim>
<claim id="c-de-01-0003" num="0003">
<claim-text>Verfahren nach Anspruch 1 oder Anspruch 2, wobei es sich bei der 5'-phosphat-abhängigen Ligation um eine Stumpfe-Enden-Ligation handelt.</claim-text></claim>
<claim id="c-de-01-0004" num="0004">
<claim-text>Verfahren nach einem der Ansprüche 1-3, wobei das Verfahren Auffüllen des 5'-Überhangs vor Ligieren des ersten Nukleinsäureadapters an den Nukleinsäurestrang, der von der Nuklease geschnitten wurde, umfasst.</claim-text></claim>
<claim id="c-de-01-0005" num="0005">
<claim-text>Verfahren nach einem der Ansprüche 1-4, wobei das Bestimmen unter Schritt (c) ferner Sequenzieren des über die PCR-Reaktion unter Schritt c(ii) erhaltenen Fragments umfasst; und/oder
<claim-text>wobei die Bibliothek von Kandidaten-Nukleinsäuremolekülen wenigstens 10<sup>8</sup>, wenigstens 10<sup>9</sup>, wenigstens 10<sup>10</sup>, wenigstens 10<sup>11</sup> oder wenigstens 10<sup>12</sup> unterschiedliche Kandidaten-Nuklease-Spaltstellen umfasst; und/oder</claim-text>
<claim-text>wobei es sich bei der Nuklease um eine therapeutische Nuklease handelt, die eine spezifische Nuklease-Zielstelle in einem mit einer Krankheit assoziierten Gen schneidet, gegebenenfalls wobei das Verfahren ferner Bestimmen einer Maximalkonzentration der therapeutischen Nuklease umfasst, bei der die Nuklease die spezifische Nuklease-Zielstelle schneidet und nicht mehr als 10, mehr als 5,<!-- EPO <DP n="184"> --> mehr als 4, mehr als 3, mehr als 2, mehr als 1 oder keine zusätzlichen Nuklease-Zielstellen schneidet.</claim-text></claim-text></claim>
<claim id="c-de-01-0006" num="0006">
<claim-text>Verfahren nach einem der Ansprüche 1-5, wobei es sich bei der Nuklease um eine RNA-programmierbare Nuklease handelt, die einen Komplex mit einem RNA-Molekül bildet, und wobei der Nuklease:RNA-Komplex eine Nukleinsäuresequenz, die komplementär zur Sequenz des RNA-Moleküls ist, spezifisch bindet, gegebenenfalls wobei es sich bei dem RNA-Molekül um eine Single-guide-RNA (sgRNA) handelt und gegebenenfalls wobei es sich bei der Nuklease um eine Cas9-Nuklease handelt.</claim-text></claim>
<claim id="c-de-01-0007" num="0007">
<claim-text>Verfahren nach einem vorhergehenden Anspruch, wobei es sich bei der Nuklease um eine Cas9-Nuklease im Komplex mit einer sgRNA handelt.</claim-text></claim>
<claim id="c-de-01-0008" num="0008">
<claim-text>Verfahren nach einem vorhergehenden Anspruch, wobei die Zielstelle eine [sgRNA-Komplementärsequenz]-[PAM(Protospacer Adjacent Motif)]-Struktur umfasst und die Nuklease die Zielstelle innerhalb der sgRNA-Komplementärsequenz schneidet.</claim-text></claim>
<claim id="c-de-01-0009" num="0009">
<claim-text>Verfahren nach einem vorhergehenden Anspruch, wobei die konstante Insertionssequenz nicht mehr als 70, nicht mehr als 60 oder nicht mehr als 55 Nukleotide umfasst.</claim-text></claim>
<claim id="c-de-01-0010" num="0010">
<claim-text>Verfahren zum Auswählen einer Nuklease, die eine Konsensus-Zielstelle spezifisch schneidet, aus mehreren Nukleasen, wobei das Verfahren Folgendes umfasst:
<claim-text>(a) Bereitstellen mehrerer Kandidaten-Nukleasen, die die gleiche Konsensussequenz schneiden;</claim-text>
<claim-text>(b) für jede der Kandidaten-Nukleasen aus Schritt (a) Identifizieren einer von der Kandidaten-Nuklease gespaltenen Nuklease-Zielstelle, die von<!-- EPO <DP n="185"> --> der Konsensus-Zielstelle verschieden ist, unter Verwendung des Verfahrens nach einem der Ansprüche 1-9; und</claim-text>
<claim-text>(c) Auswählen einer Nuklease anhand der in Schritt (b) identifizierten Nuklease-Zielstelle(n), die die Konsensus-Zielstelle mit der höchsten Spezifität spaltet.</claim-text></claim-text></claim>
<claim id="c-de-01-0011" num="0011">
<claim-text>Verfahren nach Anspruch 10, wobei die Nuklease-Zielstelle eine [sgRNA-Komplementärsequenz]-[PAM(Protospacer Adjacent Motif)]-Struktur umfasst und die Nuklease die Zielstelle innerhalb der sgRNA-Komplementärsequenz schneidet, gegebenenfalls wobei die sgRNA-Komplementärsequenz 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 oder 30 Nukleotide umfasst.</claim-text></claim>
<claim id="c-de-01-0012" num="0012">
<claim-text>Verfahren nach Anspruch 10 oder Anspruch 11, wobei es sich bei der Nuklease, die die Konsensus-Zielstelle mit der höchsten Spezifität spaltet, um eine handelt, bei der
<claim-text>(i) die Nuklease die geringste Anzahl von Zielstellen, die von der Konsensusstelle verschieden sind, spaltet oder</claim-text>
<claim-text>(ii) die Nuklease die geringste Anzahl von Zielstellen, die sich von der Konsensusstelle im Kontext eines Zielgenoms unterscheiden, spaltet.</claim-text></claim-text></claim>
<claim id="c-de-01-0013" num="0013">
<claim-text>Verfahren nach einem der Ansprüche 10-12, wobei es sich bei der Nuklease, die die Konsensus-Zielstelle mit der höchsten Spezifität spaltet, um eine handelt, die:
<claim-text>(i) keine andere Zielstelle als die Konsensus-Zielstelle spaltet oder</claim-text>
<claim-text>(ii) keine andere Zielstelle als die Konsensus-Zielstelle innerhalb des Genoms eines Individuums bei einer therapeutisch wirksamen Konzentration der Nuklease spaltet.</claim-text><!-- EPO <DP n="186"> --></claim-text></claim>
<claim id="c-de-01-0014" num="0014">
<claim-text>Verfahren nach einem der Ansprüche 10-13, wobei die in Schritt (c) ausgewählte Nuklease ein Genom <i>in vitro</i> spaltet, gegebenenfalls wobei es sich bei dem Genom um das Genom eines Wirbeltiers, Säugers, Menschen, nichtmenschlichen Primaten, Nagers, einer Maus, Ratte, eines Hamsters, einer Ziege, eines Schafs, Rinds, Hunds, einer Katze, eines Reptils, Amphibiums, Fischs, Nematoden, Insekts oder einer Fliege handelt und/oder wobei sich das Genom gegebenenfalls in einer In-vitro-Lebendzelle befindet.</claim-text></claim>
<claim id="c-de-01-0015" num="0015">
<claim-text>Verfahren nach einem der Ansprüche 10-14, wobei sich die Konsensus-Zielstelle in einem Allel befindet, das mit einer Krankheit oder Störung assoziiert ist.</claim-text></claim>
<claim id="c-de-01-0016" num="0016">
<claim-text>Verfahren nach Anspruch 15, wobei es sich bei der Krankheit um HIV/AIDS und bei dem Allel gegebenenfalls um ein CCR5-Allel handelt; oder wobei es sich bei der Krankheit um eine Proliferationskrankheit und bei dem Allel gegebenenfalls um ein VEGFA-Allel handelt.</claim-text></claim>
</claims>
<claims id="claims03" lang="fr"><!-- EPO <DP n="187"> -->
<claim id="c-fr-01-0001" num="0001">
<claim-text>Procédé d'identification d'un site cible d'une nucléase, le procédé comprenant :
<claim-text>(a) la fourniture d'une nucléase qui coupe un site cible d'acide nucléique double brin, dans lequel une coupure du site cible conduit à des brins d'acide nucléique coupés comprenant une fraction de phosphate en 5' ;</claim-text>
<claim-text>(b) la mise en contact de la nucléase de l'étape (a) avec une banque de molécules d'acide nucléique candidates, dans lequel chaque molécule d'acide nucléique comprend un concatémère d'une séquence comprenant un site cible de nucléase candidat et une séquence d'insert constante d'au moins 10 et pas plus de 80 nucléotides, dans des conditions adaptées pour la nucléase pour couper une molécule d'acide nucléique candidate comprenant un site cible de la nucléase ; et</claim-text>
<claim-text>(c) l'identification de sites cibles de nucléase coupés par la nucléase dans l'étape (b) par détermination de la séquence d'un site cible de nucléase non coupé sur le brin d'acide nucléique qui a été coupé par la nucléase dans l'étape (b), dans lequel la détermination de l'étape (c) comprend (i) la ligature d'un premier adaptateur d'acide nucléique à l'extrémité 5' d'un brin d'acide nucléique qui a été coupé par la nucléase dans l'étape (b) par ligature dépendante du 5'-phosphate, et (ii) l'amplification d'un fragment du concatémère coupé par la nucléase qui comprend un site cible non coupé par l'intermédiaire d'une réaction PCR en utilisant une amorce de PCR qui s'hybride avec l'adaptateur et une<!-- EPO <DP n="188"> --> amorce de PCR qui s'hybride avec la séquence d'insert constante.</claim-text></claim-text></claim>
<claim id="c-fr-01-0002" num="0002">
<claim-text>Procédé selon la revendication 1, dans lequel l'adaptateur d'acide nucléique est fourni sous forme de double brin.</claim-text></claim>
<claim id="c-fr-01-0003" num="0003">
<claim-text>Procédé selon la revendication 1 ou la revendication 2, dans lequel la ligature dépendante du 5'-phosphate est une ligature à extrémités franches.</claim-text></claim>
<claim id="c-fr-01-0004" num="0004">
<claim-text>Procédé selon l'une quelconque des revendications 1 à 3, où le procédé comprend le remplissage de l'extrémité saillante en 5' avant la ligature du premier adaptateur d'acide nucléique au brin d'acide nucléique qui a été coupé par la nucléase.</claim-text></claim>
<claim id="c-fr-01-0005" num="0005">
<claim-text>Procédé selon l'une quelconque des revendications 1 à 4, dans lequel la détermination de l'étape (c) comprend en outre le séquençage du fragment obtenu par la réaction PCR de l'étape c(ii) ; et/ou
<claim-text>dans lequel la banque de molécules d'acide nucléique candidates comprend au moins 10<sup>8</sup>, au moins 10<sup>9</sup>, au moins 10<sup>10</sup>, au moins 10<sup>11</sup>, ou au moins 10<sup>12</sup> sites de clivage de nucléase candidats différents ; et/ou</claim-text>
<claim-text>dans lequel la nucléase est une nucléase thérapeutique qui coupe un site cible de nucléase spécifique dans un gène associé à une maladie, facultativement où le procédé comprend en outre la détermination d'une concentration maximale de la nucléase thérapeutique à laquelle la nucléase coupe le site cible de nucléase spécifique, et ne coupe pas plus de 10, plus de 5, plus de 4, plus de 3, plus de 2, plus de 1, ou aucun, sites cibles de nucléase supplémentaires.</claim-text></claim-text></claim>
<claim id="c-fr-01-0006" num="0006">
<claim-text>Procédé selon l'une quelconque des revendications 1 à 5, dans lequel la nucléase est une nucléase programmable par ARN qui forme un complexe avec une molécule d'ARN, et dans lequel le complexe nucléase:ARN<!-- EPO <DP n="189"> --> se lie spécifiquement à une séquence d'acide nucléique complémentaire de la séquence de la molécule d'ARN, facultativement dans lequel la molécule d'ARN est un ARN guide unique (ARNsg), et facultativement dans lequel la nucléase est une nucléase Cas9.</claim-text></claim>
<claim id="c-fr-01-0007" num="0007">
<claim-text>Procédé selon l'une quelconque des revendications précédentes, dans lequel la nucléase est une nucléase Cas9 complexée à un ARNsg.</claim-text></claim>
<claim id="c-fr-01-0008" num="0008">
<claim-text>Procédé selon l'une quelconque des revendications précédentes, dans lequel le site cible comprend une structure [séquence complémentaire d'ARNsg]-[motif adjacent de protoespaceur (PAM)], et la nucléase coupe le site cible dans la séquence complémentaire d'ARNsg.</claim-text></claim>
<claim id="c-fr-01-0009" num="0009">
<claim-text>Procédé selon l'une quelconque des revendications précédentes, dans lequel la séquence d'insert constante ne comprend pas plus de 70, pas plus de 60, ou pas plus de 55 nucléotides.</claim-text></claim>
<claim id="c-fr-01-0010" num="0010">
<claim-text>Procédé de sélection d'une nucléase qui coupe spécifiquement un site cible consensus parmi une pluralité de nucléases, le procédé comprenant :
<claim-text>(a) la fourniture d'une pluralité de nucléases candidates qui coupent la même séquence consensus ;</claim-text>
<claim-text>(b) pour chacune des nucléases candidates de l'étape (a), l'identification d'un site cible de nucléase clivé par la nucléase candidate qui diffère du site cible consensus au moyen du procédé selon l'une quelconque des revendications 1 à 9 ; et</claim-text>
<claim-text>(c) la sélection d'une nucléase sur la base du ou des sites cibles de nucléase identifiés dans l'étape (b) qui clive le site cible consensus avec la plus haute spécificité.</claim-text></claim-text></claim>
<claim id="c-fr-01-0011" num="0011">
<claim-text>Procédé selon la revendication 10, dans lequel le site cible de nucléase comprend une structure [séquence complémentaire d'ARNsg]-[motif adjacent de protoespaceur<!-- EPO <DP n="190"> --> (PAM)], et la nucléase coupe le site cible dans la séquence complémentaire d'ARNsg, facultativement dans lequel la séquence complémentaire d'ARNsg comprend 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, ou 30 nucléotides.</claim-text></claim>
<claim id="c-fr-01-0012" num="0012">
<claim-text>Procédé selon la revendication 10 ou la revendication 11, dans lequel la nucléase qui clive le site cible consensus avec la plus haute spécificité est une nucléase <b>caractérisée en ce que</b>
<claim-text>(i) la nucléase clive le plus petit nombre de sites cibles qui diffèrent du site consensus, ou</claim-text>
<claim-text>(ii) la nucléase clive le plus petit nombre de sites cibles qui sont différents du site consensus dans le contexte d'un génome cible.</claim-text></claim-text></claim>
<claim id="c-fr-01-0013" num="0013">
<claim-text>Procédé selon l'une quelconque des revendications 10 à 12, dans lequel la nucléase qui clive le site cible consensus avec la plus haute spécificité est une nucléase qui :
<claim-text>(i) ne clive aucun site cible autre que le site cible consensus, ou</claim-text>
<claim-text>(ii) ne clive aucun site cible autre que le site cible consensus dans le génome d'un sujet à une concentration thérapeutiquement efficace de la nucléase.</claim-text></claim-text></claim>
<claim id="c-fr-01-0014" num="0014">
<claim-text>Procédé selon l'une quelconque des revendications 10 à 13, dans lequel la nucléase sélectionnée dans l'étape (c) clive un génome <i>in vitro,</i> facultativement dans lequel le génome est un génome de vertébré, mammifère, humain, primate non humain, rongeur, souris, rat, hamster, chèvre, mouton, bovin, chien, chat, reptile, amphibien, poisson, nématode, insecte ou mouche, et/ou dans lequel le génome est facultativement dans une cellule vivante <i>in vitro.</i></claim-text></claim>
<claim id="c-fr-01-0015" num="0015">
<claim-text>Procédé selon l'une quelconque des revendications 10 à 14, dans lequel le site cible<!-- EPO <DP n="191"> --> consensus est dans un allèle qui est associé à une maladie ou un trouble.</claim-text></claim>
<claim id="c-fr-01-0016" num="0016">
<claim-text>Procédé selon la revendication 15, dans lequel la maladie est le VIH/SIDA, et l'allèle est facultativement un allèle de CCR5 ; ou dans lequel la maladie est une maladie proliférative, et l'allèle est facultativement un allèle de VEGFA.</claim-text></claim>
</claims>
<drawings id="draw" lang="en"><!-- EPO <DP n="192"> -->
<figure id="f0001" num="1A"><img id="if0001" file="imgf0001.tif" wi="99" he="75" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="193"> -->
<figure id="f0002" num="1B"><img id="if0002" file="imgf0002.tif" wi="115" he="199" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="194"> -->
<figure id="f0003" num="2A,2B"><img id="if0003" file="imgf0003.tif" wi="134" he="177" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="195"> -->
<figure id="f0004" num="2C,2D,2E,2F"><img id="if0004" file="imgf0004.tif" wi="136" he="185" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="196"> -->
<figure id="f0005" num="2G,2H"><img id="if0005" file="imgf0005.tif" wi="125" he="177" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="197"> -->
<figure id="f0006" num="3A,3B"><img id="if0006" file="imgf0006.tif" wi="150" he="175" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="198"> -->
<figure id="f0007" num="3C"><img id="if0007" file="imgf0007.tif" wi="151" he="192" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="199"> -->
<figure id="f0008" num="3D"><img id="if0008" file="imgf0008.tif" wi="152" he="188" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="200"> -->
<figure id="f0009" num="4"><img id="if0009" file="imgf0009.tif" wi="151" he="125" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="201"> -->
<figure id="f0010" num="5A,5B"><img id="if0010" file="imgf0010.tif" wi="134" he="193" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="202"> -->
<figure id="f0011" num="5C,5D"><img id="if0011" file="imgf0011.tif" wi="92" he="195" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="203"> -->
<figure id="f0012" num="5E"><img id="if0012" file="imgf0012.tif" wi="92" he="111" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="204"> -->
<figure id="f0013" num="6A,6B"><img id="if0013" file="imgf0013.tif" wi="143" he="183" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="205"> -->
<figure id="f0014" num="6C,6D,6E,6F"><img id="if0014" file="imgf0014.tif" wi="144" he="200" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="206"> -->
<figure id="f0015" num="7A,7B"><img id="if0015" file="imgf0015.tif" wi="150" he="196" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="207"> -->
<figure id="f0016" num="7C,7D,7E,7F"><img id="if0016" file="imgf0016.tif" wi="150" he="205" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="208"> -->
<figure id="f0017" num="8A,8B"><img id="if0017" file="imgf0017.tif" wi="150" he="189" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="209"> -->
<figure id="f0018" num="8C,8D,8E,8F"><img id="if0018" file="imgf0018.tif" wi="150" he="194" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="210"> -->
<figure id="f0019" num="9"><img id="if0019" file="imgf0019.tif" wi="152" he="168" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="211"> -->
<figure id="f0020" num="10A,10B,10C,10D,10E,10F"><img id="if0020" file="imgf0020.tif" wi="152" he="192" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="212"> -->
<figure id="f0021" num="10G,10H,10I,10J,10K,10L"><img id="if0021" file="imgf0021.tif" wi="151" he="189" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="213"> -->
<figure id="f0022" num="11A,11B,11C,11D,11E,11F"><img id="if0022" file="imgf0022.tif" wi="153" he="208" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="214"> -->
<figure id="f0023" num="11G,11H,11I,11J,11K,11L"><img id="if0023" file="imgf0023.tif" wi="152" he="190" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="215"> -->
<figure id="f0024" num="12A,12B,12C,12D,12E,12F"><img id="if0024" file="imgf0024.tif" wi="152" he="207" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="216"> -->
<figure id="f0025" num="12G,12H,12I,12J,12K,12L"><img id="if0025" file="imgf0025.tif" wi="151" he="202" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="217"> -->
<figure id="f0026" num="13A,13B,13C,13D,13E,13F"><img id="if0026" file="imgf0026.tif" wi="152" he="193" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="218"> -->
<figure id="f0027" num="13G,13H,13I,13J,13K,13L"><img id="if0027" file="imgf0027.tif" wi="152" he="194" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="219"> -->
<figure id="f0028" num="14A,14B,14C,14D,14E,14F"><img id="if0028" file="imgf0028.tif" wi="151" he="194" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="220"> -->
<figure id="f0029" num="14G,14H,14I,14J,14K,14L"><img id="if0029" file="imgf0029.tif" wi="151" he="196" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="221"> -->
<figure id="f0030" num="15A,15B,15C,15D,15E,15F"><img id="if0030" file="imgf0030.tif" wi="151" he="188" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="222"> -->
<figure id="f0031" num="15G,15H,15I,15J,15K,15L"><img id="if0031" file="imgf0031.tif" wi="151" he="196" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="223"> -->
<figure id="f0032" num="16A,16B,16C,16D,16E,16F"><img id="if0032" file="imgf0032.tif" wi="151" he="193" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="224"> -->
<figure id="f0033" num="16G,16H,16I,16J,16K,16L"><img id="if0033" file="imgf0033.tif" wi="152" he="193" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="225"> -->
<figure id="f0034" num="17A,17B,17C,17D,17E,17F"><img id="if0034" file="imgf0034.tif" wi="152" he="194" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="226"> -->
<figure id="f0035" num="17G,17H,17I,17J,17K,17L"><img id="if0035" file="imgf0035.tif" wi="151" he="196" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="227"> -->
<figure id="f0036" num="18A,18B"><img id="if0036" file="imgf0036.tif" wi="135" he="203" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="228"> -->
<figure id="f0037" num="18C,18D"><img id="if0037" file="imgf0037.tif" wi="134" he="204" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="229"> -->
<figure id="f0038" num="19A,19B"><img id="if0038" file="imgf0038.tif" wi="134" he="202" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="230"> -->
<figure id="f0039" num="19C,19D"><img id="if0039" file="imgf0039.tif" wi="135" he="203" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="231"> -->
<figure id="f0040" num="20A,20B"><img id="if0040" file="imgf0040.tif" wi="134" he="204" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="232"> -->
<figure id="f0041" num="20C,20D"><img id="if0041" file="imgf0041.tif" wi="134" he="203" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="233"> -->
<figure id="f0042" num="21A,21B"><img id="if0042" file="imgf0042.tif" wi="150" he="206" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="234"> -->
<figure id="f0043" num="21C,21D"><img id="if0043" file="imgf0043.tif" wi="152" he="206" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="235"> -->
<figure id="f0044" num="22A,22B"><img id="if0044" file="imgf0044.tif" wi="152" he="207" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="236"> -->
<figure id="f0045" num="22C,22D"><img id="if0045" file="imgf0045.tif" wi="151" he="206" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="237"> -->
<figure id="f0046" num="23A,23B"><img id="if0046" file="imgf0046.tif" wi="151" he="205" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="238"> -->
<figure id="f0047" num="23C,23D"><img id="if0047" file="imgf0047.tif" wi="151" he="207" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="239"> -->
<figure id="f0048" num="24A,24B"><img id="if0048" file="imgf0048.tif" wi="151" he="206" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="240"> -->
<figure id="f0049" num="24C,24D"><img id="if0049" file="imgf0049.tif" wi="149" he="205" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="241"> -->
<figure id="f0050" num="25A,25B"><img id="if0050" file="imgf0050.tif" wi="150" he="204" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="242"> -->
<figure id="f0051" num="25C,25D"><img id="if0051" file="imgf0051.tif" wi="151" he="206" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="243"> -->
<figure id="f0052" num="26A,26B"><img id="if0052" file="imgf0052.tif" wi="151" he="205" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="244"> -->
<figure id="f0053" num="26C,26D"><img id="if0053" file="imgf0053.tif" wi="150" he="203" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="245"> -->
<figure id="f0054" num="27"><img id="if0054" file="imgf0054.tif" wi="144" he="120" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="246"> -->
<figure id="f0055" num="28"><img id="if0055" file="imgf0055.tif" wi="107" he="140" img-content="drawing" img-format="tif"/></figure>
</drawings>
<ep-reference-list id="ref-list">
<heading id="ref-h0001"><b>REFERENCES CITED IN THE DESCRIPTION</b></heading>
<p id="ref-p0001" num=""><i>This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.</i></p>
<heading id="ref-h0002"><b>Patent documents cited in the description</b></heading>
<p id="ref-p0002" num="">
<ul id="ref-ul0001" list-style="bullet">
<li><patcit id="ref-pcit0001" dnum="WO2013066438A2"><document-id><country>WO</country><doc-number>2013066438</doc-number><kind>A2</kind></document-id></patcit><crossref idref="pcit0001">[0002]</crossref></li>
<li><patcit id="ref-pcit0002" dnum="WO2013066438A"><document-id><country>WO</country><doc-number>2013066438</doc-number><kind>A</kind></document-id></patcit><crossref idref="pcit0002">[0005]</crossref><crossref idref="pcit0003">[0048]</crossref></li>
<li><patcit id="ref-pcit0003" dnum="US2010055131W" dnum-type="L"><document-id><country>US</country><doc-number>2010055131</doc-number><kind>W</kind></document-id></patcit><crossref idref="pcit0004">[0088]</crossref></li>
<li><patcit id="ref-pcit0004" dnum="US61864289B"><document-id><country>US</country><doc-number>61864289</doc-number><kind>B</kind><date>20130809</date></document-id></patcit><crossref idref="pcit0005">[0137]</crossref></li>
<li><patcit id="ref-pcit0005" dnum="US14320370B"><document-id><country>US</country><doc-number>14320370</doc-number><kind>B</kind><date>20140630</date></document-id></patcit><crossref idref="pcit0006">[0137]</crossref></li>
<li><patcit id="ref-pcit0006" dnum="US14320413B"><document-id><country>US</country><doc-number>14320413</doc-number><kind>B</kind><date>20130630</date></document-id></patcit><crossref idref="pcit0007">[0137]</crossref></li>
</ul></p>
<heading id="ref-h0003"><b>Non-patent literature cited in the description</b></heading>
<p id="ref-p0003" num="">
<ul id="ref-ul0002" list-style="bullet">
<li><nplcit id="ref-ncit0001" npl-type="s"><article><author><name>PATTANAYAK, V.</name></author><author><name>RAMIREZ, C.L.</name></author><author><name>JOUNG, J.K.</name></author><author><name>LIU, D.R.</name></author><atl>Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection</atl><serial><sertitle>Nature methods</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate><vid>8</vid></serial><location><pp><ppf>765</ppf><ppl>770</ppl></pp></location></article></nplcit><crossref idref="ncit0001">[0005]</crossref><crossref idref="ncit0042">[0048]</crossref><crossref idref="ncit0064">[0136]</crossref><crossref idref="ncit0067">[0136]</crossref></li>
<li><nplcit id="ref-ncit0002" npl-type="s"><article><author><name>JINEK M.</name></author><author><name>CHYLINSKI K.</name></author><author><name>FONFARA I.</name></author><author><name>HAUER M.</name></author><author><name>DOUDNA J.A.</name></author><author><name>CHARPENTIER E.</name></author><atl/><serial><sertitle>Science</sertitle><pubdate><sdate>20120000</sdate><edate/></pubdate><vid>337</vid></serial><location><pp><ppf>816</ppf><ppl>821</ppl></pp></location></article></nplcit><crossref idref="ncit0002">[0019]</crossref></li>
<li><nplcit id="ref-ncit0003" npl-type="s"><article><author><name>FERRETTI J.J.</name></author><author><name>MCSHAN W.M.</name></author><author><name>AJDIC D.J.</name></author><author><name>SAVIC D.J.</name></author><author><name>SAVIC G.</name></author><author><name>LYON K.</name></author><author><name>PRIMEAUX C.</name></author><author><name>SEZATE S.</name></author><author><name>SUVOROV A.N.</name></author><author><name>KENTON S.</name></author><atl>Complete genome sequence of an M1 strain of Streptococcus pyogenes</atl><serial><sertitle>Proc. Natl. Acad. Sci. U.S.A.</sertitle><pubdate><sdate>20010000</sdate><edate/></pubdate><vid>98</vid></serial><location><pp><ppf>4658</ppf><ppl>4663</ppl></pp></location></article></nplcit><crossref idref="ncit0003">[0019]</crossref><crossref idref="ncit0014">[0034]</crossref></li>
<li><nplcit id="ref-ncit0004" npl-type="s"><article><author><name>DELTCHEVA E.</name></author><author><name>CHYLINSKI K.</name></author><author><name>SHARMA C.M.</name></author><author><name>GONZALES K.</name></author><author><name>CHAO Y.</name></author><author><name>PIRZADA Z.A.</name></author><author><name>ECKERT M.R.</name></author><author><name>VOGEL J.</name></author><author><name>CHARPENTIER E.</name></author><atl>CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III</atl><serial><sertitle>Nature</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate><vid>471</vid></serial><location><pp><ppf>602</ppf><ppl>607</ppl></pp></location></article></nplcit><crossref idref="ncit0004">[0019]</crossref><crossref idref="ncit0015">[0034]</crossref></li>
<li><nplcit id="ref-ncit0005" npl-type="s"><article><author><name>JINEK M.</name></author><author><name>CHYLINSKI K.</name></author><author><name>FONFARA I.</name></author><author><name>HAUER M.</name></author><author><name>DOUDNA J.A.</name></author><author><name>CHARPENTIER E.</name></author><atl>A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity</atl><serial><sertitle>Science</sertitle><pubdate><sdate>20120000</sdate><edate/></pubdate><vid>337</vid></serial><location><pp><ppf>816</ppf><ppl>821</ppl></pp></location></article></nplcit><crossref idref="ncit0005">[0019]</crossref><crossref idref="ncit0016">[0034]</crossref></li>
<li><nplcit id="ref-ncit0006" npl-type="s"><article><author><name>CHYLINSKI</name></author><author><name>RHUN</name></author><author><name>CHARPENTIER</name></author><atl>The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems</atl><serial><sertitle>RNA Biology</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate><vid>10</vid><ino>5</ino></serial><location><pp><ppf>726</ppf><ppl>737</ppl></pp></location></article></nplcit><crossref idref="ncit0006">[0019]</crossref></li>
<li><nplcit id="ref-ncit0007" npl-type="s"><article><author><name>K. C. NICOLAOU</name></author><author><name>A. L. SMITH</name></author><author><name>E. W. YUE</name></author><atl>Chemistry and biology of natural and designed enediynes</atl><serial><sertitle>PNAS</sertitle><pubdate><sdate>19930000</sdate><edate/></pubdate><vid>90</vid><ino>13</ino></serial><location><pp><ppf>5881</ppf><ppl>5888</ppl></pp></location></article></nplcit><crossref idref="ncit0007">[0024]</crossref></li>
<li><nplcit id="ref-ncit0008" npl-type="s"><article><author><name>S. WALKER</name></author><author><name>R. LANDOVITZ</name></author><author><name>W.D. DING</name></author><author><name>G.A. ELLESTAD</name></author><author><name>D. KAHNE</name></author><atl>Cleavage behavior of calicheamicin gamma 1 and calicheamicin T</atl><serial><sertitle>Proc Natl Acad Sci U.S.A.</sertitle><pubdate><sdate>19920000</sdate><edate/></pubdate><vid>89</vid><ino>10</ino></serial><location><pp><ppf>4608</ppf><ppl>12</ppl></pp></location></article></nplcit><crossref idref="ncit0008">[0024]</crossref></li>
<li><nplcit id="ref-ncit0009" npl-type="s"><article><author><name>ADRIAN L. SMITH</name></author><author><name>K. C. BICOLAOU</name></author><atl>The Enediyne Antibiotics</atl><serial><sertitle>J. Med. Chem.</sertitle><pubdate><sdate>19960000</sdate><edate/></pubdate><vid>39</vid><ino>11</ino></serial><location><pp><ppf>2103</ppf><ppl>2117</ppl></pp></location></article></nplcit><crossref idref="ncit0009">[0024]</crossref></li>
<li><nplcit id="ref-ncit0010" npl-type="b"><article><atl/><book><author><name>DONALD BORDERS</name></author><book-title>Enediyne antibiotics as antitumor agents</book-title><imprint><name>Informa Healthcare</name><pubdate>19941123</pubdate></imprint></book></article></nplcit><crossref idref="ncit0010">[0024]</crossref></li>
<li><nplcit id="ref-ncit0011" npl-type="s"><article><author><name>EDGELL DR</name></author><atl>Selfish DNA: homing endonucleases find a home</atl><serial><sertitle>Curr Biol</sertitle><pubdate><sdate>20090200</sdate><edate/></pubdate><vid>19</vid><ino>3</ino></serial><location><pp><ppf>R115</ppf><ppl>R117</ppl></pp></location></article></nplcit><crossref idref="ncit0011">[0025]</crossref></li>
<li><nplcit id="ref-ncit0012" npl-type="s"><article><author><name>JASIN M</name></author><atl>Genetic manipulation of genomes with rare-cutting endonucleases</atl><serial><sertitle>Trends Genet</sertitle><pubdate><sdate>19960600</sdate><edate/></pubdate><vid>12</vid><ino>6</ino></serial><location><pp><ppf>224</ppf><ppl>8</ppl></pp></location></article></nplcit><crossref idref="ncit0012">[0025]</crossref></li>
<li><nplcit id="ref-ncit0013" npl-type="s"><article><author><name>BURT A</name></author><author><name>KOUFOPANOU V</name></author><atl>Homing endonuclease genes: the rise and fall and rise again of a selfish element</atl><serial><sertitle>Curr Opin Genet Dev</sertitle><pubdate><sdate>20041200</sdate><edate/></pubdate><vid>14</vid><ino>6</ino></serial><location><pp><ppf>609</ppf><ppl>15</ppl></pp></location></article></nplcit><crossref idref="ncit0013">[0025]</crossref></li>
<li><nplcit id="ref-ncit0014" npl-type="s"><article><author><name>CONG, L. et al.</name></author><atl>Multiplex genome engineering using CRISPR/Cas systems</atl><serial><sertitle>Science</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate><vid>339</vid></serial><location><pp><ppf>819</ppf><ppl>823</ppl></pp></location></article></nplcit><crossref idref="ncit0017">[0035]</crossref><crossref idref="ncit0055">[0136]</crossref></li>
<li><nplcit id="ref-ncit0015" npl-type="s"><article><author><name>MALI, P. et al.</name></author><atl>RNA-guided human genome engineering via Cas9</atl><serial><sertitle>Science</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate><vid>339</vid></serial><location><pp><ppf>823</ppf><ppl>826</ppl></pp></location></article></nplcit><crossref idref="ncit0018">[0035]</crossref><crossref idref="ncit0056">[0136]</crossref></li>
<li><nplcit id="ref-ncit0016" npl-type="s"><article><author><name>HWANG, W.Y. et al.</name></author><atl>Efficient genome editing in zebrafish using a CRISPR-Cas system</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate><vid>31</vid></serial><location><pp><ppf>227</ppf><ppl>229</ppl></pp></location></article></nplcit><crossref idref="ncit0019">[0035]</crossref><crossref idref="ncit0057">[0136]</crossref></li>
<li><nplcit id="ref-ncit0017" npl-type="s"><article><author><name>JINEK, M. et al.</name></author><atl>RNA-programmed genome editing in human cells</atl><serial><sertitle>eLife</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate><vid>2</vid></serial><location><pp><ppf>e00471</ppf><ppl/></pp></location></article></nplcit><crossref idref="ncit0020">[0035]</crossref><crossref idref="ncit0058">[0136]</crossref></li>
<li><nplcit id="ref-ncit0018" npl-type="s"><article><author><name>DICARLO, J.E. et al.</name></author><atl>Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems</atl><serial><sertitle>Nucleic acids research</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate></serial></article></nplcit><crossref idref="ncit0021">[0035]</crossref><crossref idref="ncit0059">[0136]</crossref></li>
<li><nplcit id="ref-ncit0019" npl-type="s"><article><author><name>JIANG, W. et al.</name></author><atl>RNA-guided editing of bacterial genomes using CRISPR-Cas systems</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate><vid>31</vid></serial><location><pp><ppf>233</ppf><ppl>239</ppl></pp></location></article></nplcit><crossref idref="ncit0022">[0035]</crossref></li>
<li><nplcit id="ref-ncit0020" npl-type="s"><article><author><name>ESVELT</name></author><author><name>WANG</name></author><atl/><serial><sertitle>Molecular Systems Biology</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate><vid>9</vid></serial><location><pp><ppf>641</ppf><ppl/></pp></location></article></nplcit><crossref idref="ncit0023">[0039]</crossref></li>
<li><nplcit id="ref-ncit0021" npl-type="s"><article><author><name>MILLER, JEFFREY</name></author><atl>A TALE nuclease architecture for efficient genome editing</atl><serial><sertitle>Nature Biotechnology</sertitle><pubdate><sdate>20110200</sdate><edate/></pubdate><vid>29</vid><ino>2</ino></serial><location><pp><ppf>143</ppf><ppl>8</ppl></pp></location></article></nplcit><crossref idref="ncit0024">[0040]</crossref></li>
<li><nplcit id="ref-ncit0022" npl-type="s"><article><author><name>ZHANG, FENG</name></author><atl>Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription</atl><serial><sertitle>Nature Biotechnology</sertitle><pubdate><sdate>20110200</sdate><edate/></pubdate><vid>29</vid><ino>2</ino></serial><location><pp><ppf>149</ppf><ppl>53</ppl></pp></location></article></nplcit><crossref idref="ncit0025">[0040]</crossref><crossref idref="ncit0030">[0041]</crossref></li>
<li><nplcit id="ref-ncit0023" npl-type="b"><article><atl>Transcriptional Activators of Human Genes with Programmable DNA-Specificity</atl><book><author><name>GEIβLER, R.</name></author><author><name>SCHOLZE, H.</name></author><author><name>HAHN, S.</name></author><author><name>STREUBEL, J.</name></author><author><name>BONAS, U.</name></author><author><name>BEHRENS, S. E.</name></author><author><name>BOCH, J.</name></author><book-title>PLoS ONE</book-title><imprint><name/><pubdate>20110000</pubdate></imprint><vid>6</vid><location><pp><ppf>e19509</ppf><ppl/></pp></location></book></article></nplcit><crossref idref="ncit0026">[0040]</crossref><crossref idref="ncit0031">[0041]</crossref></li>
<li><nplcit id="ref-ncit0024" npl-type="s"><article><author><name>BOCH, JENS</name></author><atl>TALEs of genome targeting</atl><serial><sertitle>Nature Biotechnology</sertitle><pubdate><sdate>20110200</sdate><edate/></pubdate><vid>29</vid><ino>2</ino></serial><location><pp><ppf>135</ppf><ppl>6</ppl></pp></location></article></nplcit><crossref idref="ncit0027">[0040]</crossref></li>
<li><nplcit id="ref-ncit0025" npl-type="s"><article><author><name>BOCH, JENS</name></author><atl>Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors</atl><serial><sertitle>Science</sertitle><pubdate><sdate>20091200</sdate><edate/></pubdate><vid>326</vid><ino>5959</ino></serial><location><pp><ppf>1509</ppf><ppl>12</ppl></pp></location></article></nplcit><crossref idref="ncit0028">[0040]</crossref></li>
<li><nplcit id="ref-ncit0026" npl-type="s"><article><author><name>MOSCOU, MATTHEW J.</name></author><author><name>ADAM J. BOGDANOVE</name></author><atl>A Simple Cipher Governs DNA Recognition by TAL Effectors</atl><serial><sertitle>Science</sertitle><pubdate><sdate>20091200</sdate><edate/></pubdate><vid>326</vid><ino>5959</ino></serial><location><pp><ppf>1501</ppf><ppl/></pp></location></article></nplcit><crossref idref="ncit0029">[0040]</crossref></li>
<li><nplcit id="ref-ncit0027" npl-type="s"><article><author><name>CERMAK, T.</name></author><author><name>DOYLE, E. L.</name></author><author><name>CHRISTIAN, M.</name></author><author><name>WANG, L.</name></author><author><name>ZHANG, Y.</name></author><author><name>SCHMIDT, C.</name></author><author><name>BALLER, J. A.</name></author><author><name>SOMIA, N. V. et al.</name></author><atl>Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting</atl><serial><sertitle>Nucleic Acids Research</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate></serial></article></nplcit><crossref idref="ncit0032">[0041]</crossref></li>
<li><nplcit id="ref-ncit0028" npl-type="s"><article><author><name>MORBITZER, R.</name></author><author><name>ELSAESSER, J.</name></author><author><name>HAUSNER, J.</name></author><author><name>LAHAYE, T.</name></author><atl>Assembly of custom TALE-type DNA binding domains by modular cloning</atl><serial><sertitle>Nucleic Acids Research</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate></serial></article></nplcit><crossref idref="ncit0033">[0041]</crossref></li>
<li><nplcit id="ref-ncit0029" npl-type="s"><article><author><name>LI, T.</name></author><author><name>HUANG, S.</name></author><author><name>ZHAO, X.</name></author><author><name>WRIGHT, D. A.</name></author><author><name>CARPENTER, S.</name></author><author><name>SPALDING, M. H.</name></author><author><name>WEEKS, D. P.</name></author><author><name>YANG, B.</name></author><atl>Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes</atl><serial><sertitle>Nucleic Acids Research</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate></serial></article></nplcit><crossref idref="ncit0034">[0041]</crossref></li>
<li><nplcit id="ref-ncit0030" npl-type="b"><article><atl>Assembly of Designer TAL Effectors by Golden Gate Cloning</atl><book><author><name>WEBER, E.</name></author><author><name>GRUETZNER, R.</name></author><author><name>WERNER, S.</name></author><author><name>ENGLER, C.</name></author><author><name>MARILLONNET, S.</name></author><book-title>PLoS ONE</book-title><imprint><name/><pubdate>20110000</pubdate></imprint><vid>6</vid><location><pp><ppf>e19722</ppf><ppl/></pp></location></book></article></nplcit><crossref idref="ncit0035">[0041]</crossref></li>
<li><nplcit id="ref-ncit0031" npl-type="s"><article><author><name>KLUG A</name></author><author><name>RHODES D</name></author><atl>Zinc fingers: a novel protein fold for nucleic acid recognition</atl><serial><sertitle>Cold Spring Harb. Symp. Quant. Biol.</sertitle><pubdate><sdate>19870000</sdate><edate/></pubdate><vid>52</vid></serial><location><pp><ppf>473</ppf><ppl>82</ppl></pp></location></article></nplcit><crossref idref="ncit0036">[0043]</crossref></li>
<li><nplcit id="ref-ncit0032" npl-type="s"><article><author><name>KRISHNA SS</name></author><author><name>MAJUMDAR I</name></author><author><name>GRISHIN NV</name></author><atl>Structural classification of zinc fingers: survey and summary</atl><serial><sertitle>Nucleic Acids Res.</sertitle><pubdate><sdate>20030100</sdate><edate/></pubdate><vid>31</vid><ino>2</ino></serial><location><pp><ppf>532</ppf><ppl>50</ppl></pp></location></article></nplcit><crossref idref="ncit0037">[0043]</crossref></li>
<li><nplcit id="ref-ncit0033" npl-type="s"><article><author><name>PABO CO</name></author><author><name>PEISACH E</name></author><author><name>GRANT RA</name></author><atl>Design and selection of novel cys2His2 Zinc finger proteins</atl><serial><sertitle>Annual Review of Biochemistry</sertitle><pubdate><sdate>20010000</sdate><edate/></pubdate><vid>70</vid></serial><location><pp><ppf>313</ppf><ppl>340</ppl></pp></location></article></nplcit><crossref idref="ncit0038">[0043]</crossref></li>
<li><nplcit id="ref-ncit0034" npl-type="s"><article><author><name>JAMIESON AC</name></author><author><name>MILLER JC</name></author><author><name>PABO CO</name></author><atl>Drug discovery with engineered zinc-finger proteins</atl><serial><sertitle>Nature Reviews Drug Discovery</sertitle><pubdate><sdate>20030000</sdate><edate/></pubdate><vid>2</vid><ino>5</ino></serial><location><pp><ppf>361</ppf><ppl>368</ppl></pp></location></article></nplcit><crossref idref="ncit0039">[0043]</crossref></li>
<li><nplcit id="ref-ncit0035" npl-type="s"><article><author><name>LIU Q</name></author><author><name>SEGAL DJ</name></author><author><name>GHIARA JB</name></author><author><name>BARBAS CF</name></author><atl>Design of polydactyl zinc-finger proteins for unique addressing within complex genomes</atl><serial><sertitle>Proc. Natl. Acad. Sci. U.S.A.</sertitle><pubdate><sdate>19970500</sdate><edate/></pubdate><vid>94</vid><ino>11</ino></serial></article></nplcit><crossref idref="ncit0040">[0043]</crossref></li>
<li><nplcit id="ref-ncit0036" npl-type="s"><article><author><name>PAVLETICH NP</name></author><author><name>PABO CO</name></author><atl>Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A</atl><serial><sertitle>Science</sertitle><pubdate><sdate>19910500</sdate><edate/></pubdate><vid>252</vid><ino>5007</ino></serial><location><pp><ppf>809</ppf><ppl>17</ppl></pp></location></article></nplcit><crossref idref="ncit0041">[0044]</crossref></li>
<li><nplcit id="ref-ncit0037" npl-type="s"><article><author><name>PATTANAYAK, V. et al.</name></author><atl/><serial><sertitle>Nature Methods</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate><vid>8</vid></serial><location><pp><ppf>765</ppf><ppl>770</ppl></pp></location></article></nplcit><crossref idref="ncit0043">[0049]</crossref></li>
<li><nplcit id="ref-ncit0038" npl-type="b"><article><atl/><book><author><name>A. R. GENNARO</name></author><book-title>Remington's The Science and Practice of Pharmacy</book-title><imprint><name>Lippincott, Williams &amp; Wilkins</name><pubdate>20060000</pubdate></imprint></book></article></nplcit><crossref idref="ncit0044">[0088]</crossref></li>
<li><nplcit id="ref-ncit0039" npl-type="s"><article><author><name>HOCKEMEYER, D. et al.</name></author><atl>Genetic engineering of human pluripotent cells using TALE nucleases</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate><vid>29</vid></serial><location><pp><ppf>731</ppf><ppl>734</ppl></pp></location></article></nplcit><crossref idref="ncit0045">[0136]</crossref></li>
<li><nplcit id="ref-ncit0040" npl-type="s"><article><author><name>ZOU, J. et al.</name></author><atl>Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells</atl><serial><sertitle>Cell stem cell</sertitle><pubdate><sdate>20090000</sdate><edate/></pubdate><vid>5</vid></serial><location><pp><ppf>97</ppf><ppl>110</ppl></pp></location></article></nplcit><crossref idref="ncit0046">[0136]</crossref></li>
<li><nplcit id="ref-ncit0041" npl-type="s"><article><author><name>HOCKEMEYER, D. et al.</name></author><atl>Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20090000</sdate><edate/></pubdate><vid>27</vid></serial><location><pp><ppf>851</ppf><ppl>857</ppl></pp></location></article></nplcit><crossref idref="ncit0047">[0136]</crossref></li>
<li><nplcit id="ref-ncit0042" npl-type="s"><article><author><name>DOYON, Y. et al.</name></author><atl>Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20080000</sdate><edate/></pubdate><vid>26</vid></serial><location><pp><ppf>702</ppf><ppl>708</ppl></pp></location></article></nplcit><crossref idref="ncit0048">[0136]</crossref></li>
<li><nplcit id="ref-ncit0043" npl-type="s"><article><author><name>MENG, X.</name></author><author><name>NOYES, M.B.</name></author><author><name>ZHU, L.J.</name></author><author><name>LAWSON, N.D.</name></author><author><name>WOLFE, S.A.</name></author><atl>Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20080000</sdate><edate/></pubdate><vid>26</vid></serial><location><pp><ppf>695</ppf><ppl>701</ppl></pp></location></article></nplcit><crossref idref="ncit0049">[0136]</crossref></li>
<li><nplcit id="ref-ncit0044" npl-type="s"><article><author><name>SANDER, J.D. et al.</name></author><atl>Targeted gene disruption in somatic zebrafish cells using engineered TALENs</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate><vid>29</vid></serial><location><pp><ppf>697</ppf><ppl>698</ppl></pp></location></article></nplcit><crossref idref="ncit0050">[0136]</crossref></li>
<li><nplcit id="ref-ncit0045" npl-type="s"><article><author><name>TESSON, L. et al.</name></author><atl>Knockout rats generated by embryo microinjection of TALENs</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate><vid>29</vid></serial><location><pp><ppf>695</ppf><ppl>696</ppl></pp></location></article></nplcit><crossref idref="ncit0051">[0136]</crossref></li>
<li><nplcit id="ref-ncit0046" npl-type="s"><article><author><name>CUI, X. et al.</name></author><atl>Targeted integration in rat and mouse embryos with zinc-finger nucleases</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate><vid>29</vid></serial><location><pp><ppf>64</ppf><ppl>67</ppl></pp></location></article></nplcit><crossref idref="ncit0052">[0136]</crossref></li>
<li><nplcit id="ref-ncit0047" npl-type="s"><article><author><name>PEREZ, E.E. et al.</name></author><atl>Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20080000</sdate><edate/></pubdate><vid>26</vid></serial><location><pp><ppf>808</ppf><ppl>816</ppl></pp></location></article></nplcit><crossref idref="ncit0053">[0136]</crossref></li>
<li><nplcit id="ref-ncit0048" npl-type="s"><article><author><name>JINEK, M. et al.</name></author><atl>A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity</atl><serial><sertitle>Science</sertitle><pubdate><sdate>20120000</sdate><edate/></pubdate><vid>337</vid></serial><location><pp><ppf>816</ppf><ppl>821</ppl></pp></location></article></nplcit><crossref idref="ncit0054">[0136]</crossref></li>
<li><nplcit id="ref-ncit0049" npl-type="s"><article><author><name>JIANG, W.</name></author><author><name>BIKARD, D.</name></author><author><name>COX, D.</name></author><author><name>ZHANG, F.</name></author><author><name>MARRAFFINI, L.A.</name></author><atl>RNA-guided editing of bacterial genomes using CRISPR-Cas systems</atl><serial><sertitle>Nature biotechnology</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate><vid>31</vid></serial><location><pp><ppf>233</ppf><ppl>239</ppl></pp></location></article></nplcit><crossref idref="ncit0060">[0136]</crossref><crossref idref="ncit0066">[0136]</crossref></li>
<li><nplcit id="ref-ncit0050" npl-type="s"><article><author><name>SAPRANAUSKAS, R. et al.</name></author><atl>The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli</atl><serial><sertitle>Nucleic acids research</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate><vid>39</vid></serial><location><pp><ppf>9275</ppf><ppl>9282</ppl></pp></location></article></nplcit><crossref idref="ncit0061">[0136]</crossref></li>
<li><nplcit id="ref-ncit0051" npl-type="s"><article><author><name>SEMENOVA, E. et al.</name></author><atl>Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence</atl><serial><sertitle>Proceedings of the National Academy of Sciences of the United States of America</sertitle><pubdate><sdate>20110000</sdate><edate/></pubdate><vid>108</vid></serial><location><pp><ppf>10098</ppf><ppl>10103</ppl></pp></location></article></nplcit><crossref idref="ncit0062">[0136]</crossref></li>
<li><nplcit id="ref-ncit0052" npl-type="s"><article><author><name>QI, L.S. et al.</name></author><atl>Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression</atl><serial><sertitle>Cell</sertitle><pubdate><sdate>20130000</sdate><edate/></pubdate><vid>152</vid></serial><location><pp><ppf>1173</ppf><ppl>1183</ppl></pp></location></article></nplcit><crossref idref="ncit0063">[0136]</crossref></li>
<li><nplcit id="ref-ncit0053" npl-type="s"><article><author><name>DOYON, J.B.</name></author><author><name>PATTANAYAK, V.</name></author><author><name>MEYER, C.B.</name></author><author><name>LIU, D.R.</name></author><atl>Directed evolution and substrate specificity profile of homing endonuclease I-SceI</atl><serial><sertitle>Journal of the American Chemical Society</sertitle><pubdate><sdate>20060000</sdate><edate/></pubdate><vid>128</vid></serial><location><pp><ppf>2477</ppf><ppl>2484</ppl></pp></location></article></nplcit><crossref idref="ncit0065">[0136]</crossref></li>
<li><nplcit id="ref-ncit0054" npl-type="s"><article><author><name>SCHNEIDER, T.D.</name></author><author><name>STEPHENS, R.M.</name></author><atl>Sequence logos: a new way to display consensus sequences</atl><serial><sertitle>Nucleic acids research</sertitle><pubdate><sdate>19900000</sdate><edate/></pubdate><vid>18</vid></serial><location><pp><ppf>6097</ppf><ppl>6100</ppl></pp></location></article></nplcit><crossref idref="ncit0068">[0136]</crossref></li>
</ul></p>
</ep-reference-list>
</ep-patent-document>
